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ABSTRACT 
Alterations to the tumour microenvironment is a common feature of many 
cancers, including breast cancer, and there is increasing evidence that alterations 
to the microenvironment, including; increased integrin expression, ECM 
deposition and protease activity, promote cancer progression. Most invasive 
breast cancers arise from a preinvasive stage, ductal carcinoma in situ (DCIS). 
Previous work in our laboratory has shown the microenvironment of DCIS is 
altered, such that myoepithelial cells (MECs) switch to a tumour-promoting 
phenotype, associated with upregulation of integrin αvβ6 and fibronectin (FN) 
expression. Mechanisms by which integrin αvβ6 and FN expression are regulated 
is unclear. We show DCIS progression into invasion is accompanied by an 
increase in MEC expression of integrin αvβ6 and periductal FN deposition, and 
their expression were associated in DCIS. These findings were modelled in 
isolated primary DCIS-MECs, primary normal MECs and MEC lines, with and 
without integrin αvβ6 expression, where integrin αvβ6-positive MECs 
upregulating FN expression. We identified integrin αvβ6-positive DCIS ducts 
were larger than integrin αvβ6-negative DCIS ducts, and mechanical stretching 
of primary normal MECs and a normal MEC line led to upregulation of integrin 
αvβ6 expression and FN deposition in a TGFβ-dependent manner. We further 
show upregulation of integrin αvβ6 and FN by MECs mediate TGFβ-dependent 
upregulation of MMP13 which promotes breast cancer cell invasion in vitro. 
These data show altered tissue mechanics in DCIS and MEC expression of 
integrin αvβ6 and FN deposition are linked, and implicate TGFβ in their activation. 
These findings suggest integrin αvβ6 and FN may be used as markers to stratify 
DCIS patients. 
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1. INTRODUCTION 
 
1.1 NORMAL BREAST 
 
1.1.1 Structure of normal breast 
The normal breast is composed of a ductal network that originates at the nipple 
and ends in one of many terminal ductal-lobular units (TDLUs) - the smallest 
functional unit of the breast. A TDLU is composed of a single terminal duct (TD) 
and multiple end ductules, known as acini, which form the lobule (Figure 1a). This 
ductal network is lined by two epithelial cell layers: the apically located luminal 
epithelial cell (LEC) layer that consists of polarised columnar cells of the ducts 
and cuboidal cells of the lobules, and the basally located myoepithelial cell (MEC) 
layer which lies in contact with the laminin (LN)-rich basement membrane (BM) 
(Figure 1b) [1]. The organisation of MECs differs between ducts and lobules. In 
the duct, MECs are elongated and arranged in an almost continuous layer which 
lies in direct contact with the BM, thereby separating LECs from the BM. While in 
the lobules, MECs are stellate-shaped and form a basket-like structure, this 
discontinuous layer exposes the basal surface of some LECs to the BM [2, 3]. 
Therefore, interaction between LECs and the surrounding stroma is mediated by 
the organisation of the MEC layer [4]. This ductal network is directly surrounded 
by a highly vascularised stroma, separated from the adipose tissue by fibrous 
connective tissue [1]. 
 
Terminal 
Ductal-Lobular 
Unit (TDLU)
Lobule
Duct
Acini
Nipple
Basement membrane (BM)
Luminal epithelial cell (LEC)
Myoepithelial cell (MEC)
Figure 1. Structure of normal breast. a) The normal breast is composed of a ductal
network that originates at the nipple and ends in one of many terminal ductal-lobular units
(TDLUs). Each TDLU is composed of a terminal duct and multiple end ductules, known as
acini, which form the lobule. This structure resides in a highly vascularised stroma which is
separated from the adipose tissue by dense fibrous tissue. b) The ductal system is lined by
two epithelial cell layers: the inner luminal epithelial cell (LEC) layer and the outer
myoepithelial cell (MEC) layer, which lies in contact with the basement membrane (BM).
Figure 1a adapted from [22] and 1b adapted from [16].
a)
b)
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1.1.2 Development of normal breast 
Development of the normal breast is a progressive process which begins during 
embryogenesis; in humans, males and females have a similar rudimentary ductal 
structure at birth [5, 6]. This consists of organised ducts, which are connected to 
the nipple but lack TDLUs. Development in the two sexes is identical until the 
onset of puberty. In puberty, under the action of the ovarian steroid hormone 
oestrogen, the ductal network undergoes branching morphogenesis in females, 
while the male ductal network remains rudimentary with some involution [5, 6]. 
Branching morphogenesis involves the growth and division of ducts and the 
development of early lobular structures, which are more primitive than the 
terminal structures of the mature resting breast [7]. Branching morphogenesis is 
accompanied by an increase in the volume of adipose and fibrous tissue [7]. 
Further development of the lobules continues with the onset of menstruation and 
pregnancy, with full terminal differentiation occurring only if lactation occurs [6]. 
 
1.1.3 Cyclical variations to normal breast 
The breast undergoes cycles of growth and involution, regulated by steroid 
hormone activity in the menstrual cycle, and pregnancy and lactation [8]. In the 
mature breast, LECs and MECs are represented in equal numbers [9]. In the 
premenstrual phase, increased steroid hormone levels induce LEC proliferation 
and increase the number of acini per lobule. At the end of the cycle the levels of 
steroid hormones decrease and the breast involutes by apoptosis. In pregnancy, 
LECs proliferate and expand in response to steroid hormones, in order to prepare 
for lactation, during which prolactin allows LECs to synthesise milk proteins [8]. 
Following birth, the level of these steroid hormones decreases, and milk is ejected 
by the systemic contraction of MECs in response to suckling-mediated release of 
oxytocin [10]. After weaning, the breast involutes by apoptosis resulting in a 
decrease in breast size to the pre-pregnancy state. Involution occurs in response 
to decreased steroid hormone levels, as seen at the end of the menstrual cycle 
and post-pregnancy, and also with the decreased ovarian function that 
accompanies ageing [8]. In ageing, the lobules involute, with a reduction in the 
number and size of acini per lobule, and the glandular and fibrous tissue is 
progressively replaced by adipose tissue, resulting in a reduction in breast density 
[11]. Lobule involution is particularly pronounced after menopause [12]. 
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1.2 BREAST CANCER
1.2.1 Classification of breast cancer 
Histological types of breast cancer 
Breast cancers may be classified into subgroups according to histological type 
and grade to provide prognostic value. Histological type refers to the cellular 
morphology of the lesion, and in general, breast cancers are classified as lobular 
and ductal histological subtypes [13]. The lobular subtype consists of small, 
nonpolarised cells which resemble cuboidal cells of the normal breast acini, while 
the ductal subtype consists of moderate to large, polarised cells that resemble 
columnar cells of the normal breast ducts [13]. The terms ‘ductal’ and ‘lobular’ 
were previously used to classify lesions based on their origin and localisation to 
either the duct or lobules respectively, however most breast cancers ultimately 
arise in the same anatomical site - the TDLU [14, 15]. Ductal and lobular lesions 
of the breast are further classified into in situ and invasive lesions. In situ lesions 
are characterised by tumour cell proliferation confined within the ductal-lobular 
network by an intact or focally disrupted MEC-BM interface, while invasive lesions 
are characterised by the loss of the MEC population, the degradation of the BM 
and the invasion of tumour cells into the surrounding stroma [16]. In situ precursor 
lesions in the development of invasive lobular carcinoma (ILC) include: atypical 
lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS), whereas 
precursor lesions in the development of invasive ductal carcinoma (IDC) include: 
usual epithelial ductal hyperplasia (UDH), flat epithelial atypia (FEA), atypical 
ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS) [13].   
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Histological grades of breast cancer 
Histological grade refers to the degree of differentiation and proliferation of a 
tumour. These characteristics have been incorporated in multiple prognostic 
algorithms to determine the clinical management of DCIS, particularly to identify 
patients at risk of recurrence. The Van Nuys classification system is based on 
age at diagnosis and tumour features; size, margins, nuclear grade and necrosis. 
These factors are used to score DCIS lesions between 4 and 12 to determine risk 
of recurrence. Patients least likely to recur, score 4 and include older patients 
with small, low-grade, well-excised lesions, while patients most likely to recur, 
score 12 and include younger patients with large, high-grade, poorly-excised 
lesions [17]. The National Coordinating Group for Breast Screening Pathology 
has proposed a classification system based on growth pattern, nuclear 
morphology and necrosis [18]. These factors are used to subclassify DCIS into 
low-, intermediate- and high-grade. Low-grade DCIS consists of small, cohesive, 
polarised, uniform cells of low proliferative capacity, while high-grade DCIS 
consists of large, pleomorphic cells of high proliferative capacity with necrosis. 
Intermediate-grade DCIS shares characteristics of both grades [18]. Both 
classification systems demonstrate an association with high-scoring or high-
grade DCIS and recurrence [19, 20]. However, these classification systems have 
limited reproducibility due to subjective interpretation of breast histology [21], 
particularly as individual DCIS lesions demonstrate heterogeneity in grade [22], 
and therefore are unable to inform on appropriate treatment alone [23]. With this, 
no single classification system for DCIS has been universally accepted [24]. 
Molecular characterisation of DCIS may improve the prognostic stratification of 
patients using such classification systems. 
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1.2.2 Model of progression of breast cancer 
Progression to invasive breast cancer has been suggested to follow a step-wise 
transition through clinical and pathologically defined stages [25]. For the ductal 
subtype, two models have been proposed. The classical model suggests breast 
cancer arises from the transformation of a TDLU into FEA; to ADH; to DCIS, 
which progresses into IDC [26]. This model was proposed following the 
identification of a single anatomical site for the origin of breast cancer, and it was 
based on the speculation that these lesions are biologically related due to the 
gradual histological continuity between them [14, 15, 27]. This model is supported 
by the elevated risk of developing invasive disease with the progressive lesion 
[28]. Such that, patients with FEA have a 2-fold increased risk of developing 
invasive breast cancer, whereas patients with ADH and DCIS have a 5-fold and 
10-fold increased risk, respectively [29-31]. However, these studies did not 
classify DCIS into histological grade, and therefore a correlation between DCIS 
grade and subsequent invasive development was not assessed. Moreover, these 
earlier lesions more frequently coexist in breasts with synchronous invasive 
breast cancer than normal breasts [27]. An alternative model, also supported by 
histomorphological and epidemiological observations, suggests UDH, instead of 
FEA, as a direct precursor to ADH [28, 29]. UDH carries a 1.5-fold increased risk 
of invasive development [28]. However, subsequent studies have suggested this 
model is likely invalid [13]. For the lobular subtype, similar to the classical model 
for the ductal subtype, a normal TDLU transforms into ALH, which progresses to 
LCIS and culminates as ILC [13]. 
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1.2.3 Management of breast cancer 
In the symptomatic setting, DCIS accounts for 3-5% of breast cancer diagnoses, 
while in the screening setting, DCIS accounts for 20-25% [32, 33]. Screening 
programmes aim to prevent disease-specific mortality through detection and 
treatment of disease at its earliest stages, suggesting DCIS as an ideal target in 
the prevention of invasive breast cancer [34]. The expected benefit of screening 
to reduce mortality depends on existence of an effective treatment. Current 
management of DCIS involves treatment of all cases by surgical excision, by 
mastectomy if the DCIS is extensive, which has a risk of recurrence of 1-2% or, 
for more limited disease, breast conserving surgery with adjuvant radiotherapy, 
which has a risk of recurrence of 12% [35, 36]. However, it is estimated that if left 
untreated, over half of DCIS cases will not progress into invasion within a patient’s 
lifetime [37, 38]. A study followed 28 patients diagnosed with low-grade DCIS on 
biopsy, who received no further treatment. 11 patients developed invasive 
disease, with a variable time of progression up to 40 years, while 17 remained 
breast-cancer free [37]. In all cases, the site of recurrence was within the same 
quadrant of the same breast the biopsy had been taken, this supports disease 
progression rather than de novo disease [37]. A comparable study followed 13 
patients diagnosed with varying grades of DCIS on biopsy, who received no 
further treatment. 10 patients recurred, 6 patients developed invasive disease, of 
those 2 low-grade DCIS recurred within 12 years, 2 intermediate-grade DCIS 
recurred within 10 years, and 2 high-grade DCIS recurred within 5 years, post-
biopsy [38]. Together, these studies suggest, all DCIS grades have progressive 
potential, with high-grade DCIS progressing into invasion more rapidly. With no 
current markers to predict progression into, or recurrence as, invasive disease, 
there are concerns surrounding overdiagnosis and overtreatment of DCIS [39-
41]. Overdiagnosis is the detection of a cancer which otherwise would not cause 
symptoms or death, while overtreatment relates to the treatment of any 
overdiagnosed cases or the unnecessary administration of more aggressive 
therapies than is necessary [42]. The main challenge in the management of DCIS 
is to determine the invasive capabilities and recurrence probabilities of DCIS 
cases, in order to generate robust prognostic and therapeutic stratification [40]. 
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1.2.4 Molecular analysis of the progressive stages of breast cancer 
 
1.2.4.1 Invasive breast cancer 
 
Genomic analysis of invasive breast cancer 
To understand breast cancer progression, molecular studies focused on the 
relationship between the genetic alterations in tumour cells and histological 
grade, as the histological grade is related to the clinical behaviour [19]. These 
studies demonstrated that specific DCIS grades exhibit distinct genomic 
differences, whereby low-grade IDCs displayed fewer overall chromosomal 
aberrations as compared to high-grade IDCs [43-45]. More specifically, low-grade 
IDCs display reoccurring chromosomal loss of 16q and gains of 1q, 16p and 8q, 
whereas high-grade IDCs exhibit recurrent losses of 8q, 11q, 13q, 1p and 18q, 
recurrent gains of 8q, 17q, 20q and 16q, and frequent high-level amplifications of 
17q12 and 11q13 [43-45]. Intermediate-grade IDC shares genomic alterations of 
both grades [46]. The pattern of 16q loss in low-grade and gain high-grade IDC 
strongly argues against the hypothesis that low-grade IDCs progress to high-
grade IDCs through accumulation of genetic alterations [47]. This suggests low-
grade IDC and high-grade IDC have distinct pathways of progression. 
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Gene-expression analysis of invasive breast cancer 
Gene-expression profiling has contributed to the understanding of biological and 
clinical heterogeneity of breast cancer [48]. A study by Perou and colleagues 
used complementary DNA (cDNA) microarrays to investigate gene-expression 
profiles of 65 breast cancer samples from 42 individuals (36 IDC, 1 DCIS, 2 LCIS 
and 3 normal) [49]. This study aimed to characterise breast cancers by alterations 
to a specific set of genes, known as the intrinsic gene set. Invasive breast cancers 
were classified into four intrinsic subtypes, including two ER positive; luminal A 
and luminal B, and two ER negative; HER2 and basal [49]. Luminal A and luminal 
B are the most common subtypes, usually representing low- to intermediate-
grade, characterised by the expression of genes characteristic of normal LECs, 
including; cytokeratin 8 (CK8) and 18 (CK18). Luminal A subtype show high 
expression of ER and PR-related genes and lack HER2 expression, with a low-
grade and low expression of proliferation-related genes. Luminal B subtype show 
a decreased expression of ER and PR and overexpress HER2, have a higher 
grade and higher expression of proliferation-related genes. Luminal subtypes 
show a better responsiveness to endocrine treatment and clinical outcome [50, 
51]. HER2 and basal subtypes usually represent high-grade, and are associated 
with poor prognosis. HER2 subtype show expression of HER2, as well as other 
genes on the HER2 amplicon (17q12-q21), and lack expression of ER and PR. 
Basal subtype show expression of genes characteristic of normal MECs, 
including; CK5/6 and epidermal growth factor receptor (EGFR), and are most 
commonly characterised by the lack of ER, PR and HER2 expression, and are 
therefore frequently known as triple negative (TN) subtype. However, the basal 
and TN subtype are not identical, and their distinction is made on five markers; 
ER, PR, HER2, EGFR and CK5/6. Basal subtype are negative for ER, PR, HER2 
and positive for EGFR and CK5/6, whilst TN subtype are negative for all five 
markers (Table 1) [52]. Subsequent follow-up studies demonstrated these 
subtypes were associated with distinct clinical outcomes, however, despite their 
clinical relevance, molecular characterisation of breast cancers using gene-
expression profiling is not routine in clinical practice, and breast cancer 
management depends on the use of conventional classification systems 
analysing histological features [51, 53].  
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Intrinsic subtype Expression profile Histological grade Outcome 
Luminal A ER+/PR+/HER2- Low Good 
Luminal B ER+/PR+/HER2+ Intermediate Intermediate 
HER2 ER-/PR-/HER2+ High Poor 
Basal ER-/PR-/HER2- EGFR+/CK5/6+ High Poor 
Triple negative ER-/PR-/HER2- EGFR-/CK5/6- High Poor 
 
Table 1. Intrinsic subtypes of invasive breast cancer. Table adapted from [54]. 
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1.2.4.2 In situ breast cancer 
 
Genomic analysis of in situ breast cancer 
Several genomic studies have demonstrated that DCIS exhibits distinct 
alterations associated with histological grade [44-46]. Using CGH, Buerger and 
colleagues demonstrated the frequent loss of 16q in low-grade DCIS, whereas 
more complex genomic alterations including, loss of 8p, 11q, 13q and 14q, gains 
of 1q, 5p, 8q and 17q, and high level amplification of 17q12 and 11q13 in high-
grade DCIS [45]. As seen in IDC, intermediate-grade DCIS shares genomic 
alterations of both grades [45]. Analysis of CGH data generated from 
synchronous DCIS and IDC revealed a near-identical pattern of genomic 
alterations supporting the direct precursor relationship between DCIS and IDC 
[44-46]. Yao and colleagues utilised CGH in conjunction with serial analysis of 
gene expression (SAGE) to demonstrate an overall trend towards an increase in 
the number and amplitude of gains and losses during breast cancer progression 
[55]. Together, these data support DCIS as a direct precursor to IDC, and that 
distinct genetic pathways between low-grade and high-grade disease exists. 
 
In the low-grade pathway, FEA is suggested as the precursor to ADH, and ADH 
as the precursor to low-grade DCIS, this notion is supported by shared 
histomorphological features and epidemiological data [14, 15, 27, 29-31]. 
Extending this, several loss-of-heterozygosity (LOH) studies identified loss of 16q 
in ADH, an alteration which is frequently observed in low-grade DCIS [56-58]. 
Moreover, the genetic profile of FEA overlaps with ADH and low-grade DCIS. 
Specifically, Moinfar and colleagues reported loss of 16q in FEA [59], and these 
were further supported by similar studies [26]. Notably, these common genomic 
alterations are not observed in UDH. This lesion displays rare and randomly 
distributed chromosomal alterations, or no changes at all, that are no different 
from normal breast tissue [57], thereby discounting UDH as a precursor to ADH, 
and therefore do not support the alternative model of ductal breast cancer 
progression. Identification of the precursor lesion of high-grade DCIS, with 17q12 
amplification, remains elusive [13]. These observations support the role of FEA 
as the precursor to ADH, and ADH as the precursor to low-grade DCIS. 
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Gene-expression analysis of in situ breast cancer 
Gene-expression analysis of DCIS demonstrated that like IDC, DCIS can also be 
categorised into the intrinsic subtypes [60]. Hannemann and colleagues used 
microarray analysis to compare the gene-expression profile of 40 DCIS and 40 
IDC cases. By performing two-dimensional hierarchical clustering, they 
demonstrated these subtypes are observable in DCIS [60]. However, the relative 
frequency of these subtypes between DCIS and IDC are different [61]. Such that, 
there is a higher frequency of the HER2 subtype in DCIS (14.9%) compared to 
IDC (3-6%), and a lower frequency of the TN and basal subtypes in DCIS (7.5% 
and 4.2%) compared to IDC (11-20% TN/basal) [61-63]. To account for the 
differential frequencies of HER2-positivity in DCIS and IDC, two hypotheses have 
been suggested; HER2 overexpression may be lost during the transition to 
invasion, or HER2-positive DCIS may not develop into IDC. To investigate this, 
Park and colleagues compared HER2 levels between DCIS and DCIS with 
invasion (DCIS/IDC), and between the DCIS and invasive components within the 
same case of DCIS/IDC [63]. They demonstrated that HER2 amplification is more 
frequently detected in DCIS, and it is maintained in DCIS and invasive-
component of DCIS/IDC. Moreover, HER2 expression is maintained in metastatic 
lesions. This suggests DCIS differs in the presence of invasive disease [63]. 
These data support that the intrinsic subtypes exist within DCIS however, these 
subtypes are unable to determine which DCIS cases will or will not progress. 
 
Together, these studies support the classical model of breast cancer progression, 
through identifying shared alterations between DCIS and IDC. Furthermore, 
distinct genomic features found in different grades of IDC are also mirrored in 
DCIS lesions of comparable grade, whereas it was previously thought that low-
grade DCIS can progress into high-grade DCIS through accumulation of genetic 
alterations. In simplistic terms it is accepted that, low-grade DCIS tends to 
progress to low-grade IDC, and high-grade DCIS tends to progress to high-grade 
IDC by accumulation of these specific gene alterations. Furthermore, FEA and 
ADH share identical genetic profiles as seen in low-grade DCIS, supporting FEA 
and ADH as the precursors to low-grade DCIS. The evolution of intermediate-
grade DCIS remains unknown. With this, these two models of progression are 
widely supported however, it may oversimplify a complex process. 
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1.2.5 Identifying markers of the progression of breast cancer 
 
1.2.5.1 Analysis of breast cancer cells 
Early models of cancer progression suggest tumour cells acquire hallmarks of 
malignancy through the accumulation of advantageous genomic alterations as 
they progress to invasion [64]. Initial studies to understand the progression of 
breast cancer focused on identifying gene-expression changes within the tumour 
cells that constitute the progressive stages; ADH, DCIS and IDC [65, 66]. 
Identifying stage-specific gene-signatures may allow for the prediction of the 
progressive potential of the lesion and inform on treatment. In a study by Ma and 
colleagues, the epithelium from 36 tissue samples with synchronous lesions, and 
matched normal breast epithelium were isolated by laser capture microdissection 
(LCM) and analysed using gene-expression microarrays [66]. This study 
identified the most pronounced alterations occur in ADH, and are maintained in 
later stages of progression, with no major alterations between DCIS and IDC [66]. 
These data support the concept that there is a clonal relationship between the 
pathological stages, and that the gene-expression patterns of early lesions reflect 
the progressive potential. However, this study is that it reflects low-grade disease 
and therefore may not be relevant to high-grade disease, which has a poorer 
prognosis [19, 20]. These finding are supported by other studies [55, 67-69]. A 
study by Castro and colleagues analysed 4 normal, 5 DCIS, 22 DCIS/IDC, and 
10 IDC cases in a similar manner [70]. This study demonstrated that tumour cells 
from DCIS exhibited the most divergent gene-expression changes, while gene-
expression changes in tumour cells from the DCIS-component of DCIS/IDC were 
very similar to tumour cells isolated from IDC [70]. Therefore, these studies 
suggest that genetic alterations occur before the morphological changes 
associated with invasion. A further study supported the predictive potential of 
early lesions. This study demonstrated the prediction of breast cancer metastatic 
potential from the gene-expression profile of the primary tumour [71].  
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Although such studies did not identify gene-expression differences that were able 
to differentiate DCIS and IDC, unique gene-expression alterations were 
associated with different histological grades [66]. In which, ADH, low-grade DCIS 
and low-grade IDCs share a common gene-expression signature that is distinct 
from the gene-expression signature in high-grade DCIS and high-grade IDCs. 
Notably, intermediate-grade DCIS exhibited a hybrid of these signatures [66]. 
These data support the different pathological grades of DCIS progress to IDC by 
two distinct pathways. In the low-grade arm, tumours are of low nuclear grade, 
are usually ER and PR positive, negative for HER2 and basal markers, and 
harbour low genetic instability and recurrent 16q loss. While those in the high-
grade arm, show a higher degree of nuclear atypia, are frequently ER and PR 
negative, frequently positive for HER2 or basal markers, and are genetically 
advanced lesions demonstrating a combination of common genomic alterations, 
including 16q gain [13]. These observations have been supported by several 
other breast cancer gene-expression profiling studies [67, 72]. Therefore, it has 
been demonstrated that histological grade, rather than stage, is associated with 
distinct gene-expression patterns and that changes in gene-expression required 
for invasive progression are already present in the early stages of breast cancer. 
Further studies are required to identify markers that may be used to develop a 
prognostic signature for patients with DCIS. 
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1.2.5.2 Analysis of the tumour microenvironment 
The breast microenvironment comprises the extracellular matrix (ECM) as well 
as numerous stromal cell types, including endothelial and immune cells, MECs, 
fibroblasts, and adipocytes [99]. Early studies demonstrated the ability of the 
normal breast microenvironment to regulate the growth and differentiation of 
tumour cells [73, 74], and multiple in vitro and in vivo studies have demonstrated 
that stromal cells have profound effects on the growth, differentiation, polarity and 
invasion of tumour cells [75-77]. For example, normal primary MECs reduced the 
invasion of breast cancer cell lines in vitro, when they were cultured alone or in 
the presence of fibroblasts, which are well-known promoters of tumour cell 
invasion [78]. Similarly, it was shown that mammary tumours only arise following 
the treatment of the microenvironmental components with carcinogen, regardless 
of whether the epithelial cells were treated with carcinogen in vitro [79]. 
Furthermore, certain histopathological features of breast cancers, including 
fibrosis, lymphocytic infiltration, lymphogenesis and angiogenesis have 
prognostic significance [80]. To investigate the role of stromal cell types in breast 
cancer progression, Polyak and colleagues performed gene-expression analysis 
of the cell types comprising normal, DCIS and IDC tissue [80]. This identified 
altered gene-expression of all cell types in DCIS and IDC, suggesting a role in 
development and progression into invasion [80]. In particular, DCIS-MECs 
showed the most significant differences, as compared with their normal 
counterpart. Interestingly, DCIS-MECs downregulated MEC-specific 
differentiation markers, including; oxytocin receptor, CK7, CK14, CK17, and LN 
[80]. This suggests DCIS-MECs are phenotypically altered. This study however, 
does not recapitulate all the diversity seen in breast cancer due to a low number 
of tissue samples used. However, in support of these findings, several studies 
have shown that DCIS-MECs show immunophenotypic differences from normal 
MECs [81]. Hilson and colleagues demonstrated that expression of MEC markers 
such as SMA, SM-MHC, CK5/6, CD10 and calponin were reduced in DCIS-MECs 
compared to normal [82]. Furthermore, Sotiriou and colleagues analysed the 
expression profiles of DCIS with clinical follow-up and demonstrated that 
decreased expression of CD10, a MEC-specific differentiation marker, was 
associated with decreased disease-free survival [83]. 
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While the function of MECs and their role in breast cancer is not well understood, 
normal MECs have been demonstrated to exert anti-proliferative, anti-invasive 
and anti-angiogenic effects on tumour cells in a paracrine manner [84]. With this, 
Polyak and colleagues focused their follow-up studies on the secreted proteins 
and cell-surface receptors abnormally expressed in DCIS-MECs. Several BM 
components (collagen; COL), proteases (cathepsins F, K and L), chemokines 
(CXCL12 and CXCL14) and protease inhibitors (thrombospondin 2) were highly 
upregulated in DCIS-MECs suggesting a role for MECs in ECM remodelling, and 
an alteration to their autocrine- and paracrine-mediated effects [80]. A study by 
Orimo and colleagues suggested that the secretion of CXCL12 by stromal cells 
promotes the growth of breast cancer cells [85]. Moreover, Polyak and colleagues 
observed an increase in the proliferation of tumour cells adjacent to MECs as 
compared with other regions of DCIS that were not in contact with MECs, as 
identified by Ki67 immunoreactivity [80]. With this, it was previously reported that 
tumour cells adjacent to a disrupted MEC layer in DCIS are molecularly and 
genetically different from their more distant counterpart, with loss of ER 
expression [86]. This was supported in a study by Zhu and colleagues, in which 
the gene-expression profile of tumour cells located at the periphery and the centre 
of DCIS ducts were significantly different [87]. In particular, they identified that 
gene-expression differences at the periphery were in genes associated with 
invasion [87]. These findings suggest that DCIS-MECs are altered, and these 
alterations may promote DCIS progression through ECM remodelling. 
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To determine whether changes in gene-expression were due to underlying 
genetic alterations, Polyak and colleagues performed comprehensive array-
CGH-based (aCGH) analysis to investigate the genetic profile of LECs and MECs 
from normal, DCIS and IDC tissue [80]. As expected, they detected no genetic 
alterations in LECs and MECs from normal breast tissue [80], while there were 
significant chromosomal gains and losses in tumour cells, as supported by other 
studies [44, 45, 88], with no changes in MECs from DCIS or IDC. However, as 
aCGH is thought to be more sensitive to the detection of copy number gains 
rather than losses, Polyak and colleagues also performed a comprehensive 
genome-wide single nucleotide polymorphism (SNP) array analysis of these cell 
types from a set of breast cancer samples. As expected, tumour cells 
demonstrated a large degree of LOH on the majority of chromosomes, while 
MECs appeared to be mostly normal [80]. These data demonstrate, that although 
DCIS-MECs are phenotypically different from normal MECs, genomic changes 
are restricted to tumour cells.  
 
In support of these data, Ma and colleagues conducted a comparative analysis 
of gene-expression changes in the epithelial and stromal cells during DCIS 
progression [69]. Following previous observations, they demonstrated significant 
gene-expression changes in both epithelial cells and stromal cells in the transition 
from normal to DCIS, while no major gene-expression differences were identified 
in epithelial cells in the transition to invasion. However, dramatic gene-expression 
changes were observed in stromal cells in the transition from DCIS to IDC. 
Specifically, 3 epithelial genes were differentially regulated at the transition to 
invasion, while 76 genes were upregulated and 229 genes were downregulated 
at this stage in stromal cells. Ma and colleagues next performed gene-enrichment 
analysis to identify biological processes associated with the transition to invasion, 
the genes upregulated included components of the extracellular matrix (ECM) 
and matrix metalloproteinases (MMPs; 2, 11 and 14), supporting ECM 
remodelling by stromal cells as a key step in invasion [69]. Together, these data 
support the role of tumour and stromal cell types in the progression of DCIS. 
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1.3 MYOEPITHELIAL CELLS 
 
1.3.1 Characteristics of myoepithelial cells 
MECs are defined by their shared properties with smooth muscle cells and 
location. MECs morphologically resemble smooth muscle cells as they express 
microfilaments and smooth muscle-specific cytoskeletal proteins such as alpha-
smooth muscle actin (α-SMA), smooth muscle-myosin heavy chain (SM-MHC), 
α-actinin, vinculin and calponin [89], which are responsible for MEC contraction. 
MECs however are epithelial cells, as they express CKs such as CK5, CK14 and 
CK17, which are characteristic for the basal layer of stratified epithelium, and 
form the major component of the intermediate filament system [90]. The CK 
network, specifically CK5 and CK14, maintains MEC cytoarchitecture [91]. MECs 
are located between LECs and the BM. MECs interact with adjacent LECs and 
MECs through desmosomes and interact with the BM through hemidesmosomes 
[92]. Desmosomes which exist between MECs and LECs are composed of 
desmocollin-2 (DSC2) and desmoglein-2 (DSG2), whereas those that exist 
between adjacent MECs are composed of DSC3 and DSG3. Therefore, DSC2 
and DSG2 are present in both MECs and LECs, while DSC3 and DSG3 are 
specific to MECs [91]. Treatment with function-blocking peptides to the cell 
adhesion recognition (CAR) sites in the MEC-specific DSC3 and DSG3 disrupts 
cell polarity, and formation of an acinar-like structure [91]. Hemidesmosomes 
which exist between MECs and the BM are composed of integrin α6β4 and 
LN322. MECs express integrin α6β4 which acts as a BM receptor for LN322 [93, 
94]. Loss of hemidesmosomes leads to the detachment of MECs from the BM. 
MECs also express classical cadherin-mediated interactions, connecting MECs 
to coordinate the contractile release of milk from the duct [95]. These structural 
features of MECs, are indistinguishably linked to function. 
 
 
 
 
 
 
 
36 
 
1.3.2 Function of myoepithelial cells  
In the breast, the main function of MECs is contractile, in order to release milk 
during lactation [2]. This function is reflected by MEC expression of α-SMA and 
SM-MHC, and oxytocin receptor to respond to the release of oxytocin during 
lactation. MECs have also been shown to provide important regulatory signals, in 
addition to structural features, essential for the maintenance of normal breast 
structure and function. MECs contribute to the synthesis and organisation of the 
BM, which is rich in COL4, LN and other molecules, as well contributing to the 
remodelling of the ECM through production of ECM-degrading enzymes and 
inhibitors [2, 96, 97]. Specifically, MECs produce the BM component, LN1, which 
induces apicobasal polarity of LECs [98]. This was identified through culturing 
LECs within a 3D COL1 gel versus a LN-rich ECM (lrECM). LECs cultured in 
COL1 gels formed acinus-like structures with reversed polarity, with apical marker 
– mucin-1 (MUC1) expressed on the external surface while basal marker - 
epithelial specific antigen (ESA) expressed on the luminal surface. Culture in 
lrECM led to the formation of acini with an organised BM at the basal pole. The 
addition of MECs prior to embedding in COL, resulted in correct LEC polarity and 
lumen formation. The effect of MECs was cell-type specific, since co-cultures of 
LECs with other breast cells; fibroblasts or non-breast cells; osteosarcoma cells 
did not lead to the correction of LEC polarity. Interestingly MECs isolated from 
invasive breast cancers were unable to exert this effect, suggesting a loss of 
normal function. Furthermore, the LN isoforms which constitute the BM (LN-1, -5 
and -10/11) were tested since Matrigel, reconstituted BM material, was initially 
shown to be sufficient for acini formation. LN1 was found to reverse the polarity 
of LECs when added to COL gels, even in the absence of MECs. Moreover, in 
comparing LECs and MECs in the production of BM components, LN1 expression 
was lacking in LECs [98]. Thereby, MECs produce LN1 to induce the correct 
polarity of LECs in 3D COL1 gels. It remains to be shown whether desmosomes 
or LN1 are sufficient for polarity or whether both are required. Coordination of 
MEC functions is necessary to maintain normal breast function; accordingly, it is 
not surprising that MEC function is compromised in breast cancer, and the loss 
of the MEC population is universally associated with invasive breast cancer.  
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Tumour suppressive function of myoepithelial cells  
MEC location suggests they may influence tumour progression through inhibiting 
the invasion of tumour cells by acting as a physical barrier. In vitro and in vivo 
studies demonstrate that MECs exert a wider suppressive effect on tumour cells 
[99], exerting anti-proliferative [100], anti-invasive [78] and anti-angiogenic [101] 
in an autocrine- and paracrine manner [102]. This tumour suppressive phenotype 
was originally based on the ability of MECs to inhibit the growth and invasion of 
breast cancer cells in coculture assays in vitro and inhibit tumour growth in 
xenograft assays [101, 103]. The mechanisms specifically underlying the 
invasion of tumour cells are incompletely understood however, matrix 
degradation by matrix metalloproteinases (MMPs), in particular the gelatinase 
enzymes, have been implicated in invasion of multiple tumour types, including 
breast cancer. Therefore, it was suggested MECs modulate MMP activity to 
inhibit invasion. Jones and colleagues demonstrated coculture of primary normal 
MECs with breast cancer cells decreased MMP expression, specifically MMP2, 
MMP9 and MT1-MMP, in breast cancer cells was observed [78]. In this manner, 
conditioned media (CM) isolated from primary normal MECs inhibited the 
invasion of breast cancer cells in coculture assays in vitro, even in the presence 
of fibroblasts, which are known promoters of tumour cell invasion. This supports 
the notion that MECs induce a tumour suppressor effect through paracrine 
mechanisms [78]. Moreover, normal MECs constitutively express high levels of 
tissue inhibitor of metalloproteinase 1 (TIMP1) and maspin [102]. These 
proteinase inhibitors act by blocking the activity of the released enzyme rather 
than by inhibiting proteolytic enzyme synthesis [102]. In this way, MECs release 
paracrine factors that inhibit protease activity however, MECs may also exert anti-
invasive properties through direct modulation of tumour and stromal cell gene 
transcription, though these mechanisms are unclear [78]. This work 
demonstrates the dominance of MECs in tumour suppression, and this function 
is due to paracrine downregulation of MMP expression in tumour cells.  
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MECs also express a variety of recognised tumour suppressor proteins such as 
p63, p73 and maspin [76]. The ability of MECs to inhibit breast cancer cell growth 
and invasion may in part be attributed to their expression of maspin. 
Overexpression of maspin in the breast cancer cell line MDA-MB-435 resulted in 
inhibition of tumour growth, invasion and angiogenesis [104]. Subsequent studies 
revealed that MECs inhibited the growth through induction of growth arrest (G2/M 
status) in breast cancer cells [100]. In order to experimentally test the role of 
MECs in the inhibition of growth and invasion of tumour cells, an experimental 
model of DCIS that is reproducible is essential, as analysis of human tissues 
allows only for correlative studies. The MCF10A series is one of few human 
models of breast cancer progression, although it is likely to reflect basal subtype 
tumours. A derivative of MCF10A cells is the MCF10ADCIS.com (MCFDCIS) cell 
line xenograft model, which reproducibly gives rise to comedo DCIS-like 
structures; surrounded by a cell layer which shows positivity for MEC markers 
such as p63, and a BM rich in LN332, that spontaneously progress to invasion 
[105]. This xenograft model highly resembles human disease with respect to 
histopathology and natural history. Using this xenograft model and coinjection 
with normal MECs, and normal and tumour-associated fibroblasts, Hu and 
colleagues identified that normal MECs suppress tumour growth and progression 
to invasion. In contrast, normal and cancer-associated fibroblasts promoted 
progression to invasion [106]. This model supports the progression of DCIS into 
invasion is accompanied by the loss of normal MEC function. 
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Collective evidence suggests that MECs also function as autocrine tumour 
suppressors by their resistance to transformation and their tendency to transform 
to benign or low-grade myoepitheliomas when they do [107]. Angèle and 
colleagues identified differences in the DNA repair capacity of LECs and MECs, 
and this may contribute to the lower rate of transformation in MECs [108]. 
Moreover, myoepitheliomas are able to secrete and accumulate an abundant 
ECM composed of both BM and non-BM components, which suppressed breast 
cancer cell invasion compared to Matrigel [109, 110]. These myoepitheliomas 
produced ECM components including; COL, fibronectin (FN) and LN [110]. In 
addition, MECs secreted large amounts of proteinase inhibitors including maspin, 
TIMP1, protease nexin II and α1-antitrypsin, and many of these accumulated 
within the MEC-derived ECM [103, 109, 110]. Transwell invasion assays with 
these cell lines inhibited breast cancer cell invasion, partly by a maspin-
dependent mechanism. These observations suggest an anti-invasive property of 
the MEC-derived ECM, which likely contributes to their low-grade biological 
behaviour. The caveat to this study, is that these immortalised MEC lines were 
derived from benign and low-grade human myoepitheliomas of the salivary gland 
and breast, and therefore may not reflect the function of normal breast MECs in 
vivo. However, they were shown to maintain the expression of MEC-specific 
differentiation markers, including; maspin, SMA and CK14, even following 
prolonged passaging in vitro [109, 111].  
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Tumour promoting function of myoepithelial cells  
Correlating with the loss of the MEC layer in the transition of DCIS to invasion, 
studies have suggested that DCIS-MECs lose their tumour suppressive 
phenotype, and switch to promote breast cancer progression. Gene-expression 
profiles demonstrate that DCIS-MECs exhibit a phenotype distinct from normal 
MECs [80]. Consistent with gene-expression profiling, DCIS-MECs exhibit 
alterations in many of their normal markers, such as reduced expression of 
oxytocin receptor [80]. Functionally, tumour-derived MECs differ from their 
normal counterpart, and are unable to polarise LECs in 3D COL1 assays due to 
a loss of their ability to synthesis sufficient or functional LN1 [98]. Consistently, 
MECs present in breast cancer tissue demonstrated little or no expression of LN1 
[98]. This suggests that cancer-associated MECs are unable to transmit the 
necessary signals to induce the correct polarity of LECs. Such that DCIS-MECs 
demonstrate a loss in hemidesmosome formation, and thereby are unable to 
interact with the BM [112], and demonstrate an alteration in ECM isoform 
expression. A study by Adams and colleagues identified that normal MECs 
express a truncated form of tenascin-C (TNC) in contrast, DCIS-MECs upregulate 
the expression of exon 14 in TNC, which was associated with progression to 
invasion [113]. These data support the notion that the loss of normal MEC 
function in DCIS may play a key role in the progression to invasion however, the 
prognostic and functional relevance of such changes is not yet established. 
 
Work within our laboratory has identified alterations to DCIS-MECs including: de 
novo expression of the integrin αvβ6 and upregulation of FN. Expression of 
integrin αvβ6 was seen in a subset of pure DCIS and is almost universal in 
DCIS/IDC. Its presence is significantly associated with progression and 
recurrence. In vitro studies found integrin αvβ6 promoted breast cancer cell 
invasion via TGFβ-dependent upregulation of MMP9, suggesting altered MECs 
participate in the transition to invasion [114]. In a separate unpublished study, 
using gene-expression microarray analysis on laser dissected normal versus 
DCIS-MECs identified further changes, including significant upregulation of FN in 
DCIS-MECs as compared with their normal counterpart. Currently, the 
relationship between integrin αvβ6 and FN in DCIS-MECs is unclear. 
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1.4 INTEGRINS 
 
1.4.1 Classification of integrins 
Integrins are a family of adhesion receptors, mediating cell-cell and cell-matrix 
interactions through their extracellular domains, and cytoskeletal interactions 
through their intracellular domains. In this way, integrins derive their name from 
their ability to ‘integrate’ the external and internal cell environment [115]. Integrins 
are heterodimeric type I transmembrane proteins consisting of an α and β subunit 
[116]. Each subunit contains a relatively large extracellular domain, a single 
transmembrane domain (TMD) and a short cytoplasmic domain [116]. All three 
domains are required to regulate integrin activity. In humans, there are 18 α 
subunits and 8 β subunits, which non-covalently associate into 24 different 
receptors with different binding specificity and distribution [117]. Integrins are 
classified based on their binding properties to distinct, although partially 
overlapping, subsets of ligand including; COL, LN or RGD (Arg-Gly-Asp) amino 
acid sequences or based on their expression on leukocytes (Figure 2) [118]. 
 
Figure 2. Classification of integrins. In humans, the integrin family contains 24
heterodimers, composed of 18 a and 8 b subunits. Integrins are classified according to their
binding properties to ligands; collagen, laminins or RGD amino acid sequences, or according
to their expression on leukocytes. Figure 2 adapted from [118].
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1.4.2 Structure of Integrins 
 
Extracellular domain 
Integrin extracellular domains are relatively large structures (approximately 800 
amino acids) responsible for ligand binding. The extracellular domain of the α and 
β subunits are comprised of several subdomains organised into a globular ligand-
binding N-terminal head domain which sit on two C-terminal legs that connect to 
the TMD and cytoplasmic domain of each respective subunit (Figure 3) [119]. The 
extracellular domain of the α subunit forms the head, a thigh domain, and two 
calf domains; calf-1 and calf-2 [120, 121]. Half of α subunits contain an additional 
domain, known as the insertion (I)-domain [122]. The presence of the α I-domain 
represents an exclusive binding site for ligands. Within this domain is a conserved 
metal-ion dependent adhesion site (MIDAS) that binds to the divalent metal 
cations; calcium (Ca2+), magnesium (Mg2+) and manganese (Mn2+) required for 
ligand binding [123]. These integrin-binding sites in ligands all contain a critical 
residue D (Asp) which interacts with the metal cation to facilitate this interaction 
[124]. Specifically, ligand binding alters the coordination of the metal cation in the 
MIDAS and shifts the I-domain from a closed, inactive conformation to an open, 
active conformation which results in integrin activation [125]. The extracellular 
domain of the β subunit contains a an I-like domain (β1), a PSI 
(plexin/semaphorin/integrin) domain, a hybrid domain, four epidermal growth 
factor (EGF) domains; and a membrane proximal β tail domain (βTD) [124]. The 
βI domain allows integrins which lack the I-domain to bind ligands. The ligand 
interacts with a metal cation in the MIDAS within the β subunit and the propeller 
domain of the α subunit to result in integrin activation [124]. 
 
Transmembrane domain 
Integrin TMDs are single membrane-spanning structures (approximately 20 
amino acids). In inactive integrin heterodimers, the α and β subunits are tightly 
packed through GxxxG dimerisation motifs within the TMDs, thereby forming 
glycine-glycine interactions [126]. 
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Cytoplasmic domain 
Integrin cytoplasmic domains are relatively small structures (10 to 70 amino 
acids, with the exception of the β4 subunit which contains over 1000 amino acids) 
which lack enzymatic activity. Nonetheless, the cytoplasmic domains of integrins 
play a key role in their activity through recruitment of scaffolding proteins, that 
couple the ECM to the actin cytoskeleton, and adaptor proteins, that are involved 
in intracellular signalling [124]. β subunit cytoplasmic domains are highly 
homologous, while α subunit cytoplasmic domains are highly divergent except for 
a single conserved sequence. The conserved GFFKR (Gly-Phe-Phe-Lys-Arg) 
and HDR(R/K)E (His-Asp-Arg(Arg/Lys)Glu) sequences located in the membrane 
proximal region of the α and β subunit, respectively, are suggested to form a salt 
bridge between R (Arg) and D (Asp) from the α and β subunit, respectively [127, 
128]. This has been suggested to maintain integrins in the low-affinity, inactive 
state and its disruption may play a key role in the regulation of integrin activation. 
Within the β subunit cytoplasmic domain are two motifs; the membrane proximal 
NpxY motif and the membrane distal NxxY motif. These motifs represent 
recognition sequences for phosphotyrosine-binding (PTB) domains and serve as 
binding sites for integrin-binding proteins [129].  
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Figure 3. Structure of integrins. Integrins are formed by non-covalently associated a and b
subunits. Each subunit has an extracellular domain, a single transmembrane domain (TMD),
and a cytoplasmic domain. The extracellular domain of the a and b subunits are comprised
of several subdomains organised into a globular ligand-binding N-terminal head domain
which rest on two extended C-terminal legs that connect to the TMD and cytoplasmic
domain of each respective subunit. The extracellular domain of the a subunit consists of a
folded seven-bladed b-propeller that forms the head domain, a thigh domain and two calf
domains; calf-1 and calf-2. The extracellular domain of the b subunit consists of a hybrid
domain that connects to the I-like domain (b1) and a PSI (plexin/semaphoring/integrin)
domain, four epidermal growth factor (EGF) domains (E1, E2, E3 and E4), and a membrane
proximal b tail domain (bTD). Figure adapted from [118].
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1.4.3 Signalling mechanisms of integrins 
Integrins are adhesion receptors; the specific binding of the extracellular domain 
of integrins to ECM proteins or, to counter-receptors on adjacent cells in some 
cases, supports cell adhesion, which is crucial for embryonic development and 
tissue homeostasis. In addition to their physical role in adhesion, integrin-
mediated interactions on either side of the cell-surface are dynamically linked; 
such that there is bi-directional signalling between the extracellular environment 
and the intracellular cytoskeleton mediated by integrin cytoplasmic tails. Through 
binding to the cytoskeleton, integrins transduce signals from inside out of the cell, 
in order to regulate their affinity for extracellular ligand. They do this by 
undergoing conformational changes in their extracellular domains that occur in 
response to signals that impinge upon the integrin cytoplasmic tail. This process 
is known as inside-out signalling or integrin activation [116]. In turn, through 
binding to the ECM, integrins transduce biochemical and biophysical extracellular 
properties from outside in of the cell, in order to regulate cellular responses such 
as cell adhesion, polarity, proliferation, differentiation, migration and ECM 
remodelling [117, 118, 130]. This process is known as outside-in signalling  
(Figure 4) [116]. Inside-out and outside-in signalling require dynamic, and 
spatially and temporally regulated assembly and disassembly of multiprotein 
complexes that form around the cytoplasmic tails of integrins. While conceptually 
these signalling pathways are considered separate, they are closely linked. Such 
that, integrin activation can increase ligand binding, resulting in outside–in 
signalling [116]. Conversely, ligand binding can generate signals that cause 
inside–out signalling [130]. In this way, these dynamic signalling pathways allow 
cells to sense and adapt to the extracellular environment.  
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Inside-out signalling 
In inside-out signalling, integrins regulate their affinity for ligands by undergoing 
conformational changes in their extracellular domains. In the normal resting, low-
affinity, inactive state, integrin extracellular domains are unbound to ligands and 
exist in a bent conformation. Activation signals from within the cell induce the 
extension of the extracellular domain and stabilise the high-affinity, active 
conformation. This conformational change exposes the external ligand-binding 
site to which ligands bind, allowing the transmission of signals from outside in 
[131]. The TMD plays a key role in integrin activation; such that interactions 
between the TMDs of α and β subunits maintain integrins in an inactive 
conformation and disruption of these TMD interactions is essential for integrins 
to adopt the active conformation [132]. Most integrin β subunits contain a 
positively charged K (Lys) or R (Arg) amino acid residue near the TMD. These 
positively charged amino acid residues ‘snorkel’ near negatively charged 
phospholipid head groups, and are thereby membrane-embedded. A stable αβ 
TMD association requires the simultaneous formation of two discrete assemblies, 
an inner and outer membrane clasp. Mutation to K/R residues causes the 
dissociation of αβ TMD clasp interactions and integrin activation [133]. In this 
manner, snorkelling residues in TMDs help maintain membrane-embedding, 
thereby regulating integrin activation state. Integrin cytoplasmic domains also 
play a key role in the regulation of integrin activation, in particular through 
interaction with the anchoring proteins - talin and kindlin. Talin and kindlin both 
bind to the β subunit cytoplasmic domain, although to distinct regions; talin binds 
to the membrane proximal NpxY motif [129], while kindlin binds to the membrane 
distal NxxY motif [135]. Together, they cooperate to regulate the affinity of 
integrins. Integrin activation follows the simultaneous binding of talin to the β 
subunit and actin cytoskeleton. However, to achieve complete integrin activation, 
the cooperation of kindlin is essential [135]. Furthermore, the synergistic effect of 
talin and kindlin on integrin activation is enhanced by the binding of vinculin to 
talin. Vinculin leads to the conformational transition of integrins to their active 
state capable of high-affinity interactions with ECM ligands [136]. In contrast to 
promoting integrin activation, on the basis of the existing data discussed here, it 
appears integrin activation may be prevented or diminished by interfering with 
TMD interactions and/or competition with talin and kindlin binding. 
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Outside-in signalling 
In outside-in signalling, integrins bind to an ECM ligand to transduce signals into 
the cell. In this way, cells are connected to the extracellular microenvironment 
through integrins at focal adhesions (FAs), to translate mechanical signals from 
the outside into biochemical signals, a process known as mechanotransduction 
[137]. Ligation to an ECM ligand induces integrin clustering. Integrin clustering 
drives the formation of FAs, followed by phosphorylation of focal adhesion kinase 
(FAK) at tyrosine 397, to stabilise FAs and drive activation of RhoGTPase-
dependent actomyosin-based cell contractility and cytoskeleton reinforcement 
[122]. Consequently, cell-generated contractile forces transmitted through 
integrins can remodel the surrounding matrix and alter matrix stiffness. This 
process is known as mechanoreciprocity [124]. In normal tissue homeostasis, this 
reciprocal interaction between cell contractility and matrix stiffness is balanced. 
Such that, cells sense external forces via integrin adhesions and respond through 
actomyosin contractile forces that are equal to that of the surrounding matrix to 
maintain normal tissue architecture. An imbalance in these reciprocal force 
interactions between the cell and matrix can result in pathological conditions such 
as fibrosis and cancer. These pathological conditions are associated with 
progressive matrix stiffening. Studies have shown that matrix stiffness 
strengthens integrin-cytoskeletal linkages and integrin clustering, as well as 
integrin expression, activity and FA formation. These changes have been shown 
to enhance cell growth and proliferation through integrin-mediated mechanisms 
[137]. Together, these bidirectional signalling events and the repertoire of 
integrins on a cells surface, integrins can dictate ECM sensing and cellular 
response. Consequently, disruption to these may promote cancer development 
and progression. 
 
ab
Intracellular
Extracellular
a)
a
b
Inactive
(bent)
Active
(extended)
Active
(clustered)
b) c)
Talin
Kindlin
‘Inside-out’
signalling
‘Outside-in’
signalling
Focal adhesion complex:
talin and kindlin
Signalling 
pathway 
activation
Actin 
cytoskeleton 
assembly
Figure 4. Signalling mechanisms of integrins. a) In the inactive resting state, integrins
exist in a bent conformation and the TMD and cytoplasmic domain of the a and b subunits
are closely associated. b) Integrins are activated by the binding of the cytoplasmic proteins,
talin and kindlin, to the integrin cytoplasmic domain a process known as inside-out signalling.
This leads to the separation of the TMD and cytoplasmic domain of the a and b subunits,
and extension of the integrins extracellular domain. Ligand binding can occur in this
conformation. c) Integrin binding to ligand results in the clustering of integrins at the cell
membrane. This transmits intracellular signals into the cell, a process known as outside-in
signaling. This leads to formation of focal adhesions (FAs), which are essential for
reorganisation of the actin cytoskeleton and activation of downstream signaling to control
various cellular responses. Figure adapted from [129].
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1.4.4 Expression of integrins 
Mechanisms regulating integrin expression at the cell surface include regulation 
of protein levels by transcriptional or post-transcriptional mechanisms, and 
mobilisation from preexisting intracellular stores [138]. Integrins are expressed in 
a cell-specific manner, and the expression of certain integrins is restricted to cells 
of a particular lineage, such as the expression of integrin β2 is restricted to 
leukoctyes [117]. The expression of integrins is regulated at the transcriptional 
level, such that each subunit is encoded by a different gene [138]. The expressed 
proteins then compete for compatible pairs in the endoplasmic reticulum, and 
only intact heterodimer αβ integrins are expressed on the cell surface [139, 140]. 
Excess unpaired α or β subunits are retained in the endoplasmic reticulum and 
degraded [140]. This mechanism is dynamically regulated such that the 
composition of integrins at the cell surface can be rapidly altered [140]. The 
number of integrins expressed at the cell surface often does not correlate with 
the expression levels of integrins as the production of α and β subunit binding 
partners may be unbalanced [141], such as αv and β1 subunits are produced in 
abundance relative to other subunits [142], which may be due to their ability to 
pair with multiple different subunits. For example, integrin αv can be found on the 
cell surface paired to any one of five different β subunits, and integrin β1 with any 
one of twelve different α subunits [118]. Each integrin heterodimer is also subject 
to post-translational modifications, which may alter their transport to the cell 
surface or alter their stability [138]. The repertoire of integrins on the cell surface 
is also altered in response to specific environmental cues [138]. Together, these 
alterations to integrin expression allows cells to respond dynamically to 
microenvironmental changes. 
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In the normal breast, integrin expression can vary however, a set of integrins are 
normally expressed and are restricted to either LECs or MECs, or their 
expression may be shared [143]. In general, MECs have higher levels of integrin 
expression as they interact with the surrounding ECM [144]. The α subunits most 
abudantly expressed by LECs and MECs include α1, α2, α3, α5, αv, α6 and α9 
while the expression of α1, α5, αv and α9 are restricted to MECs [94, 144, 145]. 
The β1 and β4 integrin subunits are expressed in both cell types, while the β3 
subunit exhibits a more restricted expression pattern [94, 144, 146]. Therefore, 
LECs and MECs in the breast are capable of assembling at least eight functional 
integrin receptors including two COL receptors (α1β1, and α2β1), three LN 
receptors (α3β1, α6β1, and α6β4) and four integrins (αvβ1, αvβ3, α5β1 and 
α9β1) which recognise RGD sequences present in ECM proteins [118]. 
Moreover, integrin expression may be polarised to distinct membrane surfaces. 
For example, α6β4 is predominantly expressed on the basal surface of MECs as 
it functions to connect MECs to the LN-rich BM through hemidesmosomes [94]. 
 
In cancer, integrin expression profiles appear to be altered in comparison to their 
normal counterparts [147-150]. In general, tumour cells demonstrate a loss of 
integrins involved in polarity and differentiation; and overexpress integrins 
involved in proliferation and invasion [143, 151]. These changes in integrin 
expression are complex and depend on tissue type, histological subtype, and 
stage [151]. Changes in the expression pattern of integrins in breast cancer have 
been reported in several studies. On one hand, α6 [152], β4 [153] and αv [154] 
are generally overexpressed in breast cancer cells, while on the other hand, the 
expression of α2β1 is lost in breast cancer [155]. Whilst these studies focus on 
alterations in the integrin repertoire on tumour cells, such changes also occur on 
stromal cells. It is likely that features of tumour cells influence the ability to interact 
with stromal cells through alterations to the integrin repertoire on these cells, 
which may be an important determinant of cancer behaviour. Work in our 
laboratory identified the de novo expression of the integrin αvβ6 by DCIS-MECs. 
It was shown that the expression of integrin αvβ6 by MECs promoted breast 
tumour cell invasion in a TGFβ-dependent upregulation of MMP9 [114]. 
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1.4.5 Function of integrins 
 
Adhesion 
The adhesion of cells to the matrix via integrins plays a major role in tissue 
formation, cellular migration and induction of adhesion-mediated signalling. 
Integrin-mediated adhesions are complex structures, with over ~150 associated 
molecules, termed the integrin adhesome complex (IAC) [158]. These adhesions 
are categorised as ‘classical’ integrin-mediated adhesions including; focal 
complexes (FXs), FAs, and fibrillar adhesions (FBs); podosomes and 
invadosomes; and hemidesmosomes  [159]. The molecular steps involved in the 
formation of these ‘classical’ integrin-mediated adhesions, involves the 
sequential formation of FXs, FAs and FBs [160]. FXs are small, dynamic, dot-like 
adhesions, which form under the protrusive lamellipodium of migrating cells and 
mediate signals that promote actin polymerisation [160]. These are transient 
structures which may disassemble and new FXs are assembled in front of them 
as the leading edge of the cell advances [160]. These cycles of FX assembly and 
disassembly persist as long as the lamellipodium advances. When the lamella 
retracts, or stops protruding, FXs disassemble and a subset of these adhesions 
grow and develop into FAs [159]. This transformation is accompanied by growth 
of the adhesion site and changes in its molecular composition [159]. Such that 
the conversion of FXs to FAs is characterised by the recruitment of zyxin to the 
membrane and the concomitant assembly of an actin bundle [161]. This transition 
depends on actomyosin-driven contractility, which applies force at cell–matrix 
adhesions [161]. The disassembly of FAs often occurs at the cell trailing edge. 
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This process involves microtubule-mediated destabilisation of the adhesions and 
plays an important role during cell migration [162]. Another mechanism leading 
to loss of FAs involves the transformation of these adhesion sites into stable FBs. 
FBs are elongated adhesions located around the cell centre, where integrin α5β1 
binds to FN fibrils [163]. FBs differ from classical FAs as the primary integrin 
receptors are integrin α5β1 and integrin αvβ3, respectively [164]. In this way, 
different integrins promote distinct modes of cellular migration and cells may alter 
their motility by expressing different integrins. FAs and FBs also differ in the 
composition of the cytoplasmic complex. Such that, FAs contain high levels of 
phosphotyrosine but display only low levels of tensin; FBs, on the other hand, 
contain none or little phosphotyrosine but high levels of tensin [164]. Highly 
migratory and invasive cells form specialised types of integrin-mediated 
adhesions; podosomes and invadopodia [159]. These differ in that they are not 
associated with large actin filament bundles and instead contain an actin-rich 
core, in which the actin polymerising machinery and actin regulatory proteins 
rapidly drive actin polymerisation to drive membrane protrusion [165]. In 
podosomes, this core is surrounded by a ring structure composed of scaffolding 
and signalling proteins, and form in immune cells and osteoclasts [166], while 
invadosomes, contain actin-rich protrusive structures, and form in invasive 
tumour cells [165]. In contrast, hemidesmosomes are non-migration-related 
adhesions [167]. In these adhesions the cytoplasmic tail of the β4 subunit 
connects the integrin α6β4 to the keratin cytoskeleton via plectin, rather than the 
adhesion molecules associated with other cell-matrix interactions [168]. 
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Polarity 
Integrin-mediated adhesions play a key role in tissue formation and cellular 
migration, which require correct cellular polarity [169]. Loss of polarity, and 
subsequent tissue disorganisation, and altered cellular migration are key features 
of tumours [169]. In tissues, at the lateral surface, tight and adheren junctions 
connect adjacent epithelial cells, whilst at the basal surface, integrins connect 
epithelial cells to the ECM to establish cellular polarity [169]. Initially, individual 
contact naïve cells have no surface polarity and express apical and basolateral 
surface proteins at all surfaces [170]. These contact naïve cells adhere to the 
surrounding collagenous ECM via integrin β1 to form initial cell-matrix interactions 
[171]. Maturation of these interactions initiates distinct membrane targeting and 
endocytic recycling pathways to direct proteins involved in apical and basolateral 
connections to the correct surface [172]. This interaction acts as a signal to 
orchestrate the polarised secretion and assembly of LNs forming the epithelial 
cell-specific BM, and also contributes to the asymmetric targeting of intracellular 
polarity protein complexes; Crumbs, Par, and Scribble [173]. The basally 
assembled BM, together with polarity complexes reinforces the alignment of 
cytoskeletal networks and thereby polarised organisation of the membrane 
trafficking networks [174]. Together, these mechanisms create a fully polarised 
epithelial cell. In cellular migration, integrins adhere to the ECM to form a leading 
edge that protrudes forward, whilst these adhesions disassemble at the trailing 
edge of the cell [159]. Currently it is unclear how the spatial organisation of 
signals that control polarity of a migrating cell is established, but similarly 
concentration of distinct protein complexes at sites of integrin-mediated 
adhesions at the asymmetrical edges of migrating cells, is likely [169]. 
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Migration 
Cell migration is a dynamic process, in which intracellular and extracellular 
signals merge to produce a coordinated response [175-177]. The migratory cycle 
consists of well-defined, integrated steps that include: front-to-back polarisation 
in response to extracellular cues, which are often chemotactic; membrane 
extension by protrusion and adhesion formation at the leading edge of the cell; 
cell-body translocation; adhesion disassembly; and retraction at the trailing edge 
of the cell [178]. Integrin-mediated adhesions serve two major functions in the 
migration cycle. It generates traction at the leading edge for cell-body 
translocation by linking the extracellular substratum to actomyosin filaments, and 
it organises the signalling networks, in particular Rho GTPases, that regulate 
actin and actomyosin polymerisation and organisation [159]. In this way, 
adhesion formation and actin polymerisation are linked. Adhesions provide 
nucleation points that support actin polymerisation; conversely, actin 
polymerisation determines the rate of adhesion assembly and potentially 
nucleates adhesions that contain activated integrins [179]. Adhesions and actin 
are physically linked, and this link coordinates adhesion assembly and 
disassembly, and the processes they regulate [178]. While integrin-dependent 
migration is important, integrin-independent mechanisms of migration also exist 
in some cell types, such as neuronal cells in the brain and tumour cells, under 
certain conditions [178]. 
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Extracellular matrix remodelling 
The ECM serves as a substratum to which cells attach via cell–matrix adhesions, 
but it is also initially constructed and remodelled by such adhesions. Integrins 
participate in the assembly of various ECM components. In BM synthesis, integrin 
β1 cooperates with the dystroglycan receptor to promote synthesis and 
polymerisation of LN chains into a multivalent network which subsequently 
incorporates COL and other components [180]. In FN matrix synthesis, integrin 
α5β1 cooperates with syndecans to promote the polymerisation of FN fibrils into 
a fibrillar network [181]. Integrins also contribute to ECM remodelling through 
regulating the expression, localisation, activation and activity of matrix-degrading 
proteases, in particular MMPs [130, 182]. Integrin ligation to the ECM can activate 
MMP synthesis, and thereby expression. Some αV [183-187] and β1 [188, 189] 
integrins have been shown to promote the expression of several MMPs. For 
example, integrin αvβ6 has been shown to promote the expression of MMP2 and 
MMP9 in cancer [183-186]. In invasive breast cancer cells, increased expression 
of integrin αvβ3 upregulates MMP2 expression following integrin binding to RGD 
peptides [187]. The localisation of MMPs also dictates their function. Localisation 
to cell membrane through the interaction with integrins has been demonstrated 
for multiple MMPs, including binding of MMP2 and MMP9 to integrin αvβ3 [190, 
191]. Specifically, MMP2 is recruited to the cell surface via binding to integrin 
αvβ3, which results in the ECM degradation to promote cancer cell invasion [190]. 
MMP activation is also regulated by integrins. MMPs are initially synthesised as 
inactive zymogens known as pro-MMPs, which is then converted into an active 
protease [182]. For example, integrin αvβ3 promotes cancer cell invasion through 
activating MMP2 [151]. MMPs are also inhibited by integrins in order to prevent 
excessive ECM degradation. A study by Brooks and colleagues found the 
hemopexin domain of MMP2 in association with integrin αvβ3 in cancers. This 
domain competed with MMP2 binding to integrin αvβ3, serving as an inhibitor of 
MMP2 activity to prevent excess angiogenesis [192]. Together, integrins play a 
diverse role in cellular functions. 
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1.5 TRANSFORMING GROWTH FACTOR-β 
 
1.5.1 Isoforms of TGFβ 
Transforming growth factor-β (TGFβ) is a multifunctional cytokine involved in 
embryogenesis, development and normal tissue homeostasis as it effects the 
regulation of proliferation, differentiation, apoptosis, inflammation, ECM 
production, integrin expression and protease activity [193]. TGFβ consists of a 
group of three isoforms; TGFβ1, TGFβ2 and TGFβ3, which belong to a 
superfamily that also includes; activins, inhibins, bone morphogenic proteins 
(BMPs), growth and differentiation factors (GDFs) and anti-Mullerian hormone 
(AMH) [194]. TGFβ’s functional diversity may be attributed to several features: 
three different isoforms of TGFβ exist, and all are secreted in a latent form either 
bound or unbound to a latent TGFβ binding protein (LTBP); three of four different 
isoforms of LTBP bind to latent TGFβ, and function to facilitate its secretion and 
localisation to the ECM; multiple mechanisms exist to liberate mature TGFβ from 
the latent complex and downstream signalling of TGFβ is complex, including both 
canonical and non-canonical pathways. Therefore, the different expression of 
TGFβ and LTBPs, combined with different activators, result in multiple 
mechanisms regulating TGFβ’s bioavailability [195]. 
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1.5.2 Synthesis and secretion of TGFβ 
TGFβ isoforms are synthesised as precursor proteins that are proteolytically 
processed. The signal peptide is removed from the pre-pro-TGFβ during transit 
through the ER. Two pro-TGFβ molecules dimerise via disulphide-bond 
formation. Following dimerisation, another cleavage occurs by the convertase 
family of endoproteases [196]. These proteases cleave the precursor into an N-
terminal propeptide homodimer, also known as latency associated peptide (LAP), 
and C-terminal mature growth factor homodimer. After cleavage, LAP and mature 
TGFβ remain associated via non-covalent bonds, this assembly is known as the 
small latent complex (SLC) [196]. LAP shields the receptor-interacting epitopes 
in mature TGFβ, maintaining TGFβ in its latent form [197]. LAP of the SLC can 
covalently attach to a LTBP via disulphide-bond formation, this assembly is 
known as the large latent complex (LLC) [198]. Specifically, LTBP1 and 3 
associate with all three LAP-β isoforms, whereas LTBP4 associates with LAP-β1 
and LTBP2 does not bind to any LAP-β isoforms. Most cell types secrete TGFβ 
as part of the LLC however, some cells secrete the SLC without bound LTBP 
[199]. In turn, LTBP1 and 4 may be secreted free of the SLC, much like LTBP2 
which cannot interact with the SLC, suggesting that these LTBPs perform roles 
independent of TGFβ. LTBP3 on the other hand, is not secreted unless bound to 
the SLC [200]. Following secretion, LTBP then facilitates the localisation of the 
LLC in the ECM through interactions with various ECM proteins (Figure 5) [201]. 
Specifically, LTBP3 and LTBP4 are dependent on fibrillin (FBN), while LTBP1 is 
dependent on FN for incorporation into the ECM [202]. TGFβ is sequestered in 
the matrix until required.  
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Figure 5. Synthesis and secretion of TGFb. TGFb is synthesised as a precursor protein
that is proteolytically processed. The signal peptide is removed from pre-pro-TGFb. Two pro-
TGFb molecules dimerise. Following dimerisation, another cleavage occurs. Pro-TGFb is
cleaved into the propeptide domain, also know as the latent associated peptide (LAP), and
mature TGFb. These homodimers remain associated to form the small latent complex
(SLC). LAP of the SLC then associates with a LTBP (structure of LTBP1 shown) to form the
large latent complex (LLC), allowing TGFb to be secreted from the cell. LTBP of the LLC
then localises latent TGFb to the extracellular matrix (ECM). Figure adapted from [195].
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1.5.3 Activation of TGFβ  
For latent TGFβ to be activated and function at adjacent or neighbouring cells, 
TGFβ must be released from LAP. An indirect mechanism of TGFβ activation 
involves the liberation of the LLC from the ECM. Release of the LLC can be 
initiated with the displacement of LTBP from the ECM. Such that, the release of 
the LLC can be initiated with the displacement of LTBP bound to FBN [203]. The 
degradation of FBN by proteolytic enzymes, such as elastase, releases 
fragments of FBN, including a fragment which binds to FBN and displaces LTBP. 
This releases the LLC from FBN and contributes to localised TGFβ activation 
[203]. Degradation of ECM components by several proteolytic enzymes, 
including; plasmin and thrombin, releases the LLC from the ECM [204]. Cleavage 
of LTBP1 occurs in a sensitive hinge region, in this way an N-terminal fragment 
remains bound to the ECM, whilst the remaining LLC is released. BMP1-like 
MMPs were shown to cleave LTBP1 at two specific sites in the hinge region to 
release the LLC and facilitate subsequent MMP-dependent LAP cleavage [205]. 
Through these mechanisms, proteolysis indirectly activates TGFβ through ECM 
digestion, releasing truncated LLCs which may be further processed to release 
active TGFβ [195]. 
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A direct mechanism of TGFβ activation involves targeting LAP (Figure 6) [204]. 
Activation can occur through proteolytic release of active TGFβ through cleavage 
of LAP by proteases, such as MMP2, MMP9, MMP13 and MMP14 [204]. Another 
important mechanism of TGFβ activation is via integrins. LAP of TGFβ1 (LAP-β1) 
and TGFβ3 (LAP-β3), but not LAP of TGFβ2 (LAP-β2), contain an RGD motif 
[195]. Several integrins including all five αv integrins, as well as α8β1 and α5β1 
have been shown to interact with the RGD-containing LAPs. Specifically, LAP-β1 
binds the RGD-binding integrins αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α8β1, and 
LAP-β3 binds αvβ6 and αvβ8 [206]. Through this interaction, integrins induce a 
conformational change that leads to the liberation or exposure of active TGFβ 
[207-209]. This mechanism depends on the binding of the integrin to LAP via the 
RGD-motif and simultaneously to the cytoskeleton via the β subunit cytoplasmic 
domain, which then releases active TGFβ by LAP conformational modification 
[209]. Integrins αvβ1, αvβ5 [209] and αvβ6 [207, 210] have been shown to 
activate TGFβ in this way. The binding of LAP to the ECM through interactions 
with LTBP is a structural precondition for mechanical activation by integrins [207, 
209, 211]. Specifically, activation of TGFβ by integrin αvβ6 is resistant to MMP 
inhibitors and requires a direct interaction of FN with LTBP1 which targets the 
LLC to the ECM [212]. As a result, TGFβ is inefficiently activated in cells which 
lack FN or the FN receptor, integrin α5β1. In contrast, activation of TGFβ by 
integrin αvβ8 is sensitive to MMP inhibitors as it requires MMP14. This 
mechanism depends on the binding of integrin αvβ8 to LAP-β1 and 
simultaneously to MMP14, which then releases active TGFβ by proteolytic 
cleavage of LAP [213]. The β8 subunit has a cytoplasmic domain is distinct, such 
that it does not interact with the cytoskeleton, and cells expressing a β8 mutant 
protein lacking the cytoplasmic domain retain the ability to activate TGFβ [206, 
213]. It remains to be identified if other integrins active TGFβ in a similar manner. 
 
Figure 6. Activation of TGFb. a) Activation of TGFb can occur through proteolytic release
of mature TGFb through cleavage of LAP by proteases, including MMPs. b) Activation of
TGFb can also occur through conformational modification of LAP that leads to the release or
exposure of mature TGFb. This mechanism requires the localisation of the LLC to the ECM,
the binding of the integrin to LAP via the RGD-motif and simultaneously to the cytoskeleton
via the b subunit cytoplasmic domain, which then releases active TGFb from LAP by
conformational modification induced by tension. c) Activation of TGFb by integrin avb8
requires the binding of avb8 to LAP1 and simultaneously to MMP14, which then releases
active TGFb by proteolytic cleavage of LAP. Figure adapted from [204].
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1.5.4 Signalling pathways of TGFβ 
 
Canonical signalling pathways of TGFβ 
All TGFβ isoforms function through the same signalling pathways (Figure 7) [214]. 
In some cells, TGFβ binds to a transmembrane proteoglycan, known as type III 
TGFβ receptor (TGFβRIII), which promotes presentation of TGFβ to type II TGFβ 
receptor (TGFβRII). In other cells, TGFβ binds to directly to TGFβRII, a dimeric 
transmembrane protein with a constitutively active and phosphorylated 
serine/threonine kinase in the cytoplasmic domain [215]. TGFβ-bound TGFβRII 
then recruits type I TGFβ receptor (TGFβRI), a dimeric transmembrane protein 
with an inactive serine/threonine kinase [216]. The formation of this heterodimeric 
receptor complex leads to the phosphorylation and activation of TGFβRI by the 
constitutively active TGFβRII [217]. Active TGFβRI then phosphorylates serine 
residues in receptor-regulated SMADs, (R-SMADs); SMAD2 and SMAD3. This 
phosphorylation exposes the nuclear localisation signal (NLS) in the R-SMAD, 
and permits the binding of importin β to the NLS [218]. Simultaneously, a complex 
containing two molecules of R-SMAD, associates with a common mediator SMAD 
(Co-SMAD, SMAD4) [214]. The bound importin β mediates the translocation of 
this complex to the nucleus [214]. After importin β dissociates in the nucleus, the 
SMAD complexes bind to specific CAGA nucleotide repeats, known as the SMAD 
binding element (SBE) [219]. These SMAD complexes have a weak binding 
affinity for the SBE, and therefore DNA-binding transcription factors are required 
to regulate such interactions [220]. SMADs and associated cofactors bind in 
concert to recognition sites on DNA, allowing specific selection of the targeted 
gene and therefore, TGFβ-mediated transcription [221]. 
 
Non-canonical signalling pathways of TGFβ 
In addition to SMAD-mediated canonical signalling, other SMAD-independent 
non-canonical signalling pathways may also be activated by TGFβ [214, 222]. 
These pathways bypass SMAD signalling and activate p38, JNK, Ras-ERK, 
PI3K-Akt, and small GTPases such as RhoA and Cdc42, among others [223, 
224]. Through these pathways, TGFβ controls the transcription of many genes, 
including; ECM proteins, integrins and proteases [225].
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Figure 7. Signalling pathways of TGFb. Canonical TGFb signalling is initiated through the
phosphorylation of TGFbRI by TGFbRII following ligand binding. TGFbRII may bind directly
to TGFb or indirectly through presentation by TGFbRIII. Active TGFbRI then induces the
phosphorylation of the receptor-regulated SMADs (R-SMAD); SMAD2 and SMAD3, which
transmit TGFb signals to the nucleus by association with the common mediator SMAD (Co-
SMAD, SMAD4) and binding to specific CAGA nucleotide repeats to control the
transcriptional activation or repression of these genes. Non-canonical TGFb signalling
bypasses SMAD proteins and includes activation of: MAPK; PI3K-AKT; RHOA and other
pathways. Figure adapted from [238].
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Regulation of signalling pathways of TGFβ 
TGFβ signalling is regulated in many ways (Figure 8) [219]. Presentation of R-
SMADs to the active TGFβR complex is promoted by the SMAD2 anchor for 
receptor activation (SARA), leading to the promotion of SMAD2-mediated TGFβ 
signalling [226]. In contrast, R-SMADs are sequestered from the TGFβR by a 
transmembrane TGFβ-inducible protein (TMEPAI), preventing their 
phosphorylation [227]. TMEPAI also sequesters phosphorylated R-SMADs, 
preventing the formation of the R-SMAD/Co-SMAD complex [227]. Activated R-
SMADs are also counteracted by phosphatases [228], or by ubiquitin-mediated 
degradation [229, 230]. In addition, inhibitory SMADs (iSMADs), SMAD6 and 
SMAD7 are transcriptionally induced upon BMP and TGFβ signalling [231]. While 
SMAD6 mainly inhibits BMP signalling [232], SMAD7 inhibits both BMP and 
TGFβ signalling. Mechanistically, SMAD7 can inhibit TGFβ signalling by 
interacting with the active TGFβRI to prevent the phosphorylation of R-SMADs or 
by inhibiting the formation of the R-SMAD/Co-SMAD complex [233]. In addition, 
SMAD7 may target the TGFβR complex for ubiquitin-mediated degradation. In 
this manner, SMAD7 recruits SMAD ubiquitin regulatory factors (SMURF1 and 
SMURF2) to the activated TGFβR complex, which leads to the ubiquitination of 
SMAD7 and results in both SMAD7 and receptor degradation [234]. Receptor 
internalisation is another essential mechanism in regulating TGFβ signalling 
[235]. TGFβRs can be constitutively internalised by clathrin-dependent or 
clathrin-independent mechanisms [235]. TGFβR internalisation via clathrin-
dependent endocytosis into EEA1-positive early endosomes (EE), where SARA 
is localised, promotes TGFβ signalling [235-237]. Here, the TGFβR can be 
recycled back to the plasma membrane for further signalling. In contrast, TGFβR 
internalisation via clathrin-independent endocytosis into caveolin-positive 
compartments, where the SMAD7/SMURF complex is localised, leads to the 
inhibition of TGFβ signalling [235]. In this manner, segregation of TGFβRs into 
these distinct endocytic compartments regulates signalling and receptor turnover, 
however the mechanisms regulating receptor segregation are unknown. 
 
Figure 8. Regulation of signalling pathways of TGFb. a) Transmembrane TGFb-inducible
protein (TMEPAI) inhibits TGFb signalling by sequestering R-SMADs from the active TGFbR
complex to prevent their phosphorylation or by binding to phosphorylated R-SMADs to
prevent their interaction with Co-SMAD. b) Inhibitory SMAD (SMAD7) inhibits TGFb
signalling by interacting with the active TGFbR complex to prevent R-SMAD phosphorylation
or by inhibiting the formation of the R-SMAD/Co-SMAD complex. c) SMAD7 may also target
the TGFbR complex for ubiquitin-mediated degradation by recruiting SMAD ubiquitin
regulatory factors (SMURFs) to the active TGFbR complex. The binding of SMAD7/SMURF
to the TGFbR complex leads to internalisation via clathrin-independent endocytosis into
caveolae-positive compartiments. SMURFs ubiquitinate (Ub) SMAD7 and TGFbR complex,
resulting in their degradation by lyososomes. d) SMAD2 anchor for receptor activation
(SARA) promotes the presentation of R-SMADs to the active TGFbR complex, facilitating
their phosphorylation at the plasma membrane. TGFbR may be internalised via clathrin-
dependent endocytosis into early endosomes, where SARA is localised, to promote TGFb
signalling. From here the TGFbR complex can then be recycled back to the plasma
membrane. Figure adapted from [227, 235].
a) TGFb
TGFbR complex
c)
P
d)
TMEPAI
P
R-SMAD Co-SMAD
b)
P
SMAD7
SARA
P
P
P P
P
SMURF
P
P
P
P
66
67 
 
1.5.5 Function of TGFβ  
In cancer, TGFβ can act paradoxically as both a tumour suppressor and tumour 
promoter [238]. At early stages of cancer development, TGFβ acts directly on 
tumour cells to suppress proliferation and activate apoptosis. With progression, 
however, TGFβ switches to stimulate the later stages of cancer progression 
through pleiotropic activities on both tumour and stromal cells. In this manner, 
TGFβ promotes the proliferation, survival, migration and invasion of tumour cells, 
while promoting angiogenesis, inflammation and fibroblast activation in the 
stroma [238]. The cues that drive the tumour suppressor and tumour promoter 
roles of TGFβ, as well as the switch between these phenotypes is not well known.  
 
Tumour suppressive functions of TGFβ 
The tumour suppressive functions of TGFβ are demonstrated by the disruption to 
components of the TGFβ signalling pathway in several cancers. Commonly, 
TGFβRII and SMAD4 are inactivated through mutation and LOH. TGFβRII-
inactivating mutations are frequently found in colon cancers that are associated 
with microsatellite instability (MSI) [239]. TGFβRI-inactivating mutations are less 
frequent; however, they been observed in pancreatic, ovarian and breast cancers 
[240-242]. Decreased SMAD4 expression has been found in various cancers, 
including pancreatic, colorectal and head and neck cancers [243]. These studies 
provide evidence that TGFβ signalling pathways may function as tumour 
suppressive, and cancers must evade these pathways in order to progress [244]. 
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Cytostatic mechanism. TGFβ exerts cellular cytostatic effects, and functions 
mechanistically to inhibit cell cycle progression through arrest in G1 phase 
through two mechanisms: mobilisation of cyclin-dependent kinase (CDK) 
inhibitors such as p15 (INK4B) and p21 (WAF1), and suppression of c-Myc. The 
expression of p15 and p21 are induced by SMAD3/SMAD4 complexes with FoxO 
and Sp1 transcription factors [245-247]. p15 functions to inhibit cell cycle 
progression in the late G1 phase by interacting with CDK4/6 and preventing their 
interaction with cyclin D [248]. Consequently, the CDK inhibitor p27 is relocated 
from cyclin D-CDK4 complexes to interact with and inhibit cyclin E-CDK2 
complexes [248]. p21 also functions to inhibit cyclin E-CDK2 complexes [248]. 
The inactivity of these CDK complexes prevents phosphorylation of pRb, which 
mediates progression through G1 into S phase [249]. Simultaneously, with the 
activation of CDK inhibitors, TGFβ functions to repress the c-Myc oncogene that 
promotes cell proliferation. c-Myc is a transcription factor that may activate or 
repress gene transcription; such that, it inhibits the transcriptional activation of 
p15 and p21 [250-252]. In this manner, TGFβ induces cell cycle arrest in G1 and 
thereby, prevents cell proliferation [253]. 
 
Proapoptotic mechanism. TGFβ can also induce apoptosis, however, the 
mechanisms remain poorly characterised. Candidates that contribute to the 
proapoptotic functions of TGFβ include; death receptor FAS [254], growth arrest 
and DNA damage inducible 45β (GADD45β) [255], proapoptotic effector BIM 
[256] and death-associated protein kinase (DAPK) [257].  
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Tumour promoting functions of TGFβ 
TGFβ is also known to function as a tumour promoter. While inactivating 
mutations in components of the TGFβ signalling pathway is one mechanism to 
evade its tumour suppressive effects, the majority of cancers do not exhibit such 
mutations and retain a functional signalling pathway [258]. Analysis of clinical 
tumour samples revealed that TGFβ signalling is strongly implicated in cancer 
progression. Such that increased TGFβ1 expression by tumour cells correlates 
with colorectal and prostate cancer progression [259, 260]. Positive TGFβ1 
immunostaining also correlates with metastases in colorectal, prostate and breast 
cancers [260-262]. Moreover, TGFβ1 staining is stronger in invading local lymph 
node metastases than in the primary tumour sites in colorectal and breast 
cancers [263, 264]. These studies provide evidence that excessive TGFβ 
signalling is a prerequisite for cancer progression.  
 
Proinvasive mechanism. TGFβ can promote tumour cell invasion and 
metastasis. For tumour cells to migrate to metastatic sites, they must lose their 
epithelial characteristics, such as cellular polarity and cell-cell interactions, in 
favour for mesenchymal characteristics, such as increased motility; a process 
known as epithelial-to-mesenchymal transition (EMT) [265]. The identification of 
TGFβ as an inducer of EMT was initially demonstrated in vitro. Treatment of 
normal mammary epithelial cells with TGFβ induced a morphological change, 
such that their cell shape was altered from cuboidal to an elongated spindle, and 
this was accompanied by a decreased expression of epithelial markers and 
increased expression of mesenchymal markers [266]. A hallmark of EMT is the 
disintegration and disassembly of epithelial cell-cell junctions [266-268]. During 
TGFβ-mediated EMT, occludins and claudins, and E-cadherin are 
downregulated, leading to the degradation of tight and adheren junctions, 
respectively [266-268]. Also during EMT, the actin cytoskeleton is also 
reorganised into actin stress fibres anchored to FA complexes that contribute to 
filopodia and promote cell motility [266-268]. In vivo, this is likely to be a transient 
differentiation event, which results in increased cellular plasticity to allow cancer 
cells to migrate from the primary tumour and disseminate to distant metastatic 
sites. It remains to be observed the extent to which EMT occurs in humans. 
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Prometastatic mechanism. TGFβ at the primary tumour site may initiate EMT, 
resulting in invasion however, once distant metastases have developed, the local 
production of TGFβ can affect metastatic growth [269]. Studies have suggested 
a prominent role for TGFβ in bone metastasis, a common site for breast cancer 
cell dissemination [269]. The bone microenvironment contains sequestered 
growth factors in the matrix, including TGFβ. MDA-MB-231 breast cancer cells 
metastasise to the bone, and activate osteoclasts which function to degrade the 
bone matrix and release activate TGFβ. Expression of a dominant-negative 
mutant of TGFβRII rendered MDA-MB-231 cells unresponsive to TGFβ. Using a 
mouse model, these cells led to the development of fewer tumours, with less 
osteoclast recruitment, less bone destruction at metastatic sites and prolonged 
survival [269]. TGFβ stimulates the secretion of parathyroid hormone-related 
protein (PTHrP) by these cells [269, 270]. TGFβ-induced expression of PTHrP in 
turn stimulated the production of RANK ligand (RANKL) in osteoblasts to promote 
the differentiation of osteoclast precursors and bone resorption [271]. 
Administration of anti-PTHrP neutralising antibodies inhibits TGFβ-mediated 
osteolytic bone metastasis in mice [272]. This is a significant finding as women 
with PTHrP-positive breast cancer are more likely to develop bone metastasis 
than those with PTHrP-negative breast cancers [273]. 
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Proangiogenic mechanism. TGFβ can induce a proangiogenic environment. 
The ability of tumour cells to induce blood vessel formation is essential for tumour 
growth and blood-borne metastasis. In multiple cancers, elevated circulating 
plasma levels of TGFβ1 and enhanced tumour angiogenesis correlates with poor 
patient prognosis [274-276]. More specifically, in breast and non-small cell lung 
cancers (NSCLCs), high levels of TGFβ1 have been associated with increased 
microvessel density, which also correlates with poor patient prognosis [274, 275]. 
The mechanisms of angiogenesis stimulation by TGFβ are both direct and 
indirect. Such that TGFβ functions to induce the expression of key angiogenic 
factors including vascular endothelial growth factor (VEGF) and connective tissue 
growth factor (CTGF) in endothelial cells and fibroblasts [277-280]. TGFβ also 
directly induces capillary formation of endothelial cells cultured on a COL matrix 
[281]. TGFβ functions indirectly by acting as a potent chemoattractant for 
monocytes, which release angiogenic cytokines [282]. TGFβ also induces the 
expression of MMPs; MMP2 and MMP9, and downregulates the expression of 
TIMPs in tumour and endothelial cells, to provide a protease-rich 
microenvironment to enhance the migratory and invasive properties of 
angiogenically active endothelial cells [283]. Moreover, TGFβ represses the 
expression of angiopoietin-1 in fibroblasts, which functions to maintain vessel 
integrity, thereby contributing to the permeability of cancer-associated blood 
vessels [284].  In this manner, TGFβ promotes tumour angiogenesis.  
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Microenvironmental mechanism. A common feature of cancers that 
overexpress TGFβ1 is a desmoplastic stromal response, which is characterised 
by excessive ECM remodelling, usually through the enhanced activation of 
stromal fibroblasts [238]. TGFβ can induce the fibroblast-to-myofibroblast 
transition. Myofibroblasts, also known as ‘cancer-associated fibroblasts’ when 
present in the TME, function to remodel the ECM through contraction, and 
secretion of numerous ECM components and remodelling enzymes [285, 286]. 
In turn, this facilitates the activation of TGFβ from the ECM, thereby creating a 
positive feedback loop. Myofibroblasts are also well-documented as potent 
promoters of tumour cell invasion [287]. Similarly, in epithelial cells TGFβ induces 
the expression of ECM proteins including FN and the de novo expression of 
several integrins that are not normally expressed in epithelial cells such integrin 
αvβ3, αvβ5 and αvβ6, which are implicated in the activation of TGFβ, therefore 
tumour cells are well equipped to activate TGFβ [225]. These changes promote 
the invasive capabilities of tumour cells. Indeed, blocking TGFβ pathways inhibits 
integrin expression, ECM deposition and protease activity, as well as TGFβ-
mediated invasion [225]. This suggests inhibiting these changes are sufficient to 
block invasion. TGFβ may also functions to repress the expression of LN and/or 
LN-binding integrins α3β1 and α6β4 to inhibit cell adhesion [141]. Together, these 
changes create a TME that promotes progression into invasion. 
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1.6 EXTRACELLULAR MATRIX 
The ECM is a complex and dynamic network of secreted proteins, glycoproteins 
and proteoglycans which assemble into diverse forms; the interstitial form within 
organs, and as specialised forms such as; the BM underlying epithelia, vascular 
endothelium, and surrounding other cell and tissue types [288, 289]. These 
provide structural support and anchorage for individual cells, tissues and organs. 
Cells adhere to the ECM via cell-surface receptors, among which integrins are 
the most prominent [116]. These cell-ECM interactions allow for the transduction 
of signals between cells and their microenvironment. In this manner, the 
biochemical and biophysical properties of the ECM can modulate cell behaviour. 
In turn, cells can modulate these properties of the ECM through synthesis, 
assembly and degradation. In addition, the ECM also serves as a reservoir for 
growth factors, cytokines, and ECM-remodelling enzymes. These interactions 
must be tightly regulated to maintain tissue development and homeostasis [288, 
289], and alterations to these interactions have been associated with various 
pathological conditions such as fibrosis and cancer [238, 288-290]. 
 
Both long-standing, as well as more recent data, has implicated the ECM as a 
significant contributor to cancer progression [75]. Excessive deposition of ECM 
proteins is a common feature of cancers with poor prognosis [291]. Moreover, 
multiple studies have demonstrated that both ECM proteins and ECM receptors 
are dysregulated in cancer progression [290, 292-295]. Such that the composition 
of the ECM is a significant predictor of clinical prognosis. Breast cancers can be 
stratified into four subclasses based solely on ECM composition, and these 
subclasses are predictive of patient outcome [296]. Unsurprisingly, those with 
high expression of protease inhibitors in their ECM are associated with a good 
prognosis, while those with high expression of integrins and proteases are 
associated with poor prognosis [296]. The different cell types which form the 
TME, produce distinct ECM profiles, which have been termed the ‘matrisome’ as 
they were identified through proteomic technologies [297]. Such studies identified 
that primary tumours of differing metastatic potential differ in the composition of 
both neoplastic and stromal cell-derived ECM components [297]. 
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More recent attention to the role of the ECM in cancer progression has focused 
on modification to the mechanical properties [298]. Current clinical techniques 
utilise tissue stiffness as a feature to detect cancer however, the function of such 
alterations in promoting progression is poorly understood. Imaging elastography 
and unconfined compression analyses have consistently revealed that the 
tumour tissue is stiffer than the surrounding uninvolved tissue. For instance, 
breast cancer tissue (4kPa) is stiffer than normal breast tissue (0.16kPa) [299, 
300]. Moreover, atomic force microscopy (AFM) indentation analysis identified 
heterogeneity of ECM stiffness within an individual’s cancer [301-304]. Such that, 
AFM indentation revealed that the invasive front of human breast tissue is stiffer 
[305], and the vasculature within the centre of the cancer is softer than the 
vasculature at the periphery [306]. Regardless of this heterogeneity, overall, 
those harbouring the stiffest regions were the most aggressive. In breast cancer, 
those with the highest number of stiff regions within the stroma were of the basal-
like subtype. Considering these basal-like breast cancers also have a poor 
prognosis, these findings imply ECM stiffness may be linked to cancer 
aggression. Accumulating experimental evidence demonstrates that this 
reduction in breast tissue compliance may be attributed to changes in the 
deposition, composition and organisation of the ECM [307]. More specifically, 
COL is known to be upregulated within the stroma of breast cancer compared to 
the stroma of normal breast; as demonstrated by the elevated quantity, 
reorganisation, crosslinking and stiffness of COL [292, 294, 300, 308]. These 
alterations promote progression in an integrin-dependent manner [299, 300] and 
likely occur through modulating both neoplastic and stromal cell behavior in the 
TME [309]. In addition to COL, the cancer-associated ECM is composed of other 
fibrillar components whose roles in promoting stiffness are less clear. In 
particular, FN, which is critical for the deposition of COL in the ECM in vivo [310].  
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1.6.1 FIBRONECTIN 
 
1.6.1.1 Expression of fibronectin  
In the normal adult breast, FN is essentially absent from the stroma [311] and the 
tissue is soft and pliable [312]. In breast cancer, a number of ECM proteins are 
significantly deregulated [294], and increased FN mRNA and protein levels have 
been detected in the stroma of breast cancer [311, 313-317]. High levels of FN in 
breast cancer have been positively associated with an invasive and metastatic 
breast cancer phenotype and negatively associated with survival of breast cancer 
patients [314, 318, 319]. Changes in the deposition of FN have been 
demonstrated to contribute to the ‘pre-metastatic niche’, which facilitates the 
adhesion of bone marrow-derived cells to promote breast cancer invasion and 
metastasis [320, 321]. Like FN, high levels of integrin α5β1 correlate with a 
decreased survival of breast cancer patients [322]. While evidence provides a 
role for FN in breast cancer progression, the mechanisms regulating FN 
expression and function in breast cancer progression are unknown. 
 
1.6.1.2 Structure of fibronectin 
FN is composed of two nearly identical ~250 kDa subunits, which are linked by a 
pair of disulphide bonds near the C-terminus. Each subunit is composed of 
repeating units of three different homologies; including, 12 type I, 2 type II and 17 
type III repeats (Figure 9) [323]. These repeats are classified based on similarities 
in amino acid sequence, although the sequences of any two repeats of a given 
type are not always identical. Type I repeats are 40 amino acids in length; type II 
repeats are 60 amino acids in length, and type III repeats are 90 amino acids in 
length [324, 325]. Type I and type II repeats are mechanically stable as they are 
stabilised by disulphide bonds, however, type III repeats lack disulphide bonds 
and are sensitive to mechanical forces. It has been proposed that the type III 
repeats unfold to provide the elasticity of FN fibrils. The majority of these domains 
are constitutively included in mature FN, however, in some cases, their presence 
and affinity for ligands can be regulated by alternative splicing [326]. 
 
Type I Type II Type III
Role in fibrillogenesis
Alternative spliced domain
Collagen
Gelatin Heparin Fibrin
Integrins
a4b1, a4b7,
ss
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Fibrin
Heparin
Integrins
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a8b1, avb3, 
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Figure 9. Structure of fibronectin. Fibronectin (FN) is composed of a series of FN type I
repeats (white boxes), type II repeats (blue ovals) and type III repeats (white ovals). These
repeats are involved in various functions, including binding to integrins or other matrix-
associated proteins (denoted), or in the formation of a FN matrix (grey).Two of the type III
repeats, as well as a type III connecting segment undergo alternative splicing (orange).
Figure adapted from [325].
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1.6.1.3 Alternative splicing of fibronectin 
FN is encoded by a single gene, which undergoes alternative splicing and various 
post-translational modifications such as cross-linking. Alternative splicing occurs 
in three regions of the pre-mRNA: exon usage or skipping leads to either the 
inclusion or exclusion of two type III repeats, extradomain A (EDA), which is 
inserted between III11 and III12 domains, and/or extradomain B (EDB), inserted 
between III7 and III8 domains. The third region of splicing is a type III connecting 
segment (IIICS), also known as the variable (V) region [326]. The splicing pattern 
at this region is more complex, this domain may be completely included or 
excluded, as well as partial inclusion or exclusion. This latter type of splicing is 
known as exon subdivision, and in humans five variants of the V region have 
been found; V0, V64, V89, V95 and V120, with the number indicating the number 
of amino acids in each variant [327]. Alternative splicing leads to protein 
diversification, and as many as twenty different isoforms of FN exist in humans 
[328]. These FN isoforms are commonly classified into two forms; plasma FN 
(pFN) - a soluble form produced by hepatocytes which circulates in the blood 
(approximately 300–400µg/ml) and cellular FN (cFN) - an insoluble form 
produced by a variety of fibroblast-like cells in tissues. pFN generally lacks EDA 
and EDB sequences and one subunit of the dimer is V0, while cFN is a more 
heterogeneous group of splice variants with variable presence of the EDA, EDB 
and V regions (Figure 10) [323]. Alternative splicing of FN is regulated by cell 
type, stage of development and age. In cancer, the splicing pattern is altered, and 
an increase in the expression of FN isoforms containing EDA and EDB is 
observed [329-331]. 
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Figure 10. Alternative splicing of fibronectin. FN is encoded by a single gene which
undergoes alternative splicing in three regions, including; two type III repeats, extradomain A
(EDA) and extradomain B (EDB), and a type III connectin segment (IIICS), known as the
variable (V) region. EDA and EDB undergo exon usage or skipping which leads to their
inclusion or exclusion, while the V region may be completely or partially included or
excluded, known as exon subdivision. This latter splicing pattern of the V region results in
five variants in humans (V0, V64, V89, V95 and V120, in which the number indicates the
length in amino acids). These FN isoforms are classified as plasma (pFN) or cellular (cFN).
pFN lacks EDA and EDB, while one subunit is V0. cFN is more heterogeneous, with
variations in the presence of the EDA, EDB and V regions. Figure adapted from [325, 327].
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1.6.1.4 Functional domains of fibronectin 
Through all of the various domains that compose FN, it is able to bind to other 
FN molecules, an essential step in the formation of a FN matrix [332, 333]. FN is 
also able to bind to a variety of other ECM components such as fibrin, COL and 
heparin, and contributes to their initial and continual assembly and stability [334]. 
Like other matrix components, FN provides structural support for adhesion 
interactions between cell-matrix and cell-cell, while at the same time the adhesion 
receptors, namely integrins, transduce signals that promote actin cytoskeletal 
reorganisation and alter cellular behaviour [335]. These domains therefore allow 
for the formation of a FN matrix, which can bind simultaneously to cells and to 
molecules within the surrounding matrix. Finally, FN controls the bioavailability of 
growth factors by regulating their activation from the ECM, such as TGFβ [208].   
 
Fibronectin matrix assembly domains 
The domains involved in matrix assembly include; the dimerisation domain, which 
includes the C-terminal pair of cysteines. The covalent linkage between FN 
subunits is essential to the multimerisation of dimers into fibrils. The cell-binding 
domain (CBD), which includes RGD cell-binding sequence (III10) and PHSRN 
(Pro-His-Ser-Arg-Asn) synergy sequence (III9). This domain localises FN to the 
cell surface. The FN self-association domain, which includes; the N-terminal 
assembly domain (I1-5), as well as III1-2 and III12-14 domains, which allow 
matrix assembly [332, 333, 336]. Notably, these sites are located in type III 
repeats, and the stretching of these repeats exposes these domains for the 
assembly of FN into fibrils, and are therefore termed cryptic sites [337]. 
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Integrin interaction domains 
Two major regions of FN: the CBD and V region, mediate cell adhesion through 
interaction with multiple integrins. For example, integrins α3β1, α5β1, α8β1, 
αvβ1, αvβ3 and αvβ6 are able to recognise the RGD sequence in the CBD of FN, 
while α4β1 and α4β7 recognise the LDV (Leu-Asp-Val) and REDV (Arg-Glu-Asp-
Val) sequence in the V region [325]. Specific recognition by the classic FN 
receptor - α5β1 requires the simultaneous engagement of both the RGD cell 
binding sequence (III10) and PHSRN synergy sequence (III9) in the CBD of FN, 
resulting in binding that is highly sensitive to the conformation of FN [116]. In 
contrast, the binding of other integrins requires only the engagement of the RGD 
sequence, resulting in binding that is less sensitive to the conformation of FN. In 
brief, the RGD sequence is separated from the PHSRN synergy sequence by 30-
40 Å, and a small rotation between III9 and III10 results in the orientation of these 
two binding sites onto the same side [338, 339]. Therefore, changes to the 
conformation of FN alters the type of integrins used by cells to bind to FN, and 
subsequent downstream signalling. In this manner, FN conformation is able to 
regulate cell activity via the specificity of integrin binding [340]. In addition, cFN 
isoforms containing EDA and EDB domains are capable of directing phenotypic 
behaviours that differ from pFN lacking these domains, it is not surprising that 
these isoforms bind and signal via different integrins [325]. EDA may bind to α4 
(α4β1 and α4β7) and α9β1 through the EDGIHEL (Glu-Asp-Gly-Ile-His-Glu-Leu) 
sequence [324]. However, these integrins are not specific for EDA, as α4 also 
binds to the V region. No specific receptors for the EDB domain have been 
identified [325].  
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Alternatively spliced domains 
All three alternatively spliced domains are positioned to affect cell adhesion: EDA 
and EDB reside on either side of the RGD and PHSRN synergy sequence in the 
CBD, whereas the EDA and V region reside on either side of the heparin binding 
domain [325]. Structural studies have suggested that the insertion of an 
alternatively spliced domain may induce a conformational change in FN that 
affects the exposure of the RGD site [338] or other epitopes [341], thereby 
altering the adhesive properties of FN. Moreover, as mentioned previously, both 
EDA and the V region have been shown to have a direct role in cell adhesion by 
binding to integrins, while cell binding to EDB has not been reported [324, 325]. 
The V region has functions other than adhesion and controls FN dimer secretion. 
Such that any V0-V0 dimers are retained in the endoplasmic reticulum and 
degraded intracellularly [342]. FN containing the V region is widely expressed 
and deposited into the ECM in essentially all tissues [343, 344]. In contrast to the 
prevalence of the V region in FN, isoforms containing the EDA and EDB domains 
are most abundant in embryogenesis [344]. These isoforms demonstrate tissue-
specific regulation and expression, and their inclusion decreases with age, with 
adult tissues usually devoid of these domains [344]. However, these isoforms are 
upregulated in specific conditions such as tissue repair and fibrosis, and 
angiogenesis in cancer [325]. They have been well-documented as vascular 
markers of solid cancers, and are often referred to as oncofetal variants [345]. 
Specific functional roles for EDA and EDB have not been clearly defined from cell 
culture experiments, and so the generation of null mutations in mice provides 
insight into their function. Homozygous mutant mice lacking EDA or EDB, EDA-
/- and EDB-/- respectively, do not show any degree of embryonic lethality, they 
grow up without any obvious defects and reproduce normally [346]. Therefore, 
the single deletion of EDA or EDB suggests these domains may compensate for 
one another. Moreover, simultaneous deletion of both EDA and EDB results in 
embryonic lethality with multiple embryonic vascular defects [347]. These 
domains are therefore essential to embryogenic vasculogenesis. Although the 
defects seen in these mice lacking both domains are severe, mechanistic insights 
into specific functions for each individual domain in vivo remain to be elucidated. 
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1.6.1.5 Matrix assembly of fibronectin 
Assembly of a FN matrix is the same for both pFN and cFN. FN is synthesised 
as a monomer, which rapidly undergoes dimerisation in the rough endoplasmic 
reticulum. FN forms a soluble, compact disulphide-bonded dimer via C-terminal 
cysteines. This conformation prevents fibril formation. Fibrillogenesis is 
dependent on the binding of FN to cells. Integrin α5β1 is the primary receptor for 
binding to FN, and it binds through the RGD and PSHRN synergy sequence in 
the CBD. Function-blocking antibodies against either the CBD or α5β1 inhibit 
fibrillogenesis [348, 349]. Although integrin α5β1 is primarily responsible for FN 
matrix assembly, other integrins can perform this function under appropriate 
conditions, such as stimulation with manganese ions (Mn2+) or activating anti-
integrin antibodies in vitro. These integrins include; α3β1 [350], α4β1 [351], αvβ1 
[352], αvβ3 [353], αvβ6 [354] and αIIbβ3 [355]. Some of these integrins bind to 
regions in FN other than the CBD, suggesting FN matrix assembly may require 
more than a single integrin or region within FN [337]. Integrin binding to FN 
promotes the formation of FAs through the recruitment of cytoplasmic molecules 
including FAK, which is rapidly phosphorylated in response to integrin binding. 
Phospho-FAK recruits Src kinase, and together activate intracellular signalling 
cascades; Ras/MAPK, Rho-GTPase and PKC which stimulate actomyosin-driven 
contractility [356]. This tension induces a conformational change in FN leading to 
the exposure of cryptic self-association sites, allowing for FN-FN interactions, 
which induce fibril formation and elongation (Figure 11) [337, 357, 358]. 
Formation of a mature FN matrix is monitored by the irreversible conversion of 
deoxycholate (DOC)-soluble FN fibrils, into a DOC-insoluble matrix [359]. 
 
Integrin a5b1
Intracellular
Actin filaments
Extracellular
Figure 11. Matrix assembly of fibronectin. a) FN is synthesised as a soluble, compact
disulphide-bonded dimer via its C-terminal cysteine residues. FN matrix assembly is initiated
by binding to cell-surface receptors, namely integrin a5b1, via its CBD. b) Binding to
integrins connects FN to the actin cytoskeleton. These interactions activate intracellular
signaling complexes and induce the reorganisation of the actin cytoskeleton.Tension
generated by actin reorganization induces conformational changes in FN, thus exposing
sequestered FN self-association domains in the bound molecule. c) Fibrils form through FN–
FN interactions. Alignment of FN molecules within fibrils might vary depending on which
domains interact, such as I1–5 binding to III1–2 versus with III12–14. Overall, an insoluble
fibrillar network forms. Figure adapted from [358].
a)
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1.6.1.6 Degradation of fibronectin  
The ECM undergoes dynamic changes in its organisation and composition as 
part of tissue homeostasis and repair. ECM remodelling involves alterations in 
the synthesis, assembly and degradation of ECM components. ECM remodelling 
is a complex and highly regulated process. Continuous polymerisation of FN is 
essential for the stabilisation of the FN matrix at the cell surface [360]. Such that 
in the absence of FN polymerisation, existing FN matrixes are lost, and increased 
levels of FN degradation are seen [360]. This suggests a steady state between 
FN polymerisation and turnover exists. The mechanisms for the degradation and 
removal of ECM proteins includes extracellular proteolysis and endocytosis 
followed by intracellular degradation. Indeed, FN is a substrate for many 
extracellular proteases including MMPs [289]. As FN is assembled into cross-
linked high-molecular-weight multimers, it is unsurprisingly some proteolytic 
activity must occur to allow FN endocytosis. It has been demonstrated that 
MMP14 promotes the turnover of FN by regulating the cleavage of large FN fibrils 
[211]. Cleaved FN which is bound to α5β1, may then be endocytosed in a 
caveolin-dependent process [361]. FN is then targeted to the lysosomes and 
degraded intracellularly [362]. 
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1.6.1.7 Function of fibronectin 
 
Assembly of other matrix proteins  
The assembly of FN into the ECM controls the deposition and stability of other 
ECM proteins including; COL [360, 363], FBN [364], fibulin [365], LTBP [366], 
and TNC [367]. Some of these proteins associate directly with the FN matrix, 
whereas others appear to use the FN matrix as a scaffold for deposition of 
independently structured fibers.  
 
Growth factor reserve  
The FN matrix can also sequester growth factors and associated proteins, 
including BMP1 [368], VEGF [369] and LTBPs [370] to regulate cell signalling 
events. Moreover, FN has been implicated in the activation of growth factors, 
including TGFβ, and this function may reflect the localisation of latent TGFβ 
complexes to the ECM. 
 
Activation of TGFβ  
FN localises latent TGFβ complexes to the ECM through interactions with LTBP1, 
this is an essential step for integrin αvβ6-dependent TGFβ activation [207, 208]. 
In addition to facilitating the localisation of latent TGFβ to the ECM, FN also 
facilitates TGFβ activation. A study by Hinz and colleagues proposed that 
although integrin-mediated force is essential, this force alone may be insufficient 
for latent TGFβ activation. They demonstrated that in addition to cell contractility, 
a stiffer FN matrix exerts a stronger force to liberate higher levels of mature 
TGFβ (Figure 12) [212]. Therefore, enhanced matrix stiffness as seen in solid 
cancers such as breast cancer, may promote the activation of TGFβ. 
Furthermore, studies have demonstrated that TGFβ is capable of driving FN 
expression [371]. Therefore, this may provide a positive feedback loop, in which 
integrin αvβ6 and FN activate TGFβ, which in turn stimulates expression of both. 
 
Actin Filaments
Integrin avb6
Fibronectin
Large Latent Complex (LLC)
Figure 12. Activation of TGFb by fibronectin. a) Following the secretion of the LLC, latent
TGFb is then localised to the ECM through interactions between LTBP1 and FN. This
localisation step is a prerequisite for the conformational release of active TGFb from LAP by
integrin avb6. This mechanism of activation depends on cell contraction to deform LAP
however, this force alone may be insufficient in liberating mature TGFb. b) Straining of ECM
fibrils, containing FN and LTBP1, primes latent TGFb for subsequent activation by integrins.
At sufficient prestrain, minimal additional length changes in the ECM fibrils mediated by cell-
contaction will be sufficient to release active TGFb by inducing a conformational change in
LAP. Figure adapted from [212].
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1.6.2 LATENT TGFβ BINDING PROTEIN 
 
1.6.2.1 Structure of LTBP 
LTBPs are extracellular glycoproteins which comprise a family of four proteins; 
LTBP1, LTBP2, LTBP3 and LTBP4, which are structurally similar to FBNs. LTBP1 
and LTBP4 exist in two isoforms, short (S) and long (L), transcribed from different 
promoters [200]. The long isoforms contain N-terminal amino acid extensions. 
LTBPs are multidomain proteins; composed primarily of EGF-like domains, the 
majority of which contain calcium binding sequences, in addition there are 
domains containing eight cysteine residues, known as 8-Cys or TGFβ-binding 
protein-like (TB) domains. These 8-Cys domains are unique to the LTBP-FBN 
superfamily. The first 8-Cys domain, located at the N-terminal, is known as the 
hybrid domain, since it shares similarities with both 8-Cys and EGF-like domains. 
Between the second 8-Cys domain (8-Cys-2) and the stretch of repeating EGF-
like motifs, there is an unstructured proline-rich region called the hinge domain, 
which shows the highest degree of sequence diversity amongst the four LTBPs 
[200, 370]. The third 8-Cys domain forms disulphide linkages with the N-terminal 
cysteines in LAP, this domain is present in LTBP1, LTBP3 and LTBP4. LTBP1 
and LTBP3 covalently bind to all TGFβ-LAP isoforms, while LTBP4 binds poorly 
and only to TGFβ1-LAP, whereas LTBP2 does not (Figure 13) [200, 372]. 
 
Non-calcium binding EGF-like repeat
Hybrid domain 8-cys repeat
a) LTBP1
CN
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LTBP4L LTBP1S
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Calcium binding EGF-like repeat
Hinge domain
Figure 13. Structure of latent TGFb binding protein. LTBPs comprise a family of four
proteins; LTBP1, LTBP2, LTBP3 and LTBP4. LTBP1 and LTBP4 exist in two isoforms; short
(S) and long (L), transcribed by two different promoters. The long isofroms contain N-
terminal amino acid extensions. LTBPs are multi domain proteins, composed of EGF-like
domains (grey boxes), many of which contain calcium binding sequences (white boxes), and
hybrid domains (white ovals), of which the majority contain eight cysteine residues (8-Cys)
(blue ovals). There is also is an unstructured proline-rich region known as the hinge domain
(dashed line). Figure adapted from [201].
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1.6.2.2 Function of LTBP 
As discussed previously, TGFβ is secreted as part of a latent complex composed 
of LAP-LTBP. LTBPs regulate TGFβ activity by facilitating secretion, localisation 
to the ECM and activation from the latent complex [200, 370]. The localisation of 
the latent TGFβ in the ECM is a key function of LTBPs, and this step is essential 
in the process of TGFβ activation [366]. LTBP1, LTBP2 and LTBP4 have been 
shown to bind to FBN1 and FBN2 by non-covalent interactions through their C-
terminus. In addition, the N-terminal regions of LTBP1 and LTBP4 interact with 
FN, providing a second site for LTBPs to interact with the ECM. The significance 
of the interaction between LTBP1 and LTBP4 with FN is difficult to assess, as 
FBN1 assembly also requires FN. However, a later study demonstrated that 
FBN1 is required for the incorporation of LTBP3 and LTBP4, but not LTBP1, 
whereas FN is essential for the incorporation of LTBP1 [202]. During ECM 
maturation, LTBP1 then shifts its association from FN to FBN [366]. FN binds to 
the hinge region in LTBP1 (amino acids 414-437), and this interaction is essential 
for the activation of TGFβ1 by integrin αvβ6 [207, 208]. It has been shown that 
the N-terminal residues (amino acids 291-441) in LTBP1 are essential for the 
crosslinking of LTBP1 to the matrix by transglutaminases [373]. Interestingly, 
these residues overlap with the domain that interacts with FN [208]. This suggests 
that transglutaminases may function to crosslink LTBP1 and FN. These 
interactions with FBN and FN are essential for the proper localisation of LTBPs.  
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1.7 MATRIX METALLOPROTEINASES 
 
1.7.1 Classification of MMPs 
Proteolytic enzymes are classified as exopeptidases or endopeptidases based 
on their ability to cleave terminal or non-terminal peptide bonds, respectively 
[374]. Endopeptidases are classified as serine, cysteine, aspartic and 
metalloproteinases based on their catalytic mechanism [374]. Metalloproteinases 
are divalent cation-dependent enzymes which are further subdivided into 
families, including the metzincins, which comprise: MMPs, a disintegrin and 
metalloproteinases (ADAM) and ADAMs with thrombospondin domains 
(ADAMTS), with MMPs being the most studied [374]. MMPs are able to cleave 
multiple ECM components, as well as non-matrix component [288]. MMP 
degradation is essential in normal physiological processes, by; degrading ECM 
components to allow cellular migration, altering ECM composition to alter cellular 
behaviour, as well as modulating growth factor and cytokine activity by direct 
cleavage or release from bound storage [374]. MMP activity is regulated at the 
transcriptional level, and at the protein level through regulation of activation, 
localisation and inhibition [374]. Altered expression and/or dysregulation of MMPs 
has been associated with cancer development and progression [288]. In humans, 
23 MMPs are known [375]. MMPs were originally classified as collagenases, 
gelatinases, stromelysins and matrilysins based on their specificity for these ECM 
components. However, as more MMPs have been identified, a sequential 
numbering system has been adopted, and MMPs are now classified according to 
their structure (Table 2) [374, 376]. 
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Enzyme MMP Substrates 
 
Secreted MMPs 
 
Minimal-domain MMP 
Matrilysin 1 
 MMP7 
Aggrecan, COL (I and IV), decorin, 
elastin, FN, fibulin, gelatin, LN, 
osteonectin, tenascin, vitronectin, casein, 
E-cadherin, fibrinogen, integrin β4, pro-
MMP1, 2 and 9, pro-TNFα, plasminogen 
Matrilysin 2 MMP26 COL4, FN, gelatin, casein, fibrinogen, pro-MMP9 
Simple hemopexin-domain-containing MMPs 
Collagenase 1 MMP1 
Aggrecan, COL (I, II, III, VII, VIII, X and 
XI), FN, gelatin, IGFBPs, LN, TN, 
vitronectin, casein, fibrin, pro-TNFα 
Stromelysin 1 MMP3 
Aggrecan, COL (III, IV, V, VII, IX, X and 
XI), decorin, elastin, FBN, FN, gelatin, 
IGFBPs, LN, osteonectin, tenascin, 
vitronectin, casein, E-cadherin, fibrin, 
fibrinogen, pro-MMP1, 7, 8, 9 and 13, 
pro-TNFα, plasminogen 
Collagenase 2 MMP8 Aggrecan, COL (I, II and III), fibrinogen, pro-TNFα, plasminogen 
Stromelysin 2 MMP10 
Aggrecan, COL (III, IV and V), elastin, 
FN, gelatin, casein, fibrinogen, pro-
MMP1, 7, 8 and 9 
Metalloelastase MMP12 
Aggrecan, COL (I and IV), elastin, FBN, 
FN, gelatin, LN, vitronectin, fibrinogen, 
pro-TNFα, plasminogen 
Collagenase 3 MMP13 
Aggrecan, COL (I, II, III, VI, IX, X and 
XIV), FBN, FN, gelatin, osteonectin, 
casein, fibrinogen 
Collagenase 4 MMP19 COL (I and IV), FN, gelatin, tenascin, casein 
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Enamelysin MMP20 Aggrecan, fragments of COL XVIII 
 MMP27 No substrates reported 
Gelatin-binding MMPs 
Gelatinase A MMP2 
Aggrecan, COL (I, III, IV, V, VII, X and 
XI), decorin, elastin, FBN, FN, fibulin, 
gelatin, IFGBPs, LN, oesteonectin, 
tenascin, vitronectin, FGFR1, fibrin, 
fibrinogen, pro-MMP9 and 13, latent 
TGFβ, pro-TNFα, plasminogen 
Gelatinase B MMP9 
Aggrecan, COL (IV, V, XI and XIV), 
decorin, elastin, FBN, gelatin, LN, 
osteonectin, vitronectin, casein, fibrin, 
fibrinogen, latent TGFβ, pro-TNFα 
Furin-activated secreted MMPs 
Stromelysin 3 MMP11 IGFBPs 
Epilysin MMP28 Casein 
Vitronectin-like insert MMPs 
 MMP21 No substrates reported 
Membrane type-MMPs (MT-MMPs) 
Transmembrane MMPs 
MT1-MMP MMP14 
COL (I, II and II), FBN, FN, gelatin, LN, 
vitronectin, fibrin, fibrinogen, integrin αv, 
pro-MMP2 and 13, pro-TNFα 
MT2-MMP MMP15 Aggrecan, FN, LN, tenascin, pro-MMP2 
93 
 
MT3-MMP MMP16 COL3, FN, pro-MMP2 
MT5-MMP MMP24 Gelatin, FN, pro-MMP2 
Glycosylphosphatidylinositol (GPI)-anchored MMPs 
MT4-MMP MMP17 Gelatin, fibrin, fibrinogen, pro-MMP2 
MT6-MMP MMP25 COL4, gelatin, FN, fibrinogen, fibrin, pro-MMP2 
Type II transmembrane MMPs 
Cysteine Array MMP MMP23A No substrates reported 
Cysteine Array MMP MMP23B No substrates reported 
 
Table 2. Classification of matrix metalloproteinases. Table adapted from [374, 376]. 
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1.7.2 Structure of MMPs 
MMPs share a conserved domain structure and activation mechanism (Figure 
14) [374]. They are synthesised as inactive zymogens, also known as pro-MMPs, 
which are composed of a signal peptide, prodomain and catalytic domain [377]. 
The signal peptide facilitates their secretion to the endoplasmic reticulum. The 
prodomain contains a zinc-interacting Cys thiol group that maintains MMPs 
inactive. The catalytic domain contains the catalytic machinery including the zinc-
binding site. With the exception of minimal domain MMPs and type II 
transmembrane MMPs, MMPs contain an additional hemopexin domain, which 
links to the catalytic domain through a hinge region [374]. The hemopexin domain 
mediates interactions with TIMPs, cell-surface molecules and proteolytic 
substrates, and therefore substrate specificity [378]. Additionally, the hinge region 
is suggested to influence specificity for proteolytic substrates [379]. Gelatin-
binding MMPs also contain inserts that resemble the type II repeats in FN, which 
are required to bind and cleave COL [380, 381]. Furin-activated secreted MMPs 
contain a recognition motif for intracellular furin-like serine proteinases between 
their prodomain and catalytic domain. This motif is also found in vitronectin-like 
insert MMPs and MT-MMPs. Transmembrane MMPs have a C-terminal domain 
composed of a single-span transmembrane domain and a short cytoplasmic 
domain. Glycosylphosphatidylinositol (GPI)-anchored MMPs share a similar 
domain structure however, the C-terminal domain contains a hydrophobic domain 
that acts as a GPI anchoring signal [382], while type II transmembrane MMPs 
contain an N-terminal signal anchor that targets it to the cell surface [383]. 
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Figure 14. Structure of matrix metalloproteinases. MMPs are classified into eight
structural classes, five of which are secreted and three of which are membrane-type MMPs
(MT-MMPs). a) Secreted MMPs: Minimal-domain MMPs contain a signal peptide (Pre), a
prodomain (Pro) with a thiol (SH) group, and a catalytic domain with a zinc-binding site (Zn).
In addition to these domains, the simple hemopexin-domain-containing MMPs have a
hemopexin domain that is linked to the catalytic domain by a hinge (H). The first and the last
of the four repeats in the hemopexin domain are linked by a disulphide bond (S–S). The
gelatin-binding MMPs contain inserts that resemble type II repeats of FN. The furin-activated
secreted MMPs contain a recognition motif for intracellular furin-like serine proteinases (Fu).
This motif is also found in vitronectin-like insert (Vn) MMPs and the MT-MMPs. b) MT-
MMPs: Transmembrane MMPs have a single-span transmembrane domain (TM) and a very
short cytoplasmic domain (Cy), while the glycosylphosphatidylinositol (GPI)-anchored MMPs
have a GPI anchor domain. The type II transmembrane MMPs contain a signal anchor (SA),
and are also characterised by cysteine-rich (Cys) and immunoglobulin (Ig)-like domains.
Figure adapted from [374]. 95
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1.7.3 Regulation of MMPs 
 
Activation  
MMP expression is primarily regulated at the transcriptional level, such that most 
cells synthesise and immediately secrete MMPs into the stroma when required 
[384]. Secreted MMPs are then localised to the cell surface through interactions 
with cell-surface receptors, while MT-MMPs are covalently linked to the cell 
membrane. The interaction between the thiol group in the prodomain and a zinc 
ion (Zn2+) bound to the catalytic domain maintains MMPs inactive. The activation 
of MMPs requires the destabilisation of the interaction or the removal of the 
prodomain [385]. Most MMPs are activated extracellularly by other activated 
MMPs or several serine proteinases. However, some MMPs can be activated 
prior to reaching the cell surface by intracellular furin-like serine proteinases due 
to their shared presence of a furin proteinase recognition motif [386]. The notable 
exception to these mechanisms of activation is MMP2, which is often 
constitutively expressed and controlled through a unique mechanism of activation 
at the cell surface involving MMP14 and TIMP2.  In this way, the N-terminal 
domain of TIMP2 binds to MMP14 and the C-terminal domain of TIMP2 binds to 
the hemopexin domain of pro-MMP2 [387]. This allows an adjacent, uninhibited 
MMP14 to cleave the bound pro-MMP2. MMP14 does not fully activate MMP2, 
and another, already activated MMP2 is required to remove a residual portion of 
the prodomain of MMP2 [388]. Data indicate that the basal expression of MMP2, 
MMP14, and TIMP2 is coregulated, which is consistent with their cooperation 
during MMP2 activation [389]. Pro-MMP2 may also be activated by MMP15 in a 
mechanism that does not require the TIMP2/MMP14 complex [390].  
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Localisation  
In addition to anchorage of MMPs to the cell surface, such as the case for MT-
MMPs, secreted MMPs may also be localised to cell surface, thereby targeting 
their catalytic activity to specific substrates within the pericellular space. The 
mechanisms for localising secreted MMPs to the cell surface include; interaction 
with cell surface receptors, such as the interaction between MMP2 and integrin 
αvβ3 [190] or MMP9 and CD44 [391], and interaction with pericellular ECM 
components, such as the interaction between MMP7 and heparin sulphate [392]. 
These mechanisms often promote MMP activation, concentrate active MMPs 
local to their substrate and modulate the access of MMP inhibitors. 
 
Catabolism and clearance  
MMPs are able to regulate their proteolytic inactivation and clearance. Some 
cleavages result in complete inactivation, whereas other cleavages generate 
truncated MMPs, which lose their ability to cleave some substrates whilst 
retaining their ability to cleave other substrates [384]. This processing can also 
diminish the affinity and ability of MMPs to be inhibited by TIMPs, such as the C-
terminal truncation of MMP2 [382]. Moreover, truncation can also prevent the 
localisation of MMPs to the cell surface. In addition, MT-MMPs may be secreted 
if they are cleaved at a juxtamembrane site before or after they reach the cell 
surface [393]. In this fashion, proteolysis of MMPs can alter their substrate 
specificity, localisation, as well as their activity. 
 
Inhibition  
MMPs are inhibited by proteinases inhibitors; TIMPs and inhibitors of 
metalloproteinases (IMPs) to prevent excessive proteolysis. All active forms of 
MMPs are inhibited by TIMPs. However, TIMPs differ in tissue-specific 
expression and ability to inhibit the various MMPs [384]. Such as TIMP2 and 
TIMP3 both inhibit MT1-MMP, whereas TIMP1 does not, and TIMP3 is most 
potent at inhibiting MMP9. TIMPs function by forming irreversible complexes with 
MMPs through interaction with their catalytic sites, and bind in a 1:1 stoichiometric 
manner [394]. Other types of MMP inhibitors include; the smaller IMPs (SIMPs) 
and larger IMPs (LIMPs). LIMP is a complex composed of TIMP2 and pro-MMP2 
[395], which inhibits gelatinases, collagenases and stromeolysins.  
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1.7.4 Function of MMPs 
 
Extracellular matrix remodelling 
Simply, MMPs degrade structural components of the ECM, and thereby facilitate 
cell migration. However, the ECM is not a passive scaffold; as well as 
sequestering growth factors and cytokines, the ECM provides contextual signals 
to cells through interactions with cell adhesion receptors [116]. By extension, 
MMPs also influence these processes by altering the organisation and 
composition of the ECM. Cleavage of ECM components by MMPs can facilitate 
their removal by endocytosis and degradation. For example, MMP14 cleaves FN 
prior to caveolin 1-dependent endocytosis and subsequent lysosomal 
degradation [211, 361, 362]. Moreover, cleavage of ECM components by MMPs 
can generate fragments with new functions; such as cleavage of LN5 by MMP2 
results in the exposure of cryptic sites that promote cellular migration [396]. 
MMPs also participate in the release and subsequent activation of growth factors 
that are sequestered in the ECM, including TGFβ. In turn, a function of TGFβ is 
to regulate MMP expression, such that activated TGFβ can both promote and 
suppress MMP gene transcription [397]. A similar mechanism of regulating MMP 
activity is seen in the interplay between COL and MMP1. COL1 acts as a ligand 
for the discoidin domain receptors (DDR1 and DDR2) which induces MMP1 
expression following receptor activation, which occurs following the binding of 
intact COL1. The DDR is then inactivated following binding of MMP1-cleaved 
COL1 [398, 399]. In this manner, MMP expression is induced by its own 
substrate, and may then be repressed once it cleaves that substrate and is no 
longer required. 
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Cell surface proteolysis 
MMPs can also modulate cell behaviour through cleaving; cell-cell interactions, 
cell-matrix interactions or cell surface molecules. Cleavage of the adheren 
junction component E-cadherin by MMP3 and MMP7 results in the release of 
ectodomain fragments which promotes cell migration due to the loss of cell-cell 
interactions [400]. It is suggested that the cleaved E-cadherin may interfere with 
the function of full length, uncleaved E-cadherin molecules. Similarly, cleavage 
of the hyaluronan receptor CD44 by MMP14 promotes cell migration due to loss 
of cell-cell and cell-ECM interactions. When the cleavage site is mutated, cell 
migration is inhibited [401]. In addition to binding to the ECM, CD44 also binds 
MMP9 localising it to the cell surface. This localisation is essential for MMP9 to 
promote cancer cell invasion and angiogenesis [391]. MMPs can also release cell 
surface molecules. Cell surface localised MMPs can activate latent TGFβ, and 
pro-TNFα. Moreover, cleavage of insulin-like growth factor-binding protein 
(IGFBP) and perlecan by MMPs releases soluble IGFs [402] and fibroblast growth 
factors (FGFs) [403], respectively. In addition to releasing and activating growth 
factors and cytokines, MMPs can also cleave their cell surface receptors. MMP2 
is able to cleave FGF receptor 1 (FGFR1) [404]. Moreover, two members of the 
epidermal growth factor receptor (EGFR) family – HER2 [405] and HER4 [406], 
as well as the hepatocyte growth factor receptor c-MET [407], are also substrates 
for MMPs, although specific MMPs involved in the cleavage of these receptors 
have not yet been identified. In all these cases, receptor cleavage releases a 
soluble receptor fragment that retains its ability to bind to the respective ligand. 
Together, these data support the role of MMPs in promoting cancer progression.  
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Cancer development and progression 
MMPs have long been associated with cancer invasion and metastasis due to 
their ability to degrade the BM to allow invasion into the surrounding environment 
[408]. A positive correlation between the progression of multiple cancer types and 
MMP expression has been demonstrated in numerous studies (Table 3) [376]. 
Such that increased MMP levels represent an independent predictor of reduced 
survival. These tissue studies have been supported by cancer mouse models, 
which either transgenically overexpress MMPs or MMP-knockout mice [376, 
409]. Together with clinical data [410, 411], these studies support a role for MMPs 
in cancer invasion and metastasis. On the basis of such studies, it was proposed 
that the pharmalogical inhibition of MMP activity may provide a mechanism to 
prevent cancer progression. However, the results from clinical trials with these 
drugs proved disappointing. Universally, the trials failed to reach their end points 
of increased survival in patients with advanced stage cancer [412-414]. These 
clinical trials were designed based on the data that supported these essential 
roles of MMPs in late stages of cancer progression; invasion and metastasis. 
However, it is now recognised that the tumour-promoting activity of MMPs may 
be important in early stages of cancer development. Conversely, studies have 
shown that several MMPs function as anti-tumourigenic proteases [415]. 
Furthermore, other MMPs which were originally identified as pro-tumourigenic 
proteases may also function as anti-tumourigenic proteases [415]. Moreover, 
other MMPs may play no role in cancer progression, but undoubtedly play normal 
physiological roles. Therefore, the mechanisms underlying the influence of MMPs 
in cancer must be fully understood in order to better design therapeutic agents.  
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It has long been assumed that cancer cells are solely responsible for the 
production of such proteolytic enzymes however, this concept was disproved 
following the demonstration that stromal cells surrounding cancer cells, and not 
the cancer cells alone, were also responsible for producing MMPs. This followed 
the development of in situ hybridisation (ISH) techniques. While some MMPs may 
be produced by cancer cells; such as MMP7 in breast cancer [416], many MMPs 
are produced by stromal cells; such as MMP13 by myofibroblasts in breast cancer 
[417]. MMP secretion from adjacent stromal cells may be induced by cancer cells. 
Indeed, cancer cells may stimulate cancer-associated stromal cells to synthesise 
MMPs in a paracrine manner through secretion of growth factors and cytokines, 
as well as other MMPs [374]. Supporting this notion, MMP expression is not 
induced by gene amplification or activating mutations, and is likely due to 
transcriptional changes rather than genetic alterations. This may be the result of 
activation of oncogenes or loss of tumour suppressors; such as, MMP7 is 
upregulated through combined activation of the transcription factors PEA3, c-
JUN, β-catenin and LEF-1 [418], which are downstream of classical oncogenes, 
and the transcription of MMP1 and MMP13 is repressed by the tumour 
suppressor p53 [419, 420]. Moreover, MMPs that are secreted by stromal cells 
can still be recruited to the cancer-cell surface. For example, MMP2 mRNA is 
expressed by stromal cells of human breast cancers, whereas MMP2 protein is 
found on both stromal and cancer-cell surface [421]. 
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MMP 
 
Localisation Expression and clinical Association 
MMP1 Cancel cells Stromal cells Positively associated with tumour stage 
MMP2 
Cancer cells 
Stromal cells at 
invasive front 
Endothelial cells 
Increased expression in tumours 
Positively associated with tumour stage, 
lymph-node and distant metastases 
Negatively associated with survival 
MMP3 
Cancer cells 
Stromal cells 
Endothelial cells 
ECM surrounding 
blood vessels 
Increased expression in tumours 
compared to normal tissue and pre-
malignant lesions 
MMP7 Cancer cells Increased expression in tumours compared to normal tissue 
MMP8 MECs Decreased expression in tumours compared to normal tissue 
MMP9 
 
Cancer cells 
MECs 
Fibroblasts 
Macrophages 
Endothelial cells 
Increased expression in tumours 
compared to normal tissue 
Positively associated with tumour stage 
and lymph-node metastases 
MMP10 ECM surrounding blood vessels 
Positively associated with lymph-node 
metastases 
MMP11 Cancer cells Stromal cells 
Increased expression in tumours  
Positively associated with lymph-node 
metastases 
Negatively associated with survival 
MMP12 Macrophages Increased expression in tumours compared to normal tissue 
MMP13 Cancer cells Myofibroblasts Positively associated with local invasion 
MMP19 Cancer cells Endothelial cells 
Increased expression in benign lesions 
compared to invasive disease 
 
Table 3. Matrix metalloproteinases in breast cancer. The localisation of MMPs in breast cancer 
was determined by in situ hybridisation (ISH) is indicated by italics, while localisation that has only 
been determined by IHC is indicated in roman font. Table adapted from [376]. 
103 
 
Anti-tumourigenic proteases. MMP8, also known as a neutrophil collagenase, 
was the first MMP to be identified as having anti-tumourigenic functions. In these 
studies, male homozygous mutant mice, MMP8-/- exhibited an increased 
incidence of skin tumours in a chemically induced cancer model system, 
compared to wild-type mice. Importantly, female MMP8-/- and wild-type mice 
demonstrated no difference in the incidence of skin tumours. Female MMP8-/- 
mice whose ovaries were removed or were treated with tamoxifen also 
demonstrated an increased incidence of skin tumours compared to wild-type 
mice, demonstrating a protective role for oestrogen in this model. Conversely, 
bone-marrow transplantation experiments in these mice showed that MMP8 
produced by neutrophils is sufficient to restore the anti-tumour protection 
mediated by MMP8.  Further studies demonstrated that loss of MMP8 leads to 
inflammatory abnormalities in response to carcinogens, which leads to a 
sustained inflammatory response that promotes cancer progression [422]. The 
relevance of MMP8 as an anti-tumourigenic protease has been further shown in 
human breast cancer cells. The downregulation of MMP8 in non-metastatic 
breast cancer cells (NM-2C5) increases their metastatic potential, while the 
upregulation of MMP8 in metastatic breast cancer cells (M-4A4) reduces their 
metastatic potential [423]. Similarly, manipulation of MMP8 expression in a model 
of normal and DCIS-MECs, demonstrated a role for MMP8 in negatively 
regulating breast cancer cell invasion. Moreover, it was found that loss of MMP8 
expression was more significantly lost in DCIS/IDC compared to pure DCIS [424]. 
Together, these data support MMP8 as an anti-tumourigenic protease.  
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MMP12 has also been implicated as having anti-tumourigenic functions. Studies 
using MMP12-/- mice revealed a protective role for stromal MMP12 in lung cancer 
development. Specifically, loss of MMP12 was associated with tumour growth 
and blood vessel formation [425]. Further studies have shown that these effects 
seem to be mediated by the ability of MMP12 to generate angiostatin, a potent 
inhibitor of angiogenesis, formed by cleavage of plasminogen by MMP12, as well 
as cleavage by MMP2, MMP3, MMP7 and MMP9 in vitro [426, 427]. Angiostatin 
functions by blocking endothelial cell proliferation and migration. Additionally, 
MMP12 may also inhibit angiogenesis by cleavage and shedding of cell surface-
bound urokinase-type plasminogen-activator receptor (uPAR), which is required 
for endothelial cell invasion into fibrin [428]. Supporting this, MMP12 expression 
in hepatocellular carcinomas was associated with hypovascularity [425]. MMP26 
expression in hormone-regulated cancers is associated with improved clinical 
outcome. The anti-tumourigenic properties of this MMP may be due to its ability 
to regulate the expression level of ERβ through its cleavage, and thereby altering 
oestrogen signalling in hormone-dependent cancers. Moreover, MMP26 
expression by macrophages and polymorphonuclear leukocytes has suggested 
that this protease may have an anti-inflammatory response, similar to MMP8, 
which contributes to its association with an improved clinical prognosis in patients 
with breast cancer [429]. 
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Pro-tumourigenic proteases. MMP3, MMP9, MMP11 and MMP19 were first 
described as pro-tumourigenic proteases, but have now been identified to have 
dual roles in cancer progression. For instance, MMP3 was initially described as 
a potent pro-tumourigenic protease [430] however, studies have demonstrated a 
protective role in skin cancer. Such that, MMP3 overexpression in a chemically 
induced skin cancer model system reduced tumour growth compared to control 
[431]. However, gene overexpression studies can be misleading, and MMP3 
overexpression may not represent the function of MMP3 when it is expressed at 
basal concentrations. MMP3-/- mice develop less carcinogen-induced papillomas 
than control mice [431]. However, the tumours that do form on MMP3-/- mice 
grow faster and have an increased metastatic potential [431], and therefore 
MMP3 has a complex role in tumourigenesis. It may be possible however, that 
MMP3 is pro-tumourigenic during early stages of cancer progression. Similar to 
MMP3, MMP9 has both pro-tumourigenic and anti-tumourigenic effects 
depending on stage of progression [376]. In a human papilloma virus (HPV) 16-
induced skin cancer model system, MMP9-/- (HPV/MMP9-/-) mice developed 
less tumours and exhibited delayed progression to invasion compared to wild-
type (HPV/MMP9). However, the MMP9-/- cancers that developed were higher 
grade than wild-type mice, suggesting an increased aggressive nature [432]. In 
this way, MMP9 may promote progression, whilst limiting development. MMP11 
also has paradoxical roles during progression, as identified in MMP11-/- mouse 
models. Such that MMP11-/- mice have fewer and smaller primary tumours 
however, more frequently display metastases in comparison to wild-type mice 
[433]. On one hand, MMP11 promotes the development of primary tumours by 
inhibiting cancer cell apoptosis [434, 435]. It is suggested that MMP11 may 
function to in this manner by releasing IGFs [402] which can act as survival 
factors [436]. On the other hand, MMP11 functions to repress the development 
of metastases [433]. A final MMP with dual roles in cancer progression is MMP19. 
The decreased susceptibility of Mmp19-/- mice to develop chemically induced 
skin tumours suggests that MMP19 may promote tumour growth [437]. However, 
it also functions to negatively regulate early stages of tumour angiogenesis and 
invasion [438] 
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2. AIMS 
The aim of this project is to investigate phenotypic and functional differences 
between normal and DCIS-MECs, with a particular focus on the function and 
regulation of FN expression by tumour-promoting integrin αvβ6-positive DCIS-
MECs. The purpose of this work is to better understand the mechanisms 
underlying the transition of DCIS to invasion, and by doing so, generate a 
biomarker signature with which DCIS patients can be better stratified. The 
objectives specifically include, to; 
 
1) Investigate the phenotypic characteristics of MECs in normal and DCIS tissue, 
with and without co-existent invasive disease 
 
2) Compare the tissue phenotype to characteristics in primary and cell line 
models of normal and DCIS MECs  
 
3) Determine the functional relevance of the phenotypic characteristics in 
primary and cell line models of normal and DCIS MECs 
 
4) Investigate the mechanisms regulating the phenotypic characteristics in 
normal and DCIS MECs 
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3. MATERIALS AND METHODS 
 
3.1 IMMUNOHISTOCHEMICAL ANALYSIS 
 
3.1.1 Human breast tumour samples 
Human breast tumour samples were obtained from surgical specimens from 
patients undergoing breast surgery between 2000 and 2015 at Barts Health NHS 
Trust London. Tissue that was deemed by a pathologist to be surplus to 
diagnostic and therapeutic requirement were collected together with associated 
clinical data under the terms of the Breast Cancer Now Tissue Bank (BCN, NRES 
Cambridgeshire 2 REC number 10/H0308/48), and Barts Cancer Institute Breast 
Tissue Bank (BCI, NRES East of England REC number 15/EE/0192), with ethical 
approval. All tissues were obtained from patients with full written informed 
consent. Samples of DCIS with (n=20; DCIS/IDC) and without (n=20; DCIS) 
invasion were selected for immunohistochemical analyses. Samples were 
matched on tumour grade (non-high-grade and high-grade) and patient age. 
Clinicopathologic details are provided in Table 4.  
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Type DCIS DCIS/IDC 
Grade Non-high-grade High-grade High-grade 
Cohort 10 10 20 
Subtype 
Luminal A 2 1 7 
Luminal B 5 2 7 
HER2 2 5 4 
TN 1 2 2 
DCIS size in mm 21.4 (12-30) 37.6 (15-50) 13.4 (4.4-40) 
Diagnosis 
Symptomatic 1 1 11 
Screen-detected 9 9 9 
Age at diagnosis 56 (50-65) 54 (43-58) 56 (51-60) 
Follow-up 
Years follow-up 5.5 (3-18) 5 (3-10) 6 (3-12) 
Recurrence (years) 0 1 (2) 3 (1) 
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Surgery 
Wide Local Excision 5 2 6 
Mastectomy 5 8 14 
Adjuvant Treatment 
None 3 2 1 
Radiotherapy 5 5 11 
Hormone Therapy 3 2 12 
Both 1 0 8 
Unknown 0 1 4 
 
Table 4. Clinical annotation of human breast tumour samples analysed  
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3.1.2 Immunohistochemical staining 
Immunohistochemical staining was performed on serial sections of formalin-fixed 
paraffin-embedded (FFPE) tissues. Sections were dewaxed in xylene (Fisher 
Scientific, X/2050) and rehydrated through graded alcohols (Fisher Scientific, 
E/0665DF) to distilled water (dH2O). Endogenous peroxidases were blocked with 
3% (v/v) hydrogen peroxide (H2O2, Fisher Scientific, H/1750) in methanol (Fisher 
Scientific, M/4056) for 10 minutes, followed by antigen retrieval. Antigen retrieval 
methods used are listed in Table 5. Sections were incubated with a blocking 
buffer of 5% (w/v) bovine serum albumin (BSA, Sigma, A8022) in phosphate 
buffered saline (PBS) for 10 minutes. Sections were then incubated with primary 
antibody diluted in blocking buffer for 1 hour at room temperature (rt). Excess 
antibody was removed by washing with PBS in triplicate for 5 minutes each. 
Sections were then incubated with horse anti-mouse biotinylated secondary 
antibody (Vector laboratories, PK-6102), diluted 1:200 in blocking buffer for 30 
minutes at rt. Primary antibodies used as listed in Table 6. Excess antibody was 
removed by washing with PBS in triplicate for 5 minutes each. Sections were then 
incubated in avidin-biotin complex (ABC, Vector Laboratories, PK-6100) for 30 
minutes at rt. Sections were then washed in PBS in triplicate for 5 minutes each 
before incubating with diaminobenzidine (DAB, Vector Laboratories, SK-4100). 
Mayers haematoxylin (Sigma, MHS16) was then used for counterstaining. 
Sections were then dehydrated through graded alcohols to xylene and mounted 
in distyrene-tricresyl phosphate-xylene (DPX, Sigma, 06522). 
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Antigen retrieval Company Product code 
Pepsin Life technologies 00-3009 
0.1M Citrate (pH 6) Fisher scientific S/3280 
10mM Tris (pH 9) Sigma T1503 
 
Table 5. Antigen retrieval methods for immunohistochemical staining 
 
 
Antibody Dilution Company Product code Antigen retrieval 
SMA 1:500 Dako M0851 Tris (pH 9) 
Integrin αvβ6 1:800 Calbiochem 407317 Pepsin 
TFN 1:500 Sigma F0916 Pepsin 
p63 1:50 Abcam ab735 Citrate (pH 6) 
 
Table 6. Primary antibodies for immunohistochemical staining 
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3.1.3 Immunohistochemical analysis 
Samples were scanned using a 3DHISTECH Panoramic digital slide scanner 
(3DHISTECH, Hungary), and analysed using the VisoPharm software 
(VisioPharm A/S, Hoersholm, Denmark). Disease scores were determined firstly 
by manually defining normal and tumour areas within H&E stained tissue samples 
and identifying regions that represented epithelium, stroma or adipose tissue and 
then training the software to recognise these defined regions. These data were 
then expressed as a percentage of the whole tissue area. All 
immunohistochemical analysis was performed on a duct-by-duct basis. Ducts 
were numbered and identified as either; normal, benign or DCIS within each case. 
Each duct was then scored as negative or positive for the expression of integrin 
αvβ6 and TFN. For samples stained with TFN, periductal staining was measured. 
Duct size was measured using the equation; 𝜋𝜋 𝑥𝑥 𝑟𝑟1 𝑥𝑥 𝑟𝑟2, where ‘𝑟𝑟1’ is the minor 
axis length and ‘𝑟𝑟2’ is the major axis length. MEC size and shape were quantified 
on SMA stained sections by measuring the minor axis length of at least 3 MECs 
per duct. MEC nuclei were quantified on p63 stained sections by counting all 
positive-nuclei within a duct and measuring the minor and major axis length of at 
least 3 positive-nuclei per duct. 
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3.2 CELL LINE AND PRIMARY CELL CULTURE 
 
3.2.1 Myoepithelial cell lines 
MEC lines with (β6-1089) and without (N-1089) integrin αvβ6 expression 
recapitulating DCIS and normal MECs respectively, were provided by Dr M. Allen 
[114]. The parental MEC line 1089 (Myo-1089) was obtained from Prof M. O’Hare 
and Prof P. Jat, Institute of Neurology, UCL, London. Myo-1089 were isolated 
from reduction mammoplasty tissue as described by Gomm and colleagues 
[439], and immortalised as described by O’Hare and colleagues [440]. Dr M. Allen 
sorted the immortalised Myo-1089 cells by using integrin β4 antibody-coated 
magnetic beads to purify the MEC population, and cells were designated β4-
1089. To generate a cell line overexpressing integrin αvβ6, cells were transfected 
with CM containing retrovirus from AM12/pBABE-β6 or AM12/pBABE-Puro cells. 
Cells were then selected using 1µg/mL puromycin. Control 1089 cells were 
designated normal (N-) 1089; β6-transduced cells were further enriched by 
positive selection using integrin β6 antibody-coated magnetic beads and 
designated β6-1089. 
 
These cell lines were shown to phenotypically drift overtime in culture; most 
notably they demonstrate a gradual downregulation of integrin α6β4 expression. 
To maintain the expression of integrin α6β4, cells were enriched by positive 
selection using β4–labelled magnetic beads every 10-12 weeks. Along with the 
downregulation of integrin α6β4, N-1089 demonstrate a gradual increase in 
integrin αvβ6 expression, induced by culturing cells on plastic, possibly as a 
wound healing response [183]. The cell lines then underwent re-selection using 
β6–labelled magnetic beads, in which β6-1089 are resorted by positive selection, 
while N-1089 are negatively selected. 
 
N-1089 and β6-1089 cells were cultured in Nutrient Mixture Ham’s F-12 (F-12, 
Sigma, N6658) supplemented with 10% foetal bovine serum (v/v) (FBS, HyClone, 
SH30071), 1µg/mL hydrocortisone (Sigma, H0888), 10ng/mL epidermal growth 
factor (EGF, Sigma, 9644), and 10µg/mL insulin (Sigma, I9278). 
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3.2.2 Breast cancer cell lines 
ER-negative, MDA-MB-231 and ER-positive, MCF-7 breast cancer cell lines were 
obtained from American Type Culture Collection (ATCC) and verified with STR 
profiling (LGC Standards, Teddington, UK, tracking number 710081047). MDA-
MB-231 and MCF-7 cells were cultured in Dulbecco’s modified eagle medium 
(DMEM, Sigma, D6429) supplemented with 10% FBS. 
 
3.2.3 Primary breast cells 
Primary normal and DCIS breast cells were isolated from ductal organoids from 
reduction mammoplasty and DCIS tissues, respectively, obtained from the BCN 
and BCI breast tissue bank. Samples of reduction mammoplasty were matched 
on patient age (20-24 years) and menopausal status (premenopausal). Samples 
of DCIS/IDC were matched on tumour grade (high-grade). Clinicopathologic 
details are provided in Table 7. Ductal organoids were digested to a single-cell 
suspension through digestion with 0.05%/0.02% (w/v) trypsin/EDTA solution 
(Hyclone, SV30031.01) containing 0.4mg/mL DNase (10104159001, Roche Life 
Science) for 15 minutes at 37oC. The cell suspension was filtered through a cell 
strainer with 40µM pore size filter (Fisher Scientific, 352340). Pure populations of 
MECs and LECs were then isolated through either magnetic bead separation or 
FACS separation. For magnetic bead separation of primary normal breast cells, 
a single-cell suspension was incubated at 4oC for 20 minutes with CD10-labelled 
magnetic beads to isolate MECs, followed by incubation at 4oC for 20 minutes 
with EpCAM-labelled magnetic beads to isolate LECs. For FACS isolation of 
DCIS breast cells, a single-cell suspension of 20x106 cells in 1mL serum and 
growth factor-free (SGF) Roswell Park Memorial Institute medium (RPMI, Sigma, 
R5886) was incubated with 0.25µg/mL allophycocyanin (APC)-conjugated 
mouse anti-human integrin αvβ6 (R&D Systems, FAB4155A), 0.03µg/mL 
phycoerythrin (PE)-conjugated mouse anti-EpCAM (BD Biosciences, 347198) 
and 10µL Alexa-Fluor 488 anti-human integrin α6β4 (Invitrogen, MA5-23641) for 
45 minutes at 4oC. Cells were then incubated with 0.1µg/mL 4′, 6-diamidino-2-
phenylindole (DAPI, D9542) at 4oC for 10 minutes prior to separation of MECs 
and LECs based on expression of integrin α6β4 and EpCAM, respectively. FACS 
separation was performed on BD FACSAria II cell sorter (BD Biosciences).  
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Primary normal MECs were cultured on plates precoated with 10µg/cm2 COL1 
and cultured in HuMEC Ready Medium (Life Technologies, 12753-018) 
supplemented with 50µg/mL bovine pituitary extract (BPE, Invitrogen, 13028-
014), 0.5µg/mL hydrocortisone, 10ng/mL EGF, 5µg/mL insulin, 0.5µg/mL 
fungizone (Invitrogen, 15290-026) and 10µg/mL gentamicin (Sigma, G1397).  
 
Primary normal LECs were cultured in Dulbecco’s Modified Eagle’s 
Medium/Nutrient Mixture Hams F-12 (DMEM/F-12, Sigma, D8437) supplemented 
with 10% FBS (v/v), 0.5µg/mL hydrocortisone, 10ng/mL EGF, 5µg/mL insulin and 
10µg/mL apo-Transferrin (Sigma, T1147). 
 
For passaging or harvesting, cells were detached with a 0.5%/0.2% (w/v) trypsin/ 
ethylenediaminetetraacetic acid solution (EDTA, Sigma, 59418C). For long-term 
preservation, pelleted cells were resuspended in 40% complete-media (v/v), 50% 
FBS and 10% dimethyl sulphoxide (DMSO, Sigma, D2650) and frozen in a step-
wise manner, first at -80oC overnight and then placed in -196oC (liquid nitrogen). 
For experimental consistency, fresh cells were routinely thawed. All cells were 
confirmed Mycoplasma-free before experiments and were maintained at 37°C in 
a humidified 5% CO2 atmosphere.  
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Type DCIS/IDC 
Grade High-grade 
Integrin αvβ6 Positive Negative 
Cohort 2 2 
DCIS size in mm 18 (14-22) 14 (12-16) 
Age at diagnosis 62 (42-72) 43 (42-43) 
 
Table 7. Clinical annotation of DCIS organoid samples analysed 
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3.3 TRANSFECTIONS 
 
3.3.1 DNA transfection 
Cells at a density of 1x106 in 10mL SGF media were reverse transfected with 
10µg integrin β6 pcDNA1 neo (Addgene, plasmid 13580) or pcDNA1 empty 
vector (Invitrogen, V790-20) using the jetPRIME transfection reagent (PolyPlus, 
114). Transfections were carried out by mixing DNA, 1mL JetPRIME buffer and 
20µl jetPRIME reagent by vortexing for 10 seconds and incubating at rt for 10 
minutes to allow complex formation. After that the DNA-buffer-reagent complex 
was added to the dish in a drop wise manner and the plate swirled to ensure 
homogenous distribution. The media was then changed to fresh SGF media after 
24 hours. Both cells and CM were harvested for subsequent experiments 48 
hours after transfection. 
 
3.3.2 siRNA transfection 
Cells at a density of 1x106 in 8mL SGF media were reverse transfected with 9nM 
integrin β6 (Dharmacon, M-008012-01-0005), total fibronectin (TFN, Dharmacon, 
M-009853-01-0005), MMP13 (MMP13, Dharmacon, M-005955-01-0005) or non-
targeting control (NTC, Dharmacon, D-001206-14-20) small interfering RNA 
(siRNA) by using the interferin transfection reagent (PolyPlus, 409). 
Transfections were carried out by mixing siRNA and 31µL interferin in 1.6mL SGF 
media by vortexing for 10 seconds and incubating at rt for 15 minutes to allow 
complex formation. After that the siRNA-interferin complex was added to the dish 
in a drop wise manner and the plate swirled to ensure homogenous distribution. 
The media was then changed to fresh SGF media after 24 hours. Both cells and 
CM were harvested for subsequent experiments 48 hours after transfection. 
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3.4 TGFβ STIMULATION 
Immediately prior to stimulation, media was removed and cells were washed in 
PBS to remove residual media. Cells were then stimulated with 5ng/mL 
recombinant human active TGFβ1 (PeproTech, 100-21) in SGF media for 5, 15 
and 30 minutes, or for 72 hours, in which fresh TGFβ1 in SGF media was 
replaced daily. To stop stimulation, cells were washed with ice cold PBS and kept 
on ice, and harvested for subsequent experiments. 
 
3.5 TGFβRII INHIBITION 
Cells at a density of 2x106 were incubated with 10µg/mL IgG isotype control 
antibody (Merckmillipore, MABC004) or TGFβRII-blocking antibody (R&D 
Systems, AF-241-NA) in SGF media for 20 minutes at 4oC on a rotating-wheel 
before plating. The media was then changed to the respective SGF media after 
24 hours. Both cells and CM were harvested for subsequent experiments 48 
hours after antibody treatment. 
 
3.6 CONDITIONED MEDIA 
In the preparation of concentrated CM (cCM) from cell culture, CM was 
centrifuged at 1,200rcf for 3 minutes. The supernatant was transferred to a new 
tube and the pellet discarded. CM was then concentrated 24-fold with centrifugal 
filters (Fisher, 10403892) with 3K molecular weight cut off (MWCO) at 4000g for 
45 minutes at 4oC. The cCM was frozen at -80oC for later use. 
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3.7 IMMUNOBLOTTING 
 
3.7.1 Isolation of proteins 
In the isolation of protein from cells, excess media was removed and cells were 
washed in ice cold PBS. Total cellular protein was isolated by the addition of 
radio-immunoprecipitation assay (RIPA) buffer (50mM Tris-hydrochloride (Tris-
HCl, Sigma, T3253) pH 7.4, 150mM sodium chloride (NaCl, Fisher, 358-1), 1% 
IGEPAL CA-630 (Calbiochem, 490216), 0.1% sodium deoxycholate (Na-DOC, 
Sigma, D6750), 1mM EDTA (Fisher, BP 118-500), supplemented with 1:100 
protease inhibitor cocktail set (Calbiochem, 539131), 1mM activated sodium 
orthovanadate (Na3VO4, Sigma, S6508) and 1mM sodium fluoride (NaF, Sigma, 
S7920) when required). Cells were scraped and the suspension was placed in an 
Eppendorf tube, and incubated on ice for 15 minutes. The tube was then 
centrifuged at 10,000rpm at 4oC for 5 minutes. The supernatant was transferred 
to a new tube and the pellet discarded. DOC-soluble material was isolated by the 
addition of Na-DOC buffer (2% Na-DOC, 20mM Tris-HCl pH 8.8, 2mM EDTA, 
supplemented with 1:100 protease inhibitor cocktail set when required). Cells 
were scraped and the suspension was placed in an Eppendorf tube. The tube 
was then centrifuged at 16,000rpm at 4oC for 15 minutes. The supernatant was 
transferred to a new tube and the DOC-insoluble material was solubilised in 
sodium dodecyl sulphate (SDS) buffer (1% SDS (National Diagnostics, EC 874), 
20mM Tris-HCl pH 8.8, 2mM EDTA, supplemented with 1:100 protease inhibitor 
cocktail set when required). Samples were frozen at -20oC until required. 
 
3.7.2 Quantification of proteins 
Protein concentrations for both cell lysates and cCM were quantified using the 
Bio-Rad DC Protein Assay Kit (Bio-Rad Laboratories, Reagent A 500-0113, 
Reagent B -114, Reagent S -115), according to the manufacturer’s instructions. 
Absorbance was measured at 595nm using a microplate reader (Tecan, Infinite 
F50). Concentrations of samples were calculated from a standard curve 
generated from increasing concentrations of BSA, ranging from 0.1 to 5mg/mL 
versus their respective absorbance values.  
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3.7.3 Electrophoresis of proteins 
Subsequently, 30µg of protein were mixed with reducing 4x laemmli buffer (0.25M 
Tris-HCl pH 6.8, 8% SDS, 40% glycerol (Fisher, G/0600/17), 0.04% bromophenol 
blue (Sigma, B8026) and 2.5% β-mercaptoethanol (βME, Sigma, M7522)) to give 
a final concentration of 1x laemmli buffer. Samples were then denatured further 
by heating at 95oC for 5 minutes prior to loading onto 6-15% polyacrylamide gels. 
To prepare polyacrylamide gels, a resolving gel solution of varying volumes of 
30% acrylamide mix (National Diagnostics, EC 890), 1.5M Tris-Base (Fisher, 
BP152) pH 8.8, 10% SDS, 10% ammonia persulphate (APS, National 
Diagnostics, EC 504) and tetramethylethylenediamine (TEMED, Flowgen, 
H17459) was dispensed into a gel cassette (Invitrogen, NC2010). After the 
resolving gel was set, a 5% stacking gel solution of varying volumes of 30% 
acrylamide mix, 1M Tris-Base pH 6.8, 10% SDS, 10% APS and TEMED was 
overlaid the resolving gel in the cassette, and a comb was inserted. After the 
stacking gel was set, the comb was removed and the cassette inserted into a gel 
tank containing running buffer (25mM Tris-Base, 192mM Glycine and 0.1% SDS). 
Samples were then loaded into wells and electrophoresed at 150V for 90 minutes. 
 
3.7.4 Electroblotting of proteins 
Following protein separation, the gel was removed from the cassette and placed 
in a transfer assembly where the gel faces towards a 0.45µM pore size 
nitrocellulose membrane (Whatman). The inner chamber was filled with transfer 
buffer (25mM Tris-HCl, 192mM Glycine and 20% (v/v) Methanol), while the outer 
chamber was filled with H2O. Proteins were transferred at 30V for 90 minutes at 
4oC. Protein sizes were determined by comparison to a protein ladder of defined 
molecular weights (Generon, SM0671). Transfer verification was confirmed with 
Ponceau S stain (Sigma, P7170).  
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3.7.5 Immunoblotting of proteins 
Membranes were incubated with a blocking buffer of 5% (w/v) milk (Sigma, 
70166), 0.1% (v/v) Tween-20 (Applichem, A4974) in Tris Buffered Saline (TBS-
T) for 1 hour at rt. Membranes were then blotted with primary antibody diluted in 
blocking buffer overnight at 4oC. Excess antibody was removed by washing with 
TBS-T in triplicate for 5 minutes each. Depending on the species in which the 
primary antibody was raised, membranes were then incubated with horseradish 
peroxidase (HRP)-conjugated secondary antibodies, diluted in blocking buffer for 
1 hour at rt. Primary and secondary antibodies used as listed in Table 8 and Table 
9, respectively. Membranes were washed with TBS-T in triplicate for 5 minutes 
each before incubating with Enhanced Chemiluminescence (ECL) reagents 
(Amersham, RPN 2106) and exposure to film. Films were developed in a Konica 
Film Processor (SRX-101A). 
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Antibody Host Dilution Company Product code 
Integrin αvβ6 Goat 1:1,000 Santa cruz SC-6632 
TFN Mouse 1:2,000 Sigma F0916 
FN-EDA Mouse 1:1,000 Abcam ab6328 
p-SMAD2 Rabbit 1:1,000 Cell signalling 3101 
SMAD2 Rabbit 1:1,000 Cell signalling 8657 
p-ERK1/2 Rabbit 1:1,000 Cell signalling 9101 
ERK1/2 Rabbit 1:1,000 Cell signalling 9102 
HSC70 Mouse 1:10,000 Santa cruz SC-7298 
 
Table 8. Primary antibodies for immunoblotting 
 
Antibody Host Dilution Company Product Code 
Anti-Goat Rabbit 1:1,000 Dako P0449 
Anti-Mouse Rabbit 1:1,000 Dako P0260 
Anti-Rabbit Goat 1:1,000 Dako P0448 
 
Table 9. Secondary antibodies for immunoblotting 
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3.7.6 Densitometric analysis 
To compare protein signal intensities, density measurements of non-signal-
saturated bands were determined using ImageJ software (National Institutes of 
Health, Bethesda, MD, USA). Relative protein phosphorylation levels were 
obtained by normalising the level of protein phosphorylation to total protein level, 
while all signals were normalised to HSC70 on the same membrane. These 
arbitrary values were then converted into ratios by normalising to the control of 
that replicate to avoid varying intensities of each replicate. The total density of 
each replicate was then determined, and each individual band was normalised to 
the total density of that repeat. The average density of 3 replicate controls was 
then calculated. This value was then used to find the relative density of the 
normalised values of each individual band. This allows for the presentation of the 
data normalised to the control, with the control demonstrating variation also. 
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3.8 IMMUNOFLUORESCENT STAINING 
Cells were seeded onto 13mm2 glass coverslips at a density of 5x104 per well in 
1mL SGF media. At the desired time point, cells were fixed in 4% formaldehyde 
in PBS (Cell Path, BAF-0010-01A) for 10 minutes. Cells were then permeabilised 
with 0.1% Triton X-100 in PBS for 5 minutes before staining for intracellular 
proteins only. Subsequently, cells were incubated with a blocking buffer of 5% 
BSA in PBS, with the exception of staining for integrin αvβ6, in which cells were 
incubated with a blocking buffer of 5% BSA in DMEM, both for 10 minutes at rt. 
Cells were then incubated in primary antibody diluted in the respective blocking 
buffer for 1 hour at rt. Excess antibody was removed by washing with PBS in 
triplicate. Cells were then incubated with goat anti-mouse Alexa-Fluor 488 
secondary antibody (Invitrogen, A11029), diluted 1:200 in the respective blocking 
buffer for 1 hour at rt. Primary antibodies used as listed in Table 10. Cells were 
washed with PBS in triplicate and once in dH2O before mounting and 
counterstaining with ProLong Gold Antifade reagent containing DAPI (Invitrogen, 
P36931). Images were viewed on a Zeiss LSM 710 Meta microscope, and 
captured at x63 objective magnification. Fluorescence analysis was determined 
using the ZEN 2009 image analysis software. Relative fluorescence intensity was 
calculated by normalising to the control. Average fibril length was calculated by 
measuring the length of fibrils extending from at least 5 different cells within a 
minimum of 3 fields of view. The percentage of cells with FN fibrils was 
determined by counting the number of nuclei with adjacent FN fibrils compared 
to the total number of nuclei within a minimum of 3 fields of view. 
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Antibody Dilution Company Product Code 
Integrin αvβ6 1:100 Merck MAB2077Z 
TFN 1:100 Sigma F0916 
FN-EDA 1:100 Abcam ab6328 
 
Table 10. Primary antibodies for immunofluorescent staining  
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3.9 QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION  
 
3.9.1 Isolation of RNA 
In the isolation of RNA from cells, cells were detached using 0.5%/0.2% (w/v) 
trypsin/EDTA and centrifuged at 1,200rcf for 3 minutes. Cell pellets were then 
washed in ice cold PBS. RNA was then extracted from the cell pellets using the 
Quick-RNA MiniPrep Kit (Zymo Research, R1065) according to the 
manufacturer’s instructions. Following elution, RNA quantity was estimated using 
the Nanodrop system (Thermo Scientific). 
 
3.9.2 Synthesis of cDNA 
Using isolated RNA as a template, cDNA was obtained by reverse transcription 
(RT). To initiate RT, 1µL of 50ng/µL hexanucleotide primers (Sigma, H0268) and 
1µL of 10 mM deoxynucleotide (dNTPs, Sigma, GE28-4065-57) are added to 1µL 
of 50ng mRNA with 7µL of nuclease-free dH2O (HyClone, SH30538.02) to give a 
total volume of 10µL per reaction. The reaction was performed with the following 
conditions: 70oC for 10 minutes, followed by 4oC for 5 minutes in a Mastercycler 
Polymerase Chain Reaction (PCR) system (Eppendorf). To synthesise cDNA 
from the RNA-DNA hybrid by polymerisation, 1µL of Moloney-murine leukaemia 
virus (M-MLV) reverse transcriptase enzyme and 2µL of M-MLV buffer (Sigma, 
M1302) are added to the initial reaction mix with 7µL of nuclease-free deionised 
water to give a final volume of 20µL per reaction. The reaction is performed with 
the following conditions: 22oC for 10 minutes, 37oC for 50 minutes and 90oC for 
10 min. cDNA was kept at 4oC until required. 
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3.9.3 qRT-PCR 
Primer sequences are shown in Table 11. All primers were kept at 100µM stock 
concentration and used at 0.3µM final concentration. qRT-PCR was carried out 
using KiCqStart SYBR Green qPCR ReadyMix (Sigma, KCQS02-250RXN) 
according to the manufacturer’s instructions. Each reaction was prepared as: 1µL 
of 3µM forward primer, 1µL of 3µM reverse primer, 2µL SYBR Green and 5µL of 
nuclease-free deionised water to give a total volume of 9µL. This reaction mix 
was added to the plate with 1µL cDNA to give a final volume of 10µL. Each 
reaction was performed in triplicate within the same plate for each all genes. 
Reactions were run using a StepOnePlus PCR system (Applied Biosystems) 
using the following conditions: for one cycle 95oC for 10 minutes, followed by 
95oC for 15 seconds and 60oC for 1 minute for 40 cycles. The change in gene 
expression is then determined by the equation 2-(ddCT) The change in cycle 
threshold (dCT) is calculated by subtracting the average CT for the reference 
gene (18S) from the average CT of the target gene. The change in CT of the 
control is then subtracted from the change in CT of the sample (ddCT). 
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Primer Forward 5’ – 3’ Reverse 5’ – 3’ 
Integrin αvβ6 GAAGGAATGATCACGTACAAG AGCAGGGAGTCTTCACAGGT 
TFN AACAAACACTAATGTTAATTGCC TCGGGAATCTTCTCTGTCAGC 
FN-EDA CGAGCCCTGAGGATGGAATC TGTGTACTGAGAACCCGGTC 
FN-EDB CCTCACCAACCTCACTCCAG GGGACTTTCCTCTCTGCCATT 
MMP2 GCCCATCATCAAGTTCCCCG AAGGTGTTCAGGTATTGCACTG 
MMP3 GGGATTAATGGAGATGCCCAC GTGGCCAATTTCATGAGCAGC 
MMP7 GAACGCTGGACGGATGGTAG CAGAGGAATGTCCCATACCCA 
MMP9 GAACCAATCTCACCGACAGG GCCACCCGAGTGTAACCATA 
MMP10 TAACAGCAGGGACACCGTTT CAGGGTATGGATGCCTCTTGG 
MMP13 TCTACACCTACACCGGCAAA GGTTGGGGTCTTCATCTCCT 
18S CACGGGAAACCTCACCCGGC AACGGCCATGCACCACCACC 
 
Table 11. Primer sequences for qRT-PCR 
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3.10 ADHESION ASSAY 
Non-tissue culture treated 96-well plates were coated with 100µL of 0.5µg/mL 
recombinant human LAP (246-LP-025, R&D Systems) or 0.1% BSA, in triplicate. 
Coated plates were then incubated for 1 hour at 37oC, and wells were then 
washed with PBS twice. Cells were seeded at a density of 2x104 per well in 100µL 
of SGF media and allowed to adhere for 1 hour at 37oC. Media was then removed, 
and cells were fixed in 100% methanol for 10 mins at rt. Methanol was removed, 
and the cells were stained with 0.1% crystal violet for 1 hour at rt. Excess crystal 
violet was removed, and cells were washed with dH2O in triplicate. Cells were 
then solubilised with 0.2% Triton X-100 in PBS on shaker for 10 mins. 
Absorbance was measured at 550nm using a microplate reader. The background 
binding to BSA was subtracted from LAP, and relative adhesion was calculated 
by normalising to the control. 
 
3.11 MIGRATION ASSAY 
The underside of 8µM Transwell inserts (Fisher, 734-1574) were coated with 
100µL of 0.5µg/mL recombinant human LAP or 0.1% BSA, in triplicate. Coated 
inserts were then incubated for 1 hour at rt, and were then washed with PBS 
twice. Inserts were then placed into 500µL of SGF media in the outer chamber. 
Cells were then seeded into the inner chamber of the insert at a density of 2x104 
per well in 200µL of SGF media and allowed to migrate for 8 hrs at 37oC. Media 
was then removed from both the inner and outer chamber, and migrating cells 
were then quantified by adding 200µL and 500µL of 0.5%/0.2% (w/v) 
trypsin/EDTA solution to the inner and outer chamber of the Transwell insert, 
respectively and incubating for 1 hour at 37oC. This was then added to 9.8mL and 
9.5mL of isoton solution (BD Biosciences, 342003), respectively, and counted 
with a CASY counter (Schärfe System). Total cell count for each sample was 
calculated by adding the inner and outer chamber counts. Relative cell migration 
was then calculated by using the outer chamber count versus total cell count. 
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3.12 TRANSWELL INVASION ASSAY 
The upper insert of 8µM Transwell inserts were coated with 70µL of Matrigel 
(Corning, 354234) diluted 1:3 in ice cold SGF DMEM. Coated inserts were then 
incubated for 40 minutes at 37oC. 500µL of CM was then added to the outer 
chamber, in triplicate. MDA-MB-231 and MCF-7 were then seeded into the inner 
chamber of the insert at a density of 3x104 per well in 200µL of media and allowed 
to migrate for 24 and 48 hours at 37oC, respectively. Media was then removed 
from the outer chamber, and invading cells were then quantified by adding 500µL 
of 0.5%/0.2% (w/v) trypsin/EDTA solution to the outer chamber of the Transwell 
insert and incubating for 1 hour at 37oC. This solution was then added to 9.5mL 
of isoton solution and counted with a CASY counter. Relative breast cancer cell 
invasion was calculated by normalising to the control. 
 
3.13 PROLIFERATION ASSAY 
MDA-MB-231 and MCF-7 were seeded at a density of 3x104 per well of a 96-well 
plate in 200µL of CM, in triplicate and incubated for 24 and 48 hours at 37oC, 
respectively. 40µL of Cell Titer-Blue Reagent (Promega, G8081) was then added 
to each well and incubated for 2 hours at 37oC. Absorbance was then measured 
at 550nm and 600nm using a microplate reader. Relative breast cancer cell 
proliferation was calculated by normalising to the control. 
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3.14 PROTEOME PROFILER HUMAN PROTEASE ARRAY 
 
3.14.1 Sample Preparation 
250µg of cCM was prepared to a total volume of 1.5mL with blocking buffer (buffer 
6), and incubated with 15µL of antibody cocktail for 1 hour at rt. These reagents 
were provided in the Protease Array Kit.  
 
3.14.2 Protease array 
Simultaneously, membranes were incubated with blocking buffer for 1 hour at rt. 
Membranes were then incubated with the sample-antibody mixture overnight at 
4oC. Excess antibody was removed by washing with a wash buffer in triplicate for 
10 minutes each. Membranes were then incubated with streptavidin-HRP-
conjugated secondary antibody, diluted in blocking buffer for 30 minutes at rt. 
Membranes were washed with wash buffer in triplicate for 10 minutes each before 
incubating with ECL and exposing to film. 
 
3.14.3 Densitometric analysis 
To compare analyte signal intensities, density measurements of individual dots 
were determined using ImageJ software. These arbitrary values obtained were 
then expressed as ratios by normalising to the appropriate control as indicated 
on the y-axis of the respective graphs.  
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3.15 GELATIN ZYMOGRAPHY 
 
3.15.1 Sample preparation 
100µg of cCM was mixed with non-reducing 4x laemmli buffer (0.25M Tris-HCl 
pH 6.8, 8% SDS, 40% glycerol, 0.04% bromophenol blue) to give a final 
concentration of 1x laemmli buffer.  
 
3.15.2 Electrophoresis of proteins 
Precast 10% Tris-Glycine gels supplemented with 0.1% gelatin (Invitrogen, 
EC6175BOX) were inserted into a gel tank containing running buffer (25mM Tris-
Base, 192mM Glycine and 0.1% SDS). Samples were then loaded into wells and 
electrophoresed at 150V for 90 minutes. 
 
3.15.3 Detecting proteolytic expression 
The gel was then placed into a renaturing buffer of 2.5% (v/v) Triton X-100 in 
dH2O, for 30 minutes at rt with gentle agitation. Gels were then equilibrated by 
transferring them into a developing buffer of 5mM Tris-Base, 4mM HCl, 20mM 
NaCl, 0.5mM calcium chloride (CaCl2, Sigma, C7902) in dH2O and incubated 
overnight at 37oC. Gels were then stained with a staining solution of 0.1% (w/v) 
Coomassie R-250 (Thermo Scientific, 20278), 40% (v/v) ethanol and 10% (v/v) 
acetic acid (Sigma, A6283) in dH2O, for 15 minutes at rt with gentle agitation. To 
visualise protease expression, gels were destained by washing with 10% (v/v) 
ethanol and 7.5% (v/v) acetic acid in dH2O, in triplicate for 15 minutes each. 
 
3.15.4 Densitometric analysis 
To compare proteolytic expression, density measurements of bands were 
determined using ImageJ software. These arbitrary values were then converted 
into ratios by normalising to the control of that replicate to avoid varying intensities 
of each replicate. The total density of each replicate was then determined, and 
each individual band was normalised to the total density of that repeat. The 
average density of 3 replicate controls was then calculated. This value was then 
used to find the relative density of the normalised values of each individual band. 
This allows for the presentation of the data normalised to the control, with the 
control demonstrating variation also. 
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3.16 MECHANICAL STRAIN 
Cells were seeded at a density of 7x104 per well in 2mL of media into 6-well 
flexible-bottomed BioFlex culture plates coated with COL4 (Dunn Lab, BF-
3001C/IV). Immediately prior to stretching, cells were removed from the periphery 
of the well, and the media was replaced for fresh SGF media. Cells were then 
exposed to a static stretch using a computerised vacuum-operated instrument 
(Flexcell strain unit FX-5000 Tension Plus, Flexcell International). The vacuum-
induced constant stretch with 10% elongation of the flexible surface. The Bioflex 
loading station is designed to provide equibiaxial strain (uniform radial and 
circumferential strain) across a membrane surface by using cylindrical loading 
posts. The cells were exposed to stretch for 48 hours. Controls cells were plated 
on BioFlex culture plates for an equivalent time but were not subjected to stretch. 
 
3.17 STATISTICAL ANALYSIS 
Experiments were performed at least three times and statistical significance was 
determined by using two-tailed Students t-test or one-way ANOVA using Prism 
(Graphpad Software). The association between tissue composition, and MEC 
expression of integrin αvβ6 and periductal FN deposition was analysed using 
Pearson x2 test using Prism. Results were considered as significant with a p-
value equal to or less than 0.05 (‘*’ in figures), equal to or less than 0.01 (‘**’ in 
figures), and equal to or less than 0.001 (‘***’ in figures). Results with a p-value 
more than 0.05 were considered as non-significant (‘ns’ in figures). Quantitative 
data of at least 3 independent experiments are expressed as ± standard error of 
the mean (SEM). 
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4. RESULTS 
 
4.1 PHENOTYPIC CHARACTERISTICS OF MYOEPITHELIAL CELLS IN 
NORMAL AND DCIS TISSUE 
 
4.1.1 Breast tissue composition in DCIS progression 
A cohort of DCIS tissues with (DCIS/IDC; n=20) and without (n=20) invasive 
disease (Table 4), and adjacent normal tissue were selected and analysed by 
H&E staining. The presence or absence of invasion was confirmed with H&E 
staining (Figure 15a; panel 2-3), and the presence of invasion is used as a marker 
of DCIS progression. The extent of breast tissue components; epithelium, stroma 
and adipose, in each sample were measured by digital histopathology on H&E 
stained sections and calculated as the percentage tissue area occupied. Breast 
tissues were remodelled in the progression of DCIS, such that adipose tissue was 
replaced with an increase in both epithelial and stromal components (p<0.05) 
(Table 12). To identify any significant changes in tissue architecture through the 
tissue block that might impact on subsequent immunohistochemical analyses, 
H&E staining was carried out on the first (panel 2) and last (panel 3) sections cut. 
No major changes in tissue composition were observed between the different 
sections analysed (Supplementary Table S1). These findings demonstrate 
alterations in the composition of human breast cancer as a function of malignant 
progression from normal through DCIS to invasive IDC. 
 
a) DCISNormal DCIS/IDC
Figure 15. Breast tissue composition in DCIS progression. a) Haematoxylin and eosin
(H&E) staining of the first (panel 2) and last (panel 3) serial sections of human breast tumour
samples featuring areas of DCIS (n=20), DCIS with associated invasion (DCIS/IDC) (n=20)
and adjacent normal. Magnification x2. Scale bar, 200μm. b) Digital analysis of architecture
of H&E images. Bars represent the average percentage of epithelium, stroma and adipose
tissue coloured orange, blue and grey, respectively in normal (1%, 10% and 83%,
respectively), DCIS (9%, 21% and 70%) and DCIS/IDC (16%, 21% and 68%) patient
samples. c) H&E stained images of a sample and the same sample pseudo-coloured as
orange for epithelium, blue for stroma and grey for adipose. Representative images are
shown.
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Tissue area % (range) 
Epithelium Stroma Adipose 
Normal 1% (1-5%) 10% (2-17%) 83 (78-93%) 
DCIS 
Non-high-grade 5% (2-9%) 17% (8-31%) 78% (67-93%) 
High-grade 13% (4-50%) 25% (8-61%) 63% (13-88%) 
DCIS/IDC 16% (3-48%) 21% (5-33%) 68% (37-88%) 
 
Table 12. Tissue composition of DCIS and DCIS with associated invasion 
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4.1.2 DCIS progression is accompanied by integrin αvβ6 upregulation by 
myoepithelial cells and increased periductal fibronectin deposition 
We conducted an analysis of MEC expression of integrin αvβ6 and periductal 
deposition of TFN by immunohistochemical staining on a duct-by-duct basis in 
serial sections of DCIS tissues to assess their predictive value. Normal breast 
ducts, benign and DCIS lesions show an intact MEC layer as shown by SMA 
immunoreactivity (Figure 16a; panel 1-2 and Supplementary Figure S1). No 
staining for integrin αvβ6 was seen in normal ducts or benign lesions, whereas 
70% of non-high-grade pure DCIS cases exhibited staining for integrin αvβ6, 
compared to 90% of high-grade pure DCIS and DCIS/IDC cases. In these cases, 
45% (256/569) of high-grade and 27% (165/621) of non-high-grade pure DCIS 
ducts showed MEC staining for integrin αvβ6, with a significantly higher frequency 
of positivity in high-grade DCIS (p<0.05). The frequency of integrin αvβ6 
expression by MECs in high-grade DCIS/IDC ducts is significantly higher than in 
pure DCIS, with 68% (473/697) of ducts showing positivity (p<0.05) (Figure 16a; 
panel 3-4; quantified in Figure 16b; top bar graph) (Table 13). In contrast, all DCIS 
cases, with and without invasion, exhibited staining for total FN (TFN). 
Quantification of the amount of TFN surrounding each duct demonstrated that the 
stromal region bordering DCIS ducts contained more TFN than normal ducts 
(68%; 796/1170), and this significantly increased further in DCIS/IDC (87%; 
556/638) (p<0.05) (Figure 16a; panel 5-6; quantified in Figure 16b; bottom bar 
graph) (Table 14). These findings support previous work in our laboratory, with 
the de novo expression of integrin αvβ6 by MECs and increased deposition of FN 
in DCIS, and these alterations are associated with progression to invasion. These 
data suggest integrin αvβ6 and FN may be used as a marker of DCIS more likely 
to progress to invasive disease. 
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Figure 16. DCIS progression is accompanied by upregulation of integrin v6 by
myoepithelial cells and increased periductal fibronectin deposition. a)
Immunohistological staining of human breast tumour samples (staining for SMA; panel 1-2,
integrin v6; panel 3-4, and TFN; panel 5-6) featuring areas of normal, DCIS and
DCIS/IDC. Magnification x5 and x20. Scale bar, 200μm and 100mm, respectively. b)
Quantitative analysis of duct-by-duct staining (integrin v6; top bar graph, and TFN; second
bar graph). Bars represent the average percentage of ducts positive for integrin v6 or TFN
in normal (0/944 and 57/921 ducts, respectively), DCIS (421/1190 and 796/1170 ducts) and
DCIS/IDC (473/697 and 556/638 ducts) patient samples and errors bars represent ±SEM.
Representative images are shown. p-value ≤0.001 (‘***’), ≤0.01 (‘**’) and ≤0.05 (‘*’)
considered significant.
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Number of ducts (%)  
αvβ6-positive αvβ6-negative Total 
Normal 0 (0%) 944 (100%) 944 
Benign 0 (0%) 38 (100%) 38 
DCIS 
Non-high-grade 165 (27%) 456 (74%) 621 
High-grade 256 (45%) 313 (55%) 569 
DCIS/IDC 473 (68%) 224 (32%) 697 
2869 
 
Table 13. Myoepithelial cell expression of integrin αvβ6 in DCIS and DCIS with associated 
invasion 
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Number of ducts (%)  
TFN-positive TFN-negative Total 
Normal 57 (6%) 864 (94%) 921 
Benign 8 (21%) 30 (79%) 38 
DCIS 
Non-high-grade 432 (70%) 188 (30%) 620 
High-grade 364 (66%) 186 (34%) 550 
DCIS/IDC 556 (87%) 82 (13%) 638 
2767 
 
Table 14. Periductal fibronectin expression in DCIS and DCIS with associated invasion 
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4.1.3 Breast tissue composition correlates with integrin αvβ6 upregulation 
by myoepithelial cells and increased periductal fibronectin 
deposition in DCIS progression 
The number of positive DCIS ducts for both integrin αvβ6 and TFN were 
correlated to tissue composition within each case using Pearsons x2 test. This 
identified the progressive increase in the epithelial component in DCIS 
progression correlated with the upregulation of integrin αvβ6 by MECs (p<0.05) 
(Figure 17a; quantified in left bar graph). In contrast, the progressive increase in 
the stromal component correlated with the increased deposition of TFN into the 
periductal microenvironment with DCIS progression (p<0.05) (Figure 17b; 
quantified in right bar graph). These data suggest that breast tissue remodelling 
in the progression of DCIS to invasive disease, associates with specific cellular 
and matrix changes. 
 
Figure 17. Breast tissue composition correlates with integrin v6 upregulation by
myoepithelial cells and increased periductal fibronectin deposition in DCIS
progression. a) Immunohistochemical images of an integrin v6-negative and integrin
v6-positive case with low and high epithelial content (panel 1-2; left and right,
respectively). Correlation of percentage epithelial area and the percentage of integrin v6-
positive ducts within each DCIS case (scatter plot; left). Magnification x0.2 and x2. Scale bar
5000mm and 500mm respectively. b) Immunohistochemical images of a TFN-negative and
TFN-positive case with low and high stromal content (panel 1-2; left and right, respectively).
Correlation of percentage stromal area and the percentage of TFN-positive ducts within each
DCIS case (scatter plot; right). Representative images are shown.
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4.1.4 Integrin αvβ6 expression by myoepithelial cells and periductal 
fibronectin deposition are correlated in DCIS ducts 
To investigate a relationship between integrin αvβ6 and TFN, we examined on a 
matched duct-by-duct basis the dual expression of integrin αvβ6 by MECs and 
TFN deposition surrounding the duct in serial sections of DCIS tissues. A 
significant association between their expression was identified using Pearsons x2 
test (p<0.001) (Figure 18a; quantified in Figure 18b) (Table 15). These data 
support a relationship between integrin αvβ6 and FN expression in DCIS ducts. 
Together, the data presented here suggest evolving tissue mechanics during 
DCIS progression associate with the upregulation of integrin αvβ6 expression by 
MECs and increased periductal FN deposition, and their expression is associated 
in DCIS. However, it is unclear here whether integrin αvβ6-positive MECs are a 
contributing source of FN deposition in DCIS. 
 
Figure 18. Integrin v6 expression by myoepithelial cells and periductal fibronectin
deposition are correlated in DCIS ducts. a) Colocalisation of integrin v6 and TFN in
serial sections of human breast tumour samples. Magnification x10. Scale bar, 100mm. b)
Quantification of the percentage of DCIS ducts (total of 1685 matched ducts) stained
negative or positive for integrin v6 and TFN on serial tissue sections. Representative
images are shown.
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Number of ducts (%)  
αvβ6-positive αvβ6-negative Total 
TFN-positive 710 (42%) 567 (34%) 1277 
TFN-negative 47 (3%) 361 (21%) 408 
Total 757 928 1685 
 
Table 15. Myoepithelial cell expression of integrin αvβ6 and periductal fibronectin 
expression in DCIS and DCIS with associated invasion 
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4.2 PHENOTYPIC CHARACTERISTICS IN PRIMARY AND CELL LINE 
MODELS OF NORMAL AND DCIS MYOEPITHELIAL CELLS 
 
4.2.1 Integrin αvβ6-positive primary DCIS-myoepithelial cells upregulate 
fibronectin expression 
To investigate MEC expression of integrin αvβ6 in promoting the expression and 
deposition of FN, we used isolated primary DCIS-associated and normal MECs 
and established MEC lines with and without the expression of integrin αvβ6. 
Integrin αvβ6 expression by MECs in DCIS cases with organoid samples 
available was first assessed using immunohistochemical analyses. Two integrin 
αvβ6-negative (D1632 and D1730) and two integrin αvβ6-positive (β6-D2168 and 
β6-D2089) DCIS tissue samples with organoid preparations (Figure 19a; panel 
1-2 and Supplementary Figure S2) (tumour grade matched; Table 7) were then 
selected to establish whether alterations in FN expression were associated with 
integrin αvβ6 in DCIS-MECs. DCIS organoids were depleted of mature LECs 
(EpCAM+) and fractionated into MECs (ITGB4+/ITGB6-/+) and stromal cells 
(ITGB4-/ITGB6-) (Figure 19b-c; Supplementary Figure S2). Significantly more FN 
mRNA was detected in primary DCIS-MECs isolated from integrin αvβ6-positive 
than integrin αvβ6-negative DCIS cases (Figure 19d; Supplementary Figure S2). 
No integrin αvβ6 expression was seen in normal primary MECs isolated by FACS 
from reduction mammoplasty organoid samples (Supplementary Figure S3). 
These findings support the de novo expression of integrin αvβ6 by DCIS-MECs, 
and suggest the increased deposition of FN in DCIS is contributed by integrin 
αvβ6-positive MECs. 
 
Figure 19. Integrin v6-positive primary DCIS-myoepithelial cells upregulate
fibronectin expression. a) Immunohistochemical images of an integrin v6-negative and
integrin v6-positive DCIS case is shown (additional patients in Supplementary Figure S2).
Magnification x5 and x10. Scale bar, 200mm and 100mm, respectively. b, c) FACS plots of
DCIS organoid samples; D1632 (b) and 6-D2168 (c) separated by the expression of
EpCAM (phycoerythrin (PE) fluorescence; blue gate), integrin 64 and v6 (Alexa-Fluor
488 and allophycocyanin (APC) fluorescence, respectively; orange gate). d) qRT-PCR
analysis of integrin v6, TFN, FN-EDA and FN-EDB mRNA levels in D1632 and 6-D2168.
The values are presented as the mean percentage change in expression relative to D1632.
Representative images are shown, and analyses is shown as a mean of 3 independent
experiments ±SEM. p-value ≤0.01 (‘**’) and ≤0.05 (‘*’) considered significant.
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4.2.2 Integrin αvβ6 overexpression in primary normal myoepithelial cells 
upregulates fibronectin expression 
Primary normal MECs which lack integrin αvβ6 expression (N-127, N-1492 and 
N-1989), were isolated by magnetic bead separation from reduction 
mammoplasty organoid samples (patient age and menopausal status matched) 
based on their expression of CD10 [439]. To further support the findings observed 
in isolated DCIS-MECs, transient overexpression of integrin αvβ6 was induced in 
primary normal MECs to model DCIS-MECs (β6-127, β6-1492 and β6-1989, 
respectively). Overexpression of integrin αvβ6 was confirmed using 
immunoblotting (p<0.01, p<0.01, and p<0.001, respectively) (Figure 20ai-iii; 
quantified in Figure 20bi-iii, respectively). A concomitant increase in TFN and FN-
EDA expression in integrin αvβ6-overexpressing primary normal MECs was 
identified by immunoblotting (p<0.05) (Figure 20ai-iii; quantified in Figure 20bi-iii, 
respectively). These findings further support a relationship between integrin αvβ6 
expression and FN deposition by DCIS-MECs. 
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Figure 20. Integrin v6 overexpression in primary normal myoepithelial cells
upregulates fibronectin expression. a) Immunoblotting for integrin v6, TFN, FN-EDA
and HSC70 in primary normal MECs with and without integrin v6 expression ((i) 6-127
and N-127; (ii) 6-1492 and N-1492; (iii) 6-1989 and N-1989, respectively). b)
Densitometric analysis of integrin v6, TFN, FN-EDA and HSC70 signal intensities were
determined using ImageJ. The relative protein levels of integrin v6, TFN and FN-EDA
were normalised to HSC70 on the same membrane. The values are presented as the
relative level in integrin v6-positive MECs normalised to integrin v6-negative MECs.
Representative immunoblots of at least 3 independent experiments are shown, and analyses
is shown as a mean of 3 independent experiments ±SEM. p-value ≤0.001 (‘***’), ≤0.01 (‘**’)
and ≤0.05 (‘*’) considered significant.
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4.2.3 Integrin αvβ6-positive myoepithelial cell line upregulates deposition 
of a fibronectin matrix 
A MEC line with and without stable expression of integrin αvβ6 (β6-1089 and N-
1089, respectively) were used to further model DCIS and normal MECs, 
respectively. Integrin αvβ6 was confirmed to be upregulated by β6-1089 using 
immunofluorescent staining (p<0.05) and immunoblotting (p<0.05), with low 
levels of integrin αvβ6 detected in N-1089 (Figure 21a and 21c; quantified in 
Figure 21b and 21d, respectively). A concomitant increase in TFN and FN-EDA 
expression in β6-1089 was identified by immunoblotting (p<0.05 and p<0.01, 
respectively) (Figure 21c; quantified in Figure 21d). TFN and FN-EDA expression 
were also significantly upregulated in cCM obtained from β6-1089 (p<0.01) 
(Figure 21e; quantified in Figure 21f). These findings were supported at the 
mRNA level (Figure 21g). Additionally, higher levels of TFN and FN-EDA were 
detected in both DOC-soluble and DOC-insoluble material isolated from β6-1089 
compared to N-1089 (p<0.01) (Figure 22a; quantified in Figure 22b). 
Furthermore, significantly more TFN and FN-EDA was detected in DOC-insoluble 
material compared to DOC-soluble material in β6-1089 (p<0.01 and p<0.001, 
respectively). Integrin αvβ6 was only detectable in DOC-soluble material, and 
higher levels of integrin αvβ6 were confirmed in β6-1089 compared to N-1089 
(p<0.01) (Figure 22a; quantified in Figure 22b). Consistently, immunofluorescent 
staining revealed a progressive and significant increase in the incorporation of 
FN; both TFN and FN-EDA, into a fibrillar matrix surrounding β6-1089, as 
compared to N-1089 (p<0.01) (Figure 23a; quantified in Figure 23b), and these 
FN fibrils surrounding β6-1089 progressively increased in number and length 
(p<0.01) (Table 16). These data support our immunohistochemical analysis, 
which identified an association between MEC expression of integrin αvβ6 and 
periductal FN deposition. Together, these data support the use of both primary 
and MEC lines with and without integrin αvβ6 expression as a model of DCIS and 
normal MECs to investigate the tumour-promoting function of such alterations.  
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Figure 21. Integrin v6-positive myoepithelial cell line upregulates fibronectin
expression. a) Immunofluorescent staining for integrin v6 in N-1089 and 6-1089.
Magnification ×63. Scale bar, 20μm. b) Fluorescent analysis of integrin v6 signal
intensities were determined using the ZEN 2009 image analysis software. The values are
presented as the relative fluorescence in 6-1089 normalised to N-1089. c) Immunoblotting
for integrin v6, TFN, FN-EDA and HSC70 in N-1089 and 6-1089. d) Densitometric
analysis of integrin v6, TFN, FN-EDA and HSC70 signal intensities were determined
using ImageJ. The relative protein levels of integrin v6, TFN and FN-EDA were
normalised to HSC70 on the same membrane. The values are presented as the relative
level in 6-1089 normalised to N-1089. e) Immunoblotting for TFN and FN-EDA in
concentrated conditioned media (cCM) from N-1089 and 6-1089. f) Densitometric analysis
of TFN and FN-EDA signal intensities were determined using ImageJ and are presented as
the relative level in 6-1089 normalised to N-1089. g) qRT-PCR analysis of integrin v6,
TFN, FN-EDA and FN-EDB mRNA levels in N-1089 and 6-1089. The values are presented
as the mean percentage change in expression relative to N-1089. Representative
fluorescent images and immunoblots of at least 3 independent experiments are shown, and
analyses is shown as a mean of 3 independent experiments ±SEM. p-value ≤0.01 (‘**’) and
≤0.05 (‘*’) considered significant.
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Figure 22. Integrin v6-positive myoepithelial cell line upregulates DOC-soluble and
DOC-insoluble fibronectin expression. a) Immunoblotting for integrin v6, TFN, FN-EDA
and HSC70 in DOC-soluble and DOC-insoluble material from N-1089 and 6-1089. b)
Densitometric analysis of integrin v6, TFN, FN-EDA and HSC70 signal intensities in DOC-
soluble (sol) and DOC-insoluble (insol) material were determined using ImageJ. The relative
protein levels of integrin v6, TFN and FN-EDA were normalised to HSC70 on the same
membrane. The values are presented as the relative level in 6-1089 normalised to N-1089.
Representative immunoblots of 3 independent experiments are shown, and densitometric
analysis is shown as a mean of 3 independent experiments ±SEM. p-value ≤0.001 (‘***’) and
≤0.01 (‘**’) considered significant.
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Figure 23. Integrin v6-positive myoepithelial cell line upregulates deposition of a
fibronectin matrix. a) Immunofluorescent staining for TFN and FN-EDA in N-1089 and 6-
1089 cultured for 48, 72 and 96 hours. Substantially higher levels of TFN and FN-EDA were
detected in 6-1089 compared to N-1089, and FN produced by 6-1089 assembled into a
fibrillar matrix. Magnification ×63. Scale bar, 20μm. b) Fluorescence analysis of (i) TFN and
(ii) FN-EDA signal intensities were determined using the ZEN 2009 image analysis software.
The values are presented as the relative fluorescence in 6-1089 normalised to N-1089 of
the same time point. Representative fluorescent images of 3 independent experiments are
shown, and analyses is shown as a mean of 3 independent experiments ±SEM. p-value
≤0.01 (‘**’) considered significant.
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Fibril length in µm (% of cells with fibrils) 
N-1089 β6-1089 
TFN FN-EDA TFN FN-EDA 
48 hours 0 (0) 0 (0) 6.2 (40) 5.4 (55) 
72 hours 4.8 (32) 4.1 (30) 11.8 (66) 11.6 (74) 
96 hours 6.1 (48) 5.8 (41) 17.2 (91) 15.5 (92) 
 
Table 16. Integrin αvβ6-positive myoepithelial cell line upregulates deposition of a 
fibronectin matrix 
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4.3 FUNCTION OF PHENOTYPIC CHARACTERISTICS IN PRIMARY AND 
CELL LINE MODELS OF NORMAL AND DCIS MYOEPITHELIAL CELLS 
 
4.3.1 Integrin αvβ6-overexpressing primary normal myoepithelial cells 
activate TGFβ signalling in a fibronectin-dependent manner 
Previous studies have demonstrated a role for a mechanically resistant FN matrix 
in liberating active TGFβ by integrin αvβ6 [212]. Allen and colleagues 
demonstrated the ability of β6-1089 to preferentially migrate and bind to LAP, and 
activate TGFβ compared to N-1089, and these functions are mediated exclusively 
by integrin αvβ6 [114]. We next assessed the expression of phospho-SMAD2 as 
a marker of activate TGFβ signalling to analyse the role of FN in integrin αvβ6-
mediated TGFβ activation by MECs. We have then shown that overexpression of 
integrin αvβ6 in all primary normal MECs (β6-127, β6-1492 and β6-1989), led to 
the upregulation of phospho-SMAD2 under basal conditions (p<0.01, p<0.05 and 
p<0.01, respectively) (Figure 24-26a; quantified in Figure 24-26b, respectively) 
and following stimulation with exogenous TGFβ1 at all time points (p<0.05) 
(Figure 24-26c, quantified in Figure 24-26d, respectively) compared to their 
integrin αvβ6-negative counterpart (N-127, N-1492 and N-1989). The contribution 
of FN expression by integrin αvβ6-overexpressing primary MECs to activate 
TGFβ signalling was next analysed. Knockdown of TFN expression using siRNA 
targeting TFN in integrin αvβ6-overexpressing primary MECs (p<0.01) (Figure 
27ai-iii; quantified in Figure 27bi-iii) reduced the level of phospho-SMAD2 under 
basal conditions (p<0.01, p<0.01 and p<0.05, respectively) (Figure 28-30a; 
quantified in Figure 28-30b, respectively) and following stimulation with 
exogenous TGFβ1 at all time points (p<0.05) (Figure 28-30c, quantified in Figure 
28-30d, respectively). These data support the function of FN in integrin αvβ6-
mediated activation of TGFβ signaling. 
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Figure 24. Integrin v6-overexpressing primary normal myoepithelial cells promote
canonical TGF signalling. a, c) Immunoblotting for phospho-SMAD2 (p-SMAD2), SMAD2
and HSC70 in 6-127 and N-127 in (a) basal conditions and (c) stimulation with exogenous
TGF1. b, d) Densitometric analysis of p-SMAD2, SMAD2 and HSC70 signal intensities
were determined using ImageJ. The relative protein levels of p-SMAD2 and SMAD2 were
normalised to HSC70 on the same membrane. The expression of p-SMAD2 is normalised to
SMAD2 expression under the same conditions. These data are then presented as the
relative level by normalising to the control as depicted on the y-axis. Representative images
of 3 independent immunoblots are shown, and densitometric analysis is shown as a mean of
3 experiments ±SEM. p-value ≤0.01 (‘**’) and ≤0.05 (‘*’) considered significant.
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Figure 25. Integrin v6-overexpressing primary normal myoepithelial cells promote
canonical TGF signalling. a, c) Immunoblotting for p-SMAD2, SMAD2 and HSC70 in 6-
1492 and N-1492 in (a) basal conditions and (c) stimulation with exogenous TGF1. b, d)
Densitometric analysis of p-SMAD2, SMAD2 and HSC70 signal intensities were determined
using ImageJ. The relative protein levels of p-SMAD2 and SMAD2 were normalised to
HSC70 on the same membrane. The expression of p-SMAD2 is normalised to SMAD2
expression under the same conditions. These data are then presented as the relative level
by normalising to the control as depicted on the y-axis. Representative images of 3
independent immunoblots are shown, and densitometric analysis is shown as a mean of 3
experiments ±SEM. p-value ≤0.05 (‘*’) considered significant.
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Figure 26. Integrin v6-overexpressing primary normal myoepithelial cells promote
canonical TGF signalling. a, c) Immunoblotting for p-SMAD2, SMAD2 and HSC70 in 6-
1989 and N-1989 in (a) basal conditions and (c) stimulation with exogenous TGF1. b, d)
Densitometric analysis of p-SMAD2, SMAD2 and HSC70 signal intensities were determined
using ImageJ. The relative protein levels of p-SMAD2 and SMAD2 were normalised to
HSC70 on the same membrane. The expression of p-SMAD2 is normalised to SMAD2
expression under the same conditions. These data are then presented as the relative level
by normalising to the control as depicted on the y-axis. Representative images of 3
independent immunoblots are shown, and densitometric analysis is shown as a mean of 3
experiments ±SEM. p-value ≤0.01 (‘**’) and ≤0.05 (‘*’) considered significant.
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Figure 27. Knockdown of fibronectin expression in integrin v6-overexpressing
primary normal myoepithelial cells. a) Immunoblotting for integrin v6, TFN, FN-EDA
and HSC70 in integrin v6-positive primary normal MECs ((i) 6-127, (ii) 6-1492 and (iii)
6-1989) with NTC or TFN siRNA (TFN Kd). b) Densitometric analysis of integrin v6,
TFN, FN-EDA and HSC70 signal intensities were determined using ImageJ. The relative
protein levels of integrin v6, TFN and FN-EDA were normalised to HSC70 on the same
membrane. The values are presented as the relative level in TFN Kd normalised to NTC.
Representative immunoblots of at least 3 independent experiments are shown, and analyses
is shown as a mean of 3 independent experiments ±SEM. p-value ≤0.01 (‘**’) considered
significant, ‘ns’ indicates not significant.
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Figure 28. Integrin v6-overexpressing primary normal myoepithelial cells promote
canonical TGF signalling in a fibronectin-dependent manner. a, c) Immunoblotting for
p-SMAD2, SMAD2 and HSC70 in 6-127 with NTC or TFN siRNA (TFN Kd) in (a) basal
conditions and (c) stimulation with exogenous TGF1. b, d) Densitometric analysis of p-
SMAD2, SMAD2 and HSC70 signal intensities were determined using ImageJ. The relative
protein levels of p-SMAD2 and SMAD2 were normalised to HSC70 on the same membrane.
The expression of p-SMAD2 is normalised to SMAD2 expression under the same conditions.
These data are then presented as the relative level by normalising to the control as depicted
on the y-axis. Representative images of 3 independent immunoblots are shown, and
densitometric analysis is shown as a mean of 3 experiments ±SEM. p-value ≤0.01 (‘**’) and
≤0.05 (‘*’) considered significant.
160
p-SMAD2 - 60 kDa
SMAD2 - 60 kDa
HSC70 - 70 kDa
NTC TFN Kd
1492Na)
NTC TFN Kd
0 05 515 15 3030
1492N
p-SMAD2
SMAD2
HSC70
- 60 kDa
- 60 kDa
- 70 kDa
TGF:
c)
d)
(min)
b)
NTC TFN Kd
0.0
0.5
1.0
1.5
**
Re
lat
ive
 le
ve
l t
o 
NT
C
0 5 15 30 0 5 15 30
0
1
2
3
4
NTC TFN Kd
*
TGF: (min)
Re
la
tiv
e 
le
ve
l t
o
un
st
im
ul
at
ed
 N
TC
Figure 29. Integrin v6-overexpressing primary normal myoepithelial cells promote
canonical TGF signalling in a fibronectin-dependent manner. a, c) Immunoblotting for
p-SMAD2, SMAD2 and HSC70 in 6-1492 with NTC or TFN siRNA (TFN Kd) in (a) basal
conditions and (c) stimulation with exogenous TGF1. b, d) Densitometric analysis of p-
SMAD2, SMAD2 and HSC70 signal intensities were determined using ImageJ. The relative
protein levels of p-SMAD2 and SMAD2 were normalised to HSC70 on the same membrane.
The expression of p-SMAD2 is normalised to SMAD2 expression under the same conditions.
These data are then presented as the relative level by normalising to the control as depicted
on the y-axis. Representative images of 3 independent immunoblots are shown, and
densitometric analysis is shown as a mean of 3 experiments ±SEM. p-value ≤0.01 (‘**’) and
≤0.05 (‘*’) considered significant.
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Figure 30. Integrin v6-overexpressing primary normal myoepithelial cells promote
canonical TGF signalling in a fibronectin-dependent manner. a, c) Immunoblotting for
p-SMAD2, SMAD2 and HSC70 in 6-1989 with NTC or TFN siRNA (TFN Kd) in (a) basal
conditions and (c) stimulation with exogenous TGF1. b, d) Densitometric analysis of p-
SMAD2, SMAD2 and HSC70 signal intensities were determined using ImageJ. The relative
protein levels of p-SMAD2 and SMAD2 were normalised to HSC70 on the same membrane.
The expression of p-SMAD2 is normalised to SMAD2 expression under the same conditions.
These data are then presented as the relative level by normalising to the control as depicted
on the y-axis. Representative images of 3 independent immunoblots are shown, and
densitometric analysis is shown as a mean of 3 experiments ±SEM. p-value ≤0.05 (‘*’)
considered significant.
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4.3.2 Integrin αvβ6-positive myoepithelial cell line activates TGFβ 
signalling in a fibronectin-dependent manner 
Consistent with the overexpression of integrin αvβ6 in primary MECs, significantly 
more phospho-SMAD2 was detected in β6-1089 compared to N-1089 using 
immunoblotting, both under basal conditions (p<0.05) (Figure 31a; quantified in 
Figure 31bi) and following stimulation with exogenous TGFβ1 (p<0.05) (Figure 
31c; quantified in Figure 31di). Additionally, phospho-ERK1/2 was upregulated in 
β6-1089 under basal conditions (p<0.05) (Figure 32a; quantified in Figure 32bi, 
respectively) and following stimulation with exogenous TGFβ1 at all time points 
(p<0.05) (Figure 32c, quantified in Figure 32di), compared to N-1089. This effect 
was reduced by knockdown of integrin αvβ6 expression in β6-1089 using siRNA 
targeting integrin β6 (Figure 33), both at the basal level (p<0.01) (Figure 31a and 
32a; quantified in Figure 31bii and 32bii, respectively) and in response to 
exogenous TGFβ1 (p<0.05) (Figure 31c and 32c; quantified in Figure 31dii and 
32dii, respectively). Moreover, knockdown of TFN expression in β6-1089 using 
siRNA targeting TFN (Figure 34), reduced the level of phospho-SMAD2 both at 
the basal level (p<0.05) (Figure 35a; quantified in Figure 35b) and in response to 
exogenous TGFβ1 (p<0.05) (Figure 35c; quantified in Figure 35d). The role of FN 
expression by integrin αvβ6-positive MECs in their ability bind to LAP was 
analysed. Knockdown of TFN expression in β6-1089 reduced both migration 
(p<0.01) (Figure 36a) and adhesion (p<0.01) (Figure 36b) to LAP. These data 
further support FN in integrin αvβ6-mediated activation of TGFβ signalling. 
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Figure 31. Integrin v6-positive myoepithelial cell line promotes canonical TGF
signalling. a, c) Immunoblotting for p-SMAD2, SMAD2 and HSC70 in (i) N-1089 and 6-
1089, and (ii) 6-1089 with NTC or integrin 6 siRNA (6 Kd) in (a) basal conditions and (c)
stimulation with exogenous TGF1. b, d) Densitometric analysis of p-SMAD2, SMAD2 and
HSC70 signal intensities were determined using ImageJ. The relative protein levels of p-
SMAD2 and SMAD2 were normalised to HSC70 on the same membrane. The expression of
p-SMAD2 is normalised to SMAD2 expression under the same conditions. These data are
then presented as the relative level by normalising to the control as depicted on the y-axis.
Representative images of 3 independent immunoblots are shown, and densitometric
analysis is shown as a mean of 3 experiments ±SEM. p-value ≤0.01 (‘**’) and ≤0.05 (‘*’)
considered significant.
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Figure 32. Integrin v6-positive myoepithelial cell line promotes non-canonical TGF
signalling. a, c) Immunoblotting for p-ERK1/2, ERK1/2 and HSC70 in (i) N-1089 and 6-
1089, and (ii) 6-1089 with NTC or integrin 6 siRNA (6 Kd) in (a) basal conditions and (c)
stimulation with exogenous TGF1. b, d) Densitometric analysis of p-ERK1/2, ERK1/2 and
HSC70 signal intensities were determined using ImageJ. The relative protein levels of p-
ERK1/2 and ERK1/2 were normalised to HSC70 on the same membrane. The expression of
p-ERK1/2 is normalised to ERK1/2 expression under the same conditions. These data are
then presented as the relative level by normalising to the control as depicted on the y-axis.
Representative images of 3 independent immunoblots are shown, and densitometric
analysis is shown as a mean of 3 experiments ±SEM. p-value ≤0.01 (‘**’) and ≤0.05 (‘*’)
considered significant.
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Figure 33. Knockdown of integrin v6 expression in an integrin v6-positive
myoepithelial cell line. a) Immunoblotting for integrin v6, TFN, FN-EDA and HSC70 in
6-1089 with NTC or integrin 6 siRNA (6 Kd). b) Densitometric analysis of integrin v6,
TFN, FN-EDA and HSC70 signal intensities were determined using ImageJ. The relative
protein levels of integrin v6, TFN and FN-EDA were normalised to HSC70 on the same
membrane. The values are presented as the relative level in 6 Kd normalised to NTC. c)
Immunoblotting for TFN and FN-EDA in cCM from 6-1089 with NTC or integrin 6 siRNA
(6 Kd). d) Densitometric analysis of TFN and FN-EDA signal intensities were determined
using ImageJ and are presented as the relative level in 6 Kd normalised to NTC. e) qRT-
PCR analysis of integrin v6, TFN, FN-EDA and FN-EDB mRNA levels in 6-1089 with
NTC or integrin 6 siRNA (6 Kd). The values are presented as the mean percentage
change in expression relative to the NTC. Representative immunoblots of at least 3
independent experiments are shown, and analyses is shown as a mean of 3 independent
experiments ±SEM. p-value ≤0.01 (‘**’) considered significant, ‘ns’ indicates not significant.
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Figure 34. Knockdown of fibronectin expression in an integrin v6-positive
myoepithelial cell line. a) Immunoblotting for integrin v6, TFN, FN-EDA and HSC70 in
6-1089 with NTC or TFN siRNA (TFN Kd). b) Densitometric analysis of integrin v6, TFN,
FN-EDA and HSC70 signal intensities were determined using ImageJ. The relative protein
levels of integrin v6, TFN and FN-EDA were normalised to HSC70 on the same
membrane. The values are presented as the relative level in TFN Kd normalised to NTC. c)
Immunoblotting for TFN and FN-EDA in cCM from 6-1089 with NTC or TFN siRNA (TFN
Kd). d) Densitometric analysis of TFN and FN-EDA signal intensities were determined using
ImageJ and are presented as the relative level in TFN Kd normalised to NTC. e) qRT-PCR
analysis of integrin v6, TFN, FN-EDA and FN-EDB mRNA levels in 6-1089 with NTC or
TFN siRNA (TFN Kd). The values are presented as the mean percentage change in
expression relative to the NTC. Representative immunoblots of at least 3 independent
experiments are shown, and analyses is shown as a mean of 3 independent experiments
±SEM. p-value ≤0.01 (‘**’) considered significant, ‘ns’ indicates not significant.
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Figure 35. Integrin v6-positive myoepithelial cell line promotes canonical TGF
signalling in a fibronectin-dependent manner. a, c) Immunoblotting for p-SMAD2,
SMAD2 and HSC70 in 6-1089 with NTC or TFN siRNA (TFN Kd) in (a) basal conditions
and (c) stimulation with exogenous TGF1. b, d) Densitometric analysis of p-SMAD2,
SMAD2 and HSC70 signal intensities were determined using ImageJ. The relative protein
levels of p-SMAD2 and SMAD2 were normalised to HSC70 on the same membrane. The
expression of p-SMAD2 is normalised to SMAD2 expression under the same conditions.
These data are then presented as the relative level by normalising to the control as depicted
on the y-axis. Representative images of 3 independent immunoblots are shown, and
densitometric analysis is shown as a mean of 3 experiments ±SEM. p-value ≤0.05 (‘*’) were
considered significant, ‘ns’ indicates not significant.
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Figure 36. Integrin v6-positive myoepithelial cell line mediates adhesion and
migration to LAP in a fibronectin-dependent manner. a) Adhesion of 6-1089 with NTC
or TFN siRNA (TFN Kd) to BSA and LAP. Background binding to BSA was subtracted from
LAP, and the values are then presented as the relative adhesion to LAP in TFN Kd
normalised to NTC. b) Migration of 6-1089 with NTC or TFN siRNA (TFN Kd) to BSA and
LAP. The number of migrating cells was quantified by counting the cells within the Transwell
insert and on the underside of the Transwell, and the total cell count was calculated by their
addition. The values are then presented as the relative migration to LAP by using the outer
chamber count versus total cell count. Analyses is shown as a mean of 3 independent
experiments ±SEM. p-value ≤0.01 (‘**’) and ≤0.05 (‘*’) considered significant.
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4.1.1 Integrin αvβ6-positive myoepithelial cell line mediates breast cancer 
cell invasion by TGFβ-dependent upregulation of MMP13 
We next investigated the role of FN in the tumour promoting function of integrin 
αvβ6-positive MECs. Previous data demonstrated integrin αvβ6-positive MECs 
promoted breast cancer cell invasion in vitro in a TGFβ-dependent upregulation 
of MMP9 [114]. Interestingly, we identified that CM isolated following knockdown 
of TFN in β6-1089 reduced both MDA-MB-231 and MCF-7 cell invasion (p<0.01) 
(Figure 37a), with no effect on proliferation (Figure 37b). Proteases were next 
measured in the CM using a human protease array to identify potential invasive-
promoting factors. We identified β6-1089 induce an overall increase in the 
secretion of MMPs, in particular, those involved in degradation of the BM and 
surrounding collagenous stroma, including; MMP9 and MMP13 (Figure 38ai). 
These findings were supported at the mRNA level (Figure 38bi), and increased 
MMP9 expression by β6-1089 was confirmed using gelatin zymography (p<0.01) 
(Figure 39a; quantified in Figure 39bi, respectively) (Supplementary Figure 4). 
These effects were reduced following knockdown of integrin αvβ6 in β6-1089 
(p<0.01) (Figure 38aii; Figure 38bii, Figure 39a; quantified in Figure 39bii, 
respectively). Moreover, knockdown of TFN in β6-1089 reduced MMP secretion, 
as identified by human protease array analysis (Figure 40a). These alterations 
were supported at the mRNA level (Figure 40b) and using gelatin zymography to 
detect MMP9 expression (p<0.05) (Figure 40c; quantified in Figure 40d). MMP 
expression by β6-1089 was further reduced by a TGFβRII blocking antibody 
(Figure 41a), in which MMP9 and MMP13 mRNA were significantly reduced 
(p<0.01 and 0.05, respectively) (Figure 41a), as supported by gelatin zymography 
for MMP9 expression (p<0.01) (Figure 41b; quantified in Figure 41c). The 
function of MMP13 in promoting breast cancer cell invasion in vitro by β6-1089 
was analysed. CM isolated following the knockdown of MMP13 expression in β6-
1089 using siRNA targeting MMP13 (p<0.001) (Figure 42a) reduced both MDA-
MB-231 and MCF-7 cell invasion (p<0.01) (Figure 42b), with no effect on 
proliferation (Figure 42c). These data suggest that our model of DCIS-
myoepithelial cells have a protease signature that is regulated by in a TGFβ-
dependent manner. While a functional relationship is demonstrated between 
integrin αvβ6 and FN here, the mechanism regulating their expression is unclear. 
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Figure 37. Integrin v6-positive myoepithelial cell line mediates breast cancer cell
invasion in vitro in a fibronectin-dependent manner. a) Invasion of MDA-MB-231 and
MCF-7 in response to CM from 6-1089 with NTC or TFN siRNA (TFN Kd). The number of
invading cells was quantified by counting the cells on the underside of the Transwell. The
values are presented as the relative invasion of breast cancer cells in the presence of CM
from 6-1089 with TFN Kd normalised to NTC. b) Proliferation of MDA-MB-231 and MCF-7
in response to CM from 6-1089 with NTC or TFN siRNA (TFN Kd). The values are
presented as the relative proliferation of breast cancer cells in the presence of CM from 6-
1089 with TFN Kd normalised to NTC. Analyses is shown as a mean of 3 independent
experiments ±SEM. p-value ≤0.01 (‘**’) considered significant, ‘ns’ indicates not significant.
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Figure 38. Integrin v6-positive myoepithelial cell line upregulates protease
expression. a) Human protease array analysis of cCM from (i) N-1089 and 6-1089, and (ii)
6-1089 with NTC or integrin 6 siRNA (6 Kd). Signal intensities of analytes were
determined using ImageJ and presented the relative level by normalising to the control as
depicted on the y-axis. b) qRT-PCR analysis of MMP2, MMP3, MMP7, MMP9, MMP10 and
MMP13 mRNA levels in (i) N-1089 and 6-1089, and (ii) 6-1089 with NTC or integrin 6
siRNA (6 Kd). The values are presented as the mean percentage change in expression
relative to the control. Analyses is shown as a mean of 3 independent experiments ±SEM. p-
value ≤0.01 (‘**’) and ≤0.05 (‘*’) considered significant, ‘ns’ indicates not significant.
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Figure 39. Integrin v6-positive myoepithelial cell line upregulates MMP9 expression.
a) Gelatin zymography for MMP9 expression in cCM from (i) N-1089 and 6-1089, and (ii)
6-1089 with NTC or integrin 6 siRNA (6 Kd). b) Densitometric analysis of MMP9 signal
intensities were determined using ImageJ. These data are then presented as the relative
level by normalising to the control as depicted on the y-axis. Representative images of 3
independent gelatin zymograms are shown, and densitometric analysis is shown as a mean
of 3 experiments ±SEM. p-value ≤0.01 (‘**’) considered significant.
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Figure 40. Integrin v6-positive myoepithelial cell line upregulates protease
expression in a fibronectin-dependent manner. a) Human protease array analysis of
cCM from 6-1089 with NTC or TFN siRNA (TFN Kd). Signal intensities of analytes were
determined using ImageJ and presented the relative level by normalising to the NTC. b)
qRT-PCR analysis of MMP2, MMP3, MMP7, MMP9, MMP10 and MMP13 mRNA levels in
6-1089 with NTC or TFN siRNA (TFN Kd). The values are presented as the mean
percentage change in expression relative to the NTC. c) Gelatin zymography for MMP9
expression in cCM from 6-1089 with NTC or TFN siRNA (TFN Kd). d) Densitometric
analysis of MMP9 signal intensities were determined using ImageJ. These data are then
presented as the relative level by normalising to the NTC. Representative images of 3
independent gelatin zymograms are shown, and analyses is shown as a mean of 3
experiments ±SEM. p-value ≤0.01 (‘**’) and ≤0.05 (‘*’) considered significant, ‘ns’ indicates
not significant.
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Figure 41. Integrin v6-positive myoepithelial cell line upregulates protease
expression in a TGF-dependent manner. a) qRT-PCR analysis of MMP2, MMP3, MMP7,
MMP9, MMP10 and MMP13 mRNA levels in 6-1089 with IgG control or TGFRII (RII)
blocking antibody. The values are presented as the mean percentage change in expression
relative to the IgG control antibody. b) Gelatin zymography for MMP9 expression in cCM
from 6-1089 with IgG control or TGFRII (RII) blocking antibody. c) Densitometric analysis
of MMP9 signal intensities were determined using ImageJ. These data are then presented
as the relative level by normalising to the IgG control antibody. Representative images of 3
independent gelatin zymograms are shown, and analyses is shown as a mean of 3
experiments ±SEM. p-value ≤0.01 (‘**’) and ≤0.05 (‘*’) considered significant, ‘ns’ indicates
not significant.
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Figure 42. Integrin v6-positive myoepithelial cell line mediates breast cancer cell
invasion in vitro in a MMP13-dependent manner. a) qRT-PCR analysis of MMP13 mRNA
levels in 6-1089 with NTC and MMP13 siRNA (MMP13 Kd). The values are presented as
the mean percentage change in expression relative to the NTC, which was set to 100%. b)
Invasion of MDA-MB-231 and MCF-7 in response to CM from 6-1089 with NTC or MMP13
siRNA (MMP13 Kd). The number of invading cells was quantified by counting the cells on
the underside of the Transwell. The values are presented as the relative invasion of breast
cancer cells in the presence of CM from 6-1089 with MMP13 Kd normalised to NTC. c)
Proliferation of MDA-MB-231 and MCF-7 in response to CM from 6-1089 with NTC or
MMP13 siRNA (MMP13 Kd). The values are presented as the relative proliferation of breast
cancer cells in the presence of CM from 6-1089 with MMP13 Kd normalised to NTC.
Analyses is shown as a mean of 3 independent experiments ±SEM. p-value ≤0.001 (‘***’)
and ≤0.01 (‘**’) considered significant, ‘ns’ indicates not significant.
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4.4 REGULATION OF PHENOTYPIC CHARACTERISTICS IN NORMAL AND 
DCIS MYOEPITHELIAL CELLS 
 
4.4.1 DCIS-myoepithelial cell phenotype is induced in primary normal 
myoepithelial cells by TGFβ1 
TGFβ has been implicated in inducing a tumour-promoting phenotype in stromal 
cell types which constitute the breast microenvironment, including endothelial, 
immune cells and fibroblasts [285]. We next investigated the influence of TGFβ1 
on primary normal MEC phenotype. Stimulation of integrin αvβ6-negative primary 
normal MECs (N-127, N-1492 and N-1989) with TGFβ1 led to the induction of 
integrin αvβ6 expression (p<0.01, p<0.01 and p<0.05 respectively), and a 
concomitant increase in TFN and FN-EDA expression, as shown by 
immunoblotting (p<0.01, p<0.01 and p<0.05 respectively) (Figure 43ai-iii; 
quantified in Figure 43bi-iii, respectively). These findings were supported at the 
mRNA level (Figure 44ai-iii). Moreover, stimulation with TGFβ1 induced the 
secretion of MMPs, with the exception of MMP7 and 8, in N-1492 and N-1989, 
as shown using human protease arrays (Figure 45i-ii). These findings were 
supported at the mRNA level (Figure 45bi-ii). These data suggest TGFβ may be 
capable of switching the normal phenotype of MECs to that characteristic of 
tumour-promoting DCIS-MECs. 
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Figure 43. Integrin v6 and fibronectin expression is induced in primary normal
myoepithelial cells by TGF1. a) Immunoblotting for integrin v6, TFN, FN-EDA and
HSC70 in primary normal MECs (N-127, N-1492 and N-1989) with (+) and without (-) TGF1
stimulation. b) Densitometric analysis of integrin v6, TFN, FN-EDA and HSC70 signal
intensities were determined using ImageJ. The relative protein levels of integrin v6, TFN
and FN-EDA were normalised to HSC70 on the same membrane. The values are presented
as the relative level in stimulated primary normal MECs normalised to their unstimulated
control. Representative immunoblots of at least 3 independent experiments are shown, and
analyses is shown as a mean of 3 independent experiments ±SEM. p-value ≤0.01 (‘**’) and
≤0.05 (‘*’) considered significant, ‘ns’ indicates not significant.
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Figure 44. Integrin v6 and fibronectin expression is induced in primary normal
myoepithelial cells by TGF1. a) qRT-PCR analysis of integrin v6, TFN, FN-EDA and
FN-EDB mRNA levels in primary normal MECs ((i) N-127, (ii) N-1492 and (iii) N-1989) with
(+) and without (-) TGF1 stimulation. The values are presented as the mean percentage
change in expression relative to the unstimulated control. Analyses is shown as a mean of 3
independent experiments ±SEM. p-value ≤0.001 (‘***’), ≤0.01 (‘**’) and ≤0.05 (‘*’) considered
significant.
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Figure 45. Protease expression is induced in primary normal myoepithelial cells by
TGF1. a) Human protease array analysis of cCM from primary normal MECs ((i) N-1492
and (ii) N-1989) with (+) and without (-) TGF1 stimulation. Signal intensities of analytes
were determined using ImageJ and presented the relative level in stimulated primary normal
MECs normalised to their unstimulated control. b) qRT-PCR analysis of MMP2, MMP3,
MMP7, MMP9, MMP10 and MMP13 mRNA levels in primary normal MECs ((i) N-1492 and
(ii) N-1989) with (+) and without (-) TGF1 stimulation. The values are presented as the
mean percentage change in expression relative to the unstimulated control. Analyses is
shown as a mean of 3 independent experiments ±SEM. p-value ≤0.01 (‘**’) and ≤0.05 (‘*’)
considered significant, ‘ns’ indicates not significant.
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4.4.2 DCIS-myoepithelial cell phenotype is induced in a normal 
myoepithelial cell line by TGFβ1 
Consistent with TGFβ1 stimulation in primary normal MECs, stimulation of N-
1089 with TGFβ1 led to the induction of integrin αvβ6 expression (p<0.01), and a 
concomitant increase in TFN and FN-EDA expression (p<0.01) (Figure 46a; 
quantified in Figure 46b, respectively), as shown by immunoblotting. In turn, 
stimulation of β6-1089 with TGFβ1 led to a further increase in the expression of 
integrin αvβ6, TFN and FN-EDA (p<0.01) (Figure 46a; quantified in Figure 46b, 
respectively). These findings were supported at the mRNA level (Figure 46c). 
Moreover, as seen in primary normal MECs, stimulation of N-1089 with TGFβ1 
induced the expression of MMPs, with the exception of MMP7, as identified at the 
mRNA level (Figure 47). These data suggest that the consistent DCIS-MEC 
phenotype observed, with upregulation of integrin αvβ6, FN and MMP13, may be 
induced by TGFβ. However, it is unclear whether the increased level of TGFβ 
activation by integrin αvβ6-positive MECs is capable of inducing this phenotype. 
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Figure 46. Integrin v6 and fibronectin expression is induced in a normal
myoepithelial cell line by TGF1. a) Immunoblotting for integrin v6, TFN, FN-EDA and
HSC70 in N-1089 and 6-1089 with (+) and without (-) TGF1 stimulation. b) Densitometric
analysis of integrin v6, TFN, FN-EDA and HSC70 signal intensities were determined
using ImageJ. The relative protein levels of integrin v6, TFN and FN-EDA were
normalised to HSC70 on the same membrane. The values are presented as the relative
level by normalising to unstimulated N-1089. c) qRT-PCR analysis of integrin v6, TFN,
FN-EDA and FN-EDB mRNA levels in N-1089 and 6-1089 with (+) and without (-) TGF1
stimulation. The values are presented as the mean percentage change in expression relative
to the unstimulated control. Representative immunoblots of at least 3 independent
experiments are shown, and analyses is shown as a mean of 3 independent experiments
±SEM. p-value ≤ 0.001 (‘***’), ≤0.01 (‘**’) and ≤0.05 (‘*’) considered significant.
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Figure 47. Protease expression is induced in a normal myoepithelial cell line by
TGF1. qRT-PCR analysis of MMP2, MMP3, MMP7, MMP9, MMP10 and MMP13 mRNA
levels in N-1089 and 6-1089 with (+) and without (-) TGF1 stimulation. The values are
presented as the mean percentage change in expression relative to the unstimulated control.
Analyses is shown as a mean of 3 independent experiments ±SEM. p-value ≤0.05 (‘*’)
considered significant, ‘ns’ indicates not significant.
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4.4.3 Deposition of a fibronectin matrix by an integrin αvβ6-positive 
myoepithelial cell line is TGFβ-dependent 
Knockdown of integrin αvβ6 expression by siRNA targeting integrin β6 in β6-
1089, was demonstrated using immunoblotting (p<0.01) (Figure 33a; quantified 
in Figure 33b) and immunofluorescence (p<0.01) however, TFN and FN-EDA 
expression were maintained (Figure 33a and 48a; quantified in Figure 33b and 
48bi, respectively). These findings were supported at the mRNA level (Figure 
33g). However, blockade of TGFβRII with both a blocking antibody in β6-1089 
significantly reduced TFN and FN-EDA expression, as shown by 
immunofluorescent staining (p<0.001) (Figure 48a; quantified in Figure 48bii) and 
immunoblotting (p<0.001) (Figure 49a; quantified in Figure 49b). TFN and FN-
EDA expression were also significantly reduced in cCM obtained from β6-1089 
following blockade of TGFβRII (p<0.001) (Figure 49c; quantified in Figure 49d). 
These findings were supported at the mRNA level (Figure 49e). Successful 
blockade of TGFβRII was confirmed by the almost complete reduction in 
phospho-SMAD2 levels, in comparison to the partial reduction seen following the 
knockdown of integrin αvβ6 expression in β6-1089 (Figure 50a; quantified in 
Figure 50b). These data suggest the increased deposition of FN in integrin αvβ6-
positive MECs is likely to due to the increased TGFβ signalling. However, 
unanswered in our model of DCIS progression is whether TGFβ initiates the 
upregulation of integrin αvβ6 to facilitate further TGFβ activation or another 
mechanism induces the upregulation of integrin αvβ6 to activate TGFβ. 
Regardless of the initiation event, TGFβ is likely to provide a feed forward 
mechanism to promote DCIS progression. 
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Figure 48. Deposition of a fibronectin matrix by an integrin v6-positive
myoepithelial cell line is TGF-dependent. a) Immunofluorescent staining for integrin
v6, TFN and FN-EDA in 6-1089 with NTC or integrin 6 siRNA (6 Kd), and 6-1089
with IgG control or TGFRII (RII) blocking antibody. Magnification ×63. Scale bar, 20μm. b)
Fluorescent analysis of integrin v6, TFN and FN-EDA signal intensities were determined
using the ZEN 2009 image analysis software. The values are presented as the relative
fluorescence in (i) 6 Kd normalised to NTC and (ii) TGFRII blocking antibody normalised
to IgG control antibody. Representative fluorescent images of at least 3 independent
experiments are shown, and analyses is shown as a mean of 3 independent experiments
±SEM. p-value ≤0.001 (‘***’) and ≤0.01 (‘**’) considered significant, ‘ns’ indicates not
significant.
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Figure 49. Upregulation of fibronectin expression by an integrin v6-positive
myoepithelial cell line is TGF-dependent. a) Immunoblotting for integrin v6, TFN, FN-
EDA and HSC70 in 6-1089 with IgG control and TGFRII (RII) blocking antibody. b)
Densitometric analysis of integrin v6, TFN, FN-EDA and HSC70 signal intensities were
determined using ImageJ. The relative protein levels of integrin v6, TFN and FN-EDA
were normalised to HSC70 on the same membrane. The values are presented as the
relative level in TGFRII blocking antibody normalised to IgG control antibody. c)
Immunoblotting for TFN and FN-EDA in cCM from 6-1089 with IgG control and TGFRII
(RII) blocking antibody. d) Densitometric analysis of TFN and FN-EDA signal intensities
were determined using ImageJ, and are presented as the relative level in TGFRII blocking
antibody normalised to IgG control antibody. e) qRT-PCR analysis of integrin v6, TFN,
FN-EDA and FN-EDB mRNA levels in 6-1089 with IgG control and TGFRII blocking
antibody. The values are presented as the mean percentage change in expression relative to
the IgG control. Representative immunoblots of at least 3 independent experiments are
shown, and analyses is shown as a mean of 3 independent experiments ±SEM. p-value
≤0.001 (‘***’) and ≤0.01 (‘**’) considered significant, ‘ns’ indicates not significant.
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Figure 50. Integrin v6-positive myoepithelial cell line activates TGF signalling
through TGFRII. a) Immunoblotting for p-SMAD2, SMAD2 and HSC70 in 6-1089 with (i)
NTC or integrin 6 siRNA (6 Kd) and (ii) IgG control or TGFRII (RII) antibody. b)
Densitometric analysis of p-SMAD2, SMAD2 and HSC70 signal intensities were determined
using ImageJ. The relative protein levels of p-SMAD2 and SMAD2 were normalised to
HSC70 on the same membrane. The expression of p-SMAD2 is normalised to SMAD2
expression under the same conditions. These data are then presented as the relative level
by normalising to the respective control. Representative images of 3 independent
immunoblots are shown, and densitometric analysis is shown as a mean of 3 experiments
±SEM. p-value ≤0.01 (‘**’) and ≤0.05 (‘*’) considered significant.
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4.4.4 DCIS duct expansion correlates with upregulation of integrin αvβ6 by 
myoepithelial cells 
Increased ECM deposition, as demonstrated here, can disrupt normal tissue 
homeostasis, and thereby the tension breast cells experience. Solid stress due 
to the expanding tumour volume in DCIS also alters tension. These mechanical 
stimuli detected by cells, induce gene-expression changes in order to respond to 
the new tissue tension. To investigate the role of duct expansion in influencing 
MEC phenotype, normal, benign and DCIS duct sizes (420, 38 and 1369 ducts, 
respectively) were analysed within our cohort of human breast tumour samples 
on sections stained immunohistochemically for integrin αvβ6 (Figure 51a; panel 
2-3 and Supplementary Figure S5). Only cross-sectional ducts were included in 
these analyses. Quantification of duct sizes, independent of integrin αvβ6 
expression, identified an average normal duct size of 1.3mm2, compared to an 
average benign duct size of 90mm2, and DCIS duct size of 140mm2. Moreover, 
DCIS ducts from high-grade pure DCIS were larger than those from non-high-
grade pure DCIS (p<0.0001) (160mm2 compared to 81mm2, respectively), while 
those from DCIS/IDC were similar in size (163mm2). Interestingly, integrin αvβ6-
positive DCIS ducts on average were larger than integrin αvβ6-negative DCIS 
ducts (p<0.0001) (162mm2 compared to 117mm2, respectively) (Figure 51a; 
panel 2-3; quantified in Figure 51b) (Table 17). These data demonstrate high-
grade DCIS ducts are larger than non-high-grade DCIS ducts, perhaps due to 
differences in proliferation rates or tumour cell size. Moreover, these data suggest 
the pressure exerted by neoplastic epithelial cells on MECs may be a factor 
regulating the expression of integrin αvβ6.  
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Figure 51. DCIS duct expansion correlates with upregulation of integrin v6 by
myoepithelial cells. a) Immunohistological staining of human breast tumour samples
(staining for integrin v6; panel 2-3) featuring normal breast ducts, and DCIS ducts with
and without the expression of integrin v6. Magnification x5 and x20. Scale bar, 200μm and
100mm, respectively. b) Quantitative analysis of DCIS duct size with and without integrin
v6 expression (total of 713 and 656 ducts, respectively) in patient samples. Box
represents the third interquartile (IQR3) and first interquartile (IQR1) range and the median
is represented by the black line within the box. The whiskers represent the complete data
range. p-value ≤0.001 (‘***’) considered significant.
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189
190 
 
 
 
 
Duct size in mm2 (number of ducts)  
αvβ6-positive αvβ6-negative Total 
Normal - 1.3 (420) 420 
Benign - 90 (38) 38 
DCIS 
Non-high-grade 92 (125) 75 (233) 358 
High-grade 176 (235) 146 (238) 473 
DCIS/IDC 178 (353) 135 (185) 538 
1827 
 
Table 17. Quantification of DCIS duct size in relation to integrin αvβ6 expression 
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4.4.5 DCIS is associated with morphological changes in myoepithelial 
cells which correlates with integrin αvβ6 positivity  
With duct expansion in DCIS, MECs appear attenuated compared to normal 
breast ducts. The size, shape and number of 4536 MECs and 2736 MEC nuclei 
were then analysed in normal and DCIS ducts within our cohort of DCIS samples. 
The minor axis of individual MECs was determined by SMA immunoreactivity and 
the minor and major axis of MEC nuclei was determined by p63 immunoreactivity 
on serial sections to integrin αvβ6 immunohistochemical staining. In normal 
ducts, MECs appeared rounded (minor axis 6.1µm) (Figure 52a; panel 2-3), while 
in both DCIS and benign lesions appeared flattened or spindle-shaped (p<0.001) 
(2.7µm and 3.6µm, respectively) (Table 18) (Supplementary Figure S6). 
However, MEC nuclei appeared flattened in DCIS (minor axis by major axis; 
2.2µm by 8.4µm) (Figure 52a; panel 4-5), while in both normal and benign lesions 
appeared rounded (p<0.001) (minor axis by major axis; 4.3µm x 4.7µm, and 
4.3µm x 5.1µm, respectively) (Table 19) (Supplementary Figure S6). 
Interestingly, the minor axis of MECs in integrin αvβ6-positive DCIS ducts was 
significantly reduced compared to integrin αvβ6-negative DCIS ducts (p<0.0001) 
(2.5µm compared to 3.0µm) (Table 18) (Supplementary Figure S7). Similarly, 
MEC nuclei were more significantly compressed and elongated in integrin αvβ6-
positive DCIS ducts compared to integrin αvβ6-negative DCIS ducts (p<0.005) 
(minor axis by major axis; 2.1µm by 8.6µm compared to 2.4µm by 8.1µm) (Table 
19) (Supplementary Figure S7). In normal ducts, an average of 21 MECs were 
identified per duct using p63 staining, while in both benign lesions and DCIS an 
average of 20 MECs were identified (Table 20). These data suggest nuclear 
markers may help identify attenuated MECs in DCIS, and thereby help the 
distinction between DCIS and IDC. Moreover, these data suggest alteration to 
duct size in DCIS alters MEC nuclei morphology which may influence the 
transcriptional activation of integrin αvβ6. 
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Figure 52. DCIS is associated with morphological changes in myoepithelial cells
which correlates with integrin v6 positivity. a) Immunohistological staining of human
breast tumour samples (staining for -SMA; panel 2-3 and p63; panel 4-5) featuring areas of
normal, DCIS and DCIS/IDC. Magnification ×20 and x40. Scale bar, 50μm and 25μm,
respectively. b) Quantitative analysis of MEC cytoplasm minor axis. Dots represent the
average minor axis of MEC cytoplasm in each patient sample and error bars represent
standard deviation. c) Quantitative analysis of MEC nuclei minor and major axis. Dots
represent the average minor/major axis of MEC nuclei in each patient sample and error bars
represent ±SEM.
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Cell size in µm (number of cells)  
αvβ6-positive αvβ6-negative Total 
Normal - 6.0 (1635) 1635 
Benign - 3.6 (108) 108 
DCIS 
Non-high-grade 2.6 (261) 2.8 (486) 747 
High-grade 2.4 (606) 3.1 (456) 1062 
DCIS/IDC 2.6 (663) 3.1 (321) 984 
4536 
 
Table 18. Quantification of myoepithelial cell size and shape in relation to integrin αvβ6 
expression 
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Nuclei size in µm (number of cells) 
 
αvβ6-positive αvβ6-negative 
Minor Major Minor Major Total 
Normal - - 4.3 (780) 4.7 (780) 780 
Benign - - 4.3 (108) 5.0 (108) 108 
DCIS 
Non-high-grade 2.2 (171) 8.3 (171) 2.4 (258) 7.7 (258) 429 
High-grade 2.0 (309) 7.7 (309) 2.5 (285) 8.3 (285) 594 
DCIS/IDC 2.1 (549) 9.2 (549) 2.4 (276) 8.4 (276) 825 
2736 
 
Table 19. Quantification of myoepithelial nuclei size and shape in relation to integrin αvβ6 
expression 
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Number of MECs per duct (number of ducts)  
αvβ6-positive αvβ6-negative Total 
Normal - 21 (260) 260 
Benign - 20 (36) 36 
DCIS 
Non-high-grade 19 (57) 20 (86) 143 
High-grade 20 (103) 21 (95) 198 
DCIS/IDC 20 (183) 21 (92) 275 
912 
 
Table 20. Quantification of myoepithelial cell number in relation to integrin αvβ6 
expression 
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4.4.6 Mechanostimulation of integrin αvβ6 expression and fibronectin 
deposition in primary normal myoepithelial cells 
Primary normal MECs were exposed to mechanical stretch, as seen in the 
expansion of DCIS lesions, to investigate the mechanoregulation of integrin αvβ6 
here. Consistent with our immunohistochemical analyses, mechanical stretching 
of primary normal MECs (N-1492 and N-1989), revealed an increase in integrin 
αvβ6 expression using immunofluorescence (p<0.01 and p<0.001, respectively) 
(Figure 53-54a; quantified in Figure 53-54b, respectively) and immunoblotting 
(p<0.001) (Figure 53-54d; quantified in Figure 53-54e, respectively). A 
concomitant increase in TFN and FN-EDA expression in primary normal MECs 
exposed to mechanical stretching was observed (p<0.001) (Figure 53-54a and 
53-54d; quantified in Figure 53-54b and 53-54e, respectively). These findings 
were supported at the mRNA level (Figure 53-54c). These data support our 
immunohistochemical analysis, such that application of mechanical stretch to 
MECs, as seen in expansion of DCIS ducts, induces a DCIS-MEC phenotype 
associated with upregulation of integrin αvβ6 and FN expression. 
 
a) N-1492 b)
Figure 53. Mechanostimulation of integrin v6 expression and fibronectin deposition
in primary normal myoepithelial cells. a) Immunofluorescent staining for integrin v6,
TFN and FN-EDA in unstrained or strained N-1492. Magnification ×63. Scale bar, 20μm. b)
Fluorescent analysis of integrin v6, TFN and FN-EDA signal intensities were determined
using the ZEN 2009 image analysis software. The values are presented as the relative
fluorescence in strained normalised to unstrained N-1492. c) qRT-PCR analysis of integrin
v6, TFN, FN-EDA and FN-EDB mRNA levels in unstrained or strained N-1492. The
values are presented as the mean percentage change in expression relative to unstrained N-
1492. d) Immunoblotting for integrin v6, TFN, FN-EDA and HSC70 in unstrained or
strained N-1492. e) Densitometric analysis of integrin v6, TFN, FN-EDA and HSC70
signal intensities were determined using ImageJ. The relative protein levels of integrin v6,
TFN and FN-EDA were normalised to HSC70 on the same membrane. The values are
presented as the relative level in strained normalised to unstrained N-1492. Representative
fluorescent images and immunoblots of at least 3 independent experiments are shown, and
analyses is shown as a mean of 3 independent experiments ±SEM. p-value ≤0.001 (‘***’),
≤0.01 (‘**’) and ≤0.05 (‘*’) considered significant.
Integrin v6 
FN-EDA
StrainedUnstrained
TFN
Unstrained Strained
Integrin v6 - 105 kDa
TFN - 240 kDa
HSC70 - 70 kDa
FN-EDA - 240 kDa
d) e)N-1492
c)
v6 TFN FN-EDA
0
5
10
15
20
Unstrained
Strained
**
***
***
Re
lat
ive
 fl
uo
re
sc
en
ce
 to
 u
ns
tra
in
ed
v6 TFN FN-EDA FN-EDB
0
200
400
600
800
*
**
*
**
C
ha
ng
e 
in
 e
xp
re
ss
io
n 
(%
)
St
ra
in
ed
 re
la
tiv
e 
to
 u
ns
tra
in
ed
v6 TFN FN-EDA
0
5
10
15 Unstrained
Strained
***
***
***
Re
la
tiv
e 
le
ve
l t
o 
un
st
ra
in
ed
197
Figure 54. Mechanostimulation of integrin v6 expression and fibronectin deposition
in primary normal myoepithelial cells. a) Immunofluorescent staining for integrin v6,
TFN and FN-EDA in unstrained or strained N-1989. Magnification ×63. Scale bar, 20μm. b)
Fluorescent analysis of integrin v6, TFN and FN-EDA signal intensities were determined
using the ZEN 2009 image analysis software. The values are presented as the relative
fluorescence in strained normalised to unstrained N-1989. c) qRT-PCR analysis of integrin
v6, TFN, FN-EDA and FN-EDB mRNA levels in unstrained or strained N-1989. The
values are presented as the mean percentage change in expression relative to unstrained N-
1989. d) Immunoblotting for integrin v6, TFN, FN-EDA and HSC70 in unstrained or
strained N-1989. e) Densitometric analysis of integrin v6, TFN, FN-EDA and HSC70
signal intensities were determined using ImageJ. The relative protein levels of integrin v6,
TFN and FN-EDA were normalised to HSC70 on the same membrane. The values are
presented as the relative level in strained normalised to unstrained N-1989. Representative
fluorescent images and immunoblots of at least 3 independent experiments are shown, and
analyses is shown as a mean of 3 independent experiments ±SEM. p-value ≤0.001 (‘***’)
and ≤0.01 (‘**’) considered significant.
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4.4.7 Mechanostimulation of integrin αvβ6 expression and fibronectin 
deposition in a normal myoepithelial cell line 
Similarly, mechanical stretching of N-1089 revealed an increase in integrin αvβ6 
expression using immunofluorescence (p<0.001) and immunoblotting (p<0.01) 
(Figure 55a and 55d; quantified in Figure 55b and 55e, respectively). Likewise, 
we also identified a concomitant increase in TFN and FN-EDA expression in N-
1089 exposed to mechanical stretching using immunofluorescence (p<0.001) 
and immunoblotting (p<0.01) (Figure 55a and 55d; quantified in Figure 55b and 
55e, respectively). These findings were supported at the mRNA level (Figure 
55c).  These data further support the role of mechanostimulation in inducing 
integrin αvβ6 expression and FN deposition by MECs. 
 
a) N-1089 b)
Figure 55. Mechanostimulation of integrin v6 expression and fibronectin deposition
in a normal myoepithelial cell line. a) Immunofluorescent staining for integrin v6, TFN
and FN-EDA in unstrained or strained N-1089. Magnification ×63. Scale bar, 20μm. b)
Fluorescent analysis of integrin v6, TFN and FN-EDA signal intensities were determined
using the ZEN 2009 image analysis software. The values are presented as the relative
fluorescence in strained normalised to unstrained N-1089. c) qRT-PCR analysis of integrin
v6, TFN, FN-EDA and FN-EDB mRNA levels in unstrained or strained N-1089. The
values are presented as the mean percentage change in expression relative to unstrained N-
1089. d) Immunoblotting for integrin v6, TFN, FN-EDA and HSC70 in unstrained or
strained N-1089. e) Densitometric analysis of integrin v6, TFN, FN-EDA and HSC70
signal intensities were determined using ImageJ. The relative protein levels of integrin v6,
TFN and FN-EDA were normalised to HSC70 on the same membrane. The values are
presented as the relative level in strained normalised to unstrained N-1089. Representative
fluorescent images and immunoblots of at least 3 independent experiments are shown, and
analyses is shown as a mean of 3 independent experiments ±SEM. p-value ≤0.001 (‘***’),
≤0.01 (‘**’) and ≤0.05 (‘*’) considered significant.
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4.4.8 Mechanostimulation of primary normal myoepithelial cells induces 
an invasive-promoting phenotype 
We next investigated the influence of mechanical stretch on MEC function. 
Interestingly, CM isolated from primary normal MECs (N-1492 and N-1989) 
exposed to mechanical stretching increased both MDA-MB-231 (p<0.01 and 
p<0.05, respectively) and MCF-7 cell invasion (p<0.01) (Figure 56ai-ii, 
respectively), with no effect on proliferation (Figure 56bi-ii). Moreover, as seen in 
TGFβ1 stimulated primary normal MECs, application of mechanical stretching to 
these cells also induced the expression of MMPs, with the exception of MMP8, 
as identified by human protease array analysis (Figure 57ai-ii). These alterations 
were confirmed at the mRNA level (Figure 57bi-ii). Specifically, MMP13 mRNA 
expression was significantly upregulated in comparison to other MMPs analysed 
following mechanical stimulation (p<0.05 and p<0.01, respectively). These data 
demonstrate a common MEC phenotype in DCIS, with an invasive promoting 
function, which may be mechanically stimulated.  
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Figure 56. Mechanostimulation of primary normal myoepithelial cells mediates breast
cancer cell invasion in vitro. a) Invasion of MDA-MB-231 and MCF-7 in response to CM
from unstrained or strained (i) N-1492 and (i) N-1989. The number of invading cells was
quantified by counting the cells on the underside of the Transwell. The values are presented
as the relative invasion of breast cancer cells in the presence of CM from strained
normalised to unstrained. b) Proliferation of MDA-MB-231 and MCF-7 in response to CM
from unstrained or strained (i) N-1492 and (i) N-1989. The values are presented as the
relative proliferation of breast cancer cells in the presence of CM from CM from strained
normalised to unstrained. Analyses is shown as a mean of 3 independent experiments
±SEM. p-value ≤0.01 (‘**’) and ≤0.05 (‘*’) considered significant, ‘ns’ indicates not significant.
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Figure 57. Mechanostimulation of primary normal myoepithelial cells upregulates
protease expression. a) Human protease array analysis of cCM from unstrained or strained
(i) N-1492 and (ii) N-1989. Signal intensities of analytes were determined using ImageJ and
presented the relative level in strained by normalising to unstrained. b) ) qRT-PCR analysis
of MMP2, MMP3, MMP7, MMP9, MMP10 and MMP13 mRNA levels in unstrained or
strained (i) N-1492 and (ii) N-1989. The values are presented as the mean percentage
change in expression relative to unstrained. Analyses is shown as a mean of 3 independent
experiments ±SEM. p-value ≤0.01 (‘**’) and ≤0.05 (‘*’) considered significant, ‘ns’ indicates
not significant.
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4.4.9 Mechanostimulation of a normal myoepithelial cell line induces an 
invasive-promoting phenotype 
Similar to that seen in primary normal MECs, CM isolated from N-1089 exposed 
to mechanical stretching increased both MDA-MB-231 and MCF-7 cell invasion 
(p<0.01) (Figure 58a), with no effect on proliferation (Figure 58b). Moreover, as 
seen in both β6-1089 and TGFβ1 stimulated N-1089, application of mechanical 
stretching to N-1089 also induced the expression of MMPs, with the exception of 
MMP7 and MMP8, as identified by human protease array analysis (Figure 59a). 
These alterations were supported at the mRNA level (Figure 59b) and using 
gelatin zymography to detect MMP9 expression (p<0.01) (Figure 59c; quantified 
in Figure 59d). Specifically, MMP13 mRNA expression was significantly 
upregulated in comparison to other MMPs analysed following mechanical 
stretching of N-1089 (p<0.05) (Figure 59b). Mechanostimulation of integrin avb6 
expression was inhibited by siRNA targeting β6 in N-1089, as demonstrated using 
immunofluorescence (p<0.001) and immunoblotting (p<0.01) however, TFN and 
FN-EDA expression were maintained (Figure 60a and 60d; quantified in Figure 
60b and 60e, respectively). These findings were supported at the mRNA level 
(Figure 60c). CM isolated following the knockdown of integrin αvβ6 in 
mechanostimulated N-1089 resulted in a reduction in MDA-MB-231 and MCF-7 
cell invasion in vitro (p<0.001) (Figure 61a), with no effect on proliferation (Figure 
61b). Moreover, this led to the reduction in MMP9 (p<0.05) and MMP13 mRNA 
levels (Figure 62). Together, these further data support the characteristic MEC 
phenotype in DCIS, which may be activated by mechanical tension. 
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Figure 58. Mechanostimulation of a normal myoepithelial cell line mediates breast
cancer cell invasion in vitro. a) Invasion of MDA-MB-231 and MCF-7 in response to CM
from unstrained or strained N-1089. The number of invading cells was quantified by counting
the cells on the underside of the Transwell. The values are presented as the relative
invasion of breast cancer cells in the presence of CM from CM from strained normalised to
unstrained N-1089. b) Proliferation of MDA-MB-231 and MCF-7 in response to CM from
unstrained or strained N-1089. The values are presented as the relative proliferation of
breast cancer cells in the presence of CM from strained normalised to unstrained N-1089.
Analyses is shown as a mean of 3 independent experiments ±SEM. p-value ≤0.01 (‘**’)
considered significant, ‘ns’ indicates not significant.
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Figure 59. Mechanostimulation of a normal myoepithelial cell line upregulates
protease expression. a) Human protease array analysis of cCM from unstrained or strained
N-1089. Signal intensities of analytes were determined using ImageJ and presented the
relative level in strained by normalising to unstrained. b) ) qRT-PCR analysis of MMP2,
MMP3, MMP7, MMP9, MMP10 and MMP13 mRNA levels in unstrained or strained N-1089.
The values are presented as the mean percentage change in expression relative to
unstrained. c) Gelatin zymography for MMP9 expression in cCM from unstrained or strained
N-1089. d) Densitometric analysis of MMP9 signal intensities were determined using
ImageJ. These data are then presented as the relative level in strained by normalising to
unstrained N-1089. Representative images of 3 independent gelatin zymograms are shown,
and analyses is shown as a mean of 3 experiments ±SEM. p-value ≤0.01 (‘**’) and ≤0.05 (‘*’)
considered significant, ‘ns’ indicates not significant.
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a) N-1089 b)
Figure 60. Knockdown of integrin v6 expression in a mechanostimulated normal
myoepithelial cell line. a) Immunofluorescent staining for integrin v6, TFN and FN-EDA
in strained N-1089 with NTC or integrin 6 siRNA (6 Kd). Magnification ×63. Scale bar,
20μm. b) Fluorescent analysis of integrin v6, TFN and FN-EDA signal intensities were
determined using the ZEN 2009 image analysis software. The values are presented as the
relative fluorescence in 6 Kd normalised to NTC. c) qRT-PCR analysis of integrin v6,
TFN, FN-EDA and FN-EDB mRNA levels in strained N-1089 with NTC or integrin 6 siRNA
(6 Kd). The values are presented as the mean percentage change in expression relative to
NTC. d) Immunoblotting for integrin v6, TFN, FN-EDA and HSC70 in strained N-1089 with
NTC or integrin 6 siRNA (6 Kd). e) Densitometric analysis of integrin v6, TFN, FN-EDA
and HSC70 signal intensities were determined using ImageJ. The relative protein levels of
integrin v6, TFN and FN-EDA were normalised to HSC70 on the same membrane. The
values are presented as the relative level in 6 Kd normalised to NTC. Representative
fluorescent images and immunoblots of at least 3 independent experiments are shown, and
analyses is shown as a mean of 3 independent experiments ±SEM. p-value ≤0.001 (‘***’)
and ≤0.05 (‘*’) considered significant, ‘ns’ indicates not significant.
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Figure 61. Mechanostimulation of integrin v6 in a normal myoepithelial cell line
mediates breast cancer cell invasion in vitro. a) Invasion of MDA-MB-231 and MCF-7 in
response to CM from strained N-1089 with NTC or integrin 6 siRNA (6 Kd). The number of
invading cells was quantified by counting the cells on the underside of the Transwell. The
values are presented as the relative invasion of breast cancer cells in the presence of CM
from 6 Kd normalised to NTC. b) Proliferation of MDA-MB-231 and MCF-7 in response to
CM from unstrained or strained N-1089. The values are presented as the relative
proliferation of breast cancer cells in the presence of CM from 6 Kd normalised to NTC.
Analyses is shown as a mean of 3 independent experiments ±SEM. p-value ≤0.001 (‘***’)
considered significant, ‘ns’ indicates not significant.
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Figure 62. Mechanostimulation of integrin v6 in a normal myoepithelial cell line
upregulates protease expression. qRT-PCR analysis of MMP2, MMP3, MMP7, MMP9,
MMP10 and MMP13 mRNA levels in strained N-1089 with NTC or integrin 6 siRNA (6
Kd). The values are presented as the mean percentage change in expression relative to
NTC. Analyses is shown as a mean of 3 experiments ±SEM. p-value ≤0.05 (‘*’) considered
significant, ‘ns’ indicates not significant.
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4.4.10 Mechanostimulation of integrin αvβ6 expression and fibronectin 
deposition by a normal myoepithelial cell line is TGFβ-dependent 
Consistent with blockade of TGFβRII in β6-1089, TGFβRII block in N-1089 
exposed to mechanical stretching inhibited the upregulation of integrin αvβ6 
expression and FN deposition; both TFN and FN-EDA, as identified using 
immunofluorescence (p<0.001) (Figure 63a; quantified in 63b) and 
immunoblotting (p<0.05, p<0.001 and p<0.001) (Figure 63d; quantified in 63e). 
These findings were confirmed at the mRNA level (Figure 63c). These data 
suggest initiation of TGFβ activation may be mediated by mechanical stress, to 
induce the characteristic DCIS-MEC phenotype with upregulation of integrin αvβ6 
and FN deposition. Together, these data suggest that mechanostimulation of 
MECs may activate TGFβ to induce the switch in MEC phenotype to that of a 
tumour-promoting phenotype. 
 
a) N-1089 b)
Figure 63. Mechanostimulation of integrin v6 expression and fibronectin deposition
in a normal myoepithelial cell line is TGF-dependent. a) Immunofluorescent staining for
integrin v6, TFN and FN-EDA in strained N-1089 with IgG control or TGFRII (RII)
antibody. Magnification ×63. Scale bar, 20μm. b) Fluorescent analysis of integrin v6, TFN
and FN-EDA signal intensities were determined using the ZEN 2009 image analysis
software. The values are presented as the relative fluorescence in TGFRII blocking
antibody normalised to IgG control antibody. c) qRT-PCR analysis of integrin v6, TFN,
FN-EDA and FN-EDB mRNA levels in strained N-1089 with IgG control or TGFRII antibody
The values are presented as the mean percentage change in expression relative to NTC. d)
Immunoblotting for integrin v6, TFN, FN-EDA and HSC70 in strained N-1089 with IgG
control or TGFRII (RII) antibody. e) Densitometric analysis of integrin v6, TFN, FN-EDA
and HSC70 signal intensities were determined using ImageJ. The relative protein levels of
integrin v6, TFN and FN-EDA were normalised to HSC70 on the same membrane. The
values are presented as the relative level TGFRII blocking antibody normalised to IgG
control antibody. Representative fluorescent images and immunoblots of at least 3
independent experiments are shown, and analyses is shown as a mean of 3 independent
experiments ±SEM. p-value ≤0.001 (‘***’) and ≤0.05 (‘*’) considered significant.
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5. DISCUSSION 
For the majority of invasive breast cancers, progression follows transition through 
a preinvasive stage, DCIS [13]. DCIS is non-lethal however, due to its potential 
to invade and metastasise, patients are treated with surgery, radiation and/or 
hormone therapy [35, 36]. However, it is estimated that in fact only half of DCIS 
cases will progress to invasion within a patient’s lifetime, and therefore concerns 
surround the overdiagnosis and overtreatment of DCIS [37]. Studies aimed at 
identifying markers to predict DCIS progression to better direct therapeutic 
intervention have demonstrated that neoplastic epithelial cells from DCIS and 
invasive breast cancer are genetically identical, and so currently there are no 
markers to robustly predict which cases will and will not progress [55, 66-70]. 
However, these studies failed to incorporate the microenvironment of DCIS, 
which comprises the MEC population and stromal compartment. In this study, we 
show that the breast microenvironment is altered, with upregulation of integrin 
αvβ6 by MECs and increased periductal FN deposition, and these alterations are 
associated with DCIS progression to invasion. We identified a correlation 
between integrin αvβ6 and FN in DCIS ducts, and demonstrated integrin αvβ6-
positive MECs upregulate the expression of FN. Subsequently, these alterations 
parallel enhanced activation of TGFβ signalling. Accompanying the activation of 
TGFβ, our model of DCIS-MECs upregulate the expression of MMPs associated 
with invasive-promoting functions, in particular MMP13. We found the expression 
of MMP13 promoted breast cancer cell invasion in vitro, consistent with prior 
reports that MMP13 associates with DCIS progression to invasive disease [417]. 
Interestingly, we identify that integrin αvβ6 expression associates with increased 
DCIS duct size, and suggest a role for altered tissue mechanics in altering MEC 
phenotype. Moreover, we demonstrate integrin αvβ6 and FN expression by 
MECs is mechanically regulated in a TGFβ-dependent manner. We suggest that 
in vivo, DCIS duct expansion induces TGFβ activation, to drive the expression of 
integrin αvβ6 and FN, which provide a feedforward mechanism driving TGFβ 
signalling and MMP activation to promote invasion. Together, this work suggests 
that integrin αvβ6 and FN may be used as markers to identify DCIS more likely 
to progress into invasive disease, in order to stratify patients with DCIS.  
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5.1 PHENOTYPIC CHARACTERISTICS OF MYOEPITHELIAL CELLS IN 
NORMAL AND DCIS TISSUE 
Normal breast tissue is comprised of epithelium, stroma and adipose tissue, each 
of which is heterogeneous and complex in composition, and alters with 
development, menstrual cycle, pregnancy and ageing within an individual (intra-
variability), as well as between individuals (inter-variability) [6, 8]. In breast 
cancer, the composition of breast tissue is altered however, studies depicting the 
proportion of these components has not been previously documented. The 
functional relevance of breast tissue composition is supported by direct 
association between mammographic density (proportion of radiodense glandular 
and fibrous tissue) and breast cancer risk [441], and growing experimental 
evidence that the ECM may influence breast cancer development, prognosis and 
treatment response [442, 443]. A digital histopathology analysis of our DCIS 
cohort demonstrated as DCIS develops there is a consequent increase in the 
relative proportion of epithelium and stroma, with a reduction in adipose tissue, 
and this is further enhanced with progression to invasion. This transition towards 
a less fatty, more fibrous microenvironment may itself alter both tumour and 
stromal cell behaviour. Studies have shown that increasing stiffness, 
accompanied by the reduction in adipose tissue and increased stroma – provided 
by the elevated quantify, reorganisation and crosslinking of ECM proteins [292, 
294, 300, 308], can promote invasion and metastasis in in vivo models of 
mammary cancer [238, 300, 306]. Therefore, we suggest such alterations in 
breast tissue composition may promote DCIS progression.  
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Previous studies in our laboratory identified the de novo expression of integrin 
αvβ6 by DCIS-MECs, with 52% of non–high-grade and 69% of high-grade pure 
DCIS cases showing MEC staining for integrin αvβ6. The frequency of MEC 
staining for integrin αvβ6 in DCIS/IDC is significantly higher than in pure DCIS, 
with 87% of non-high-grade and 96% of high-grade DCIS/IDC cases exhibiting 
staining [114]. It already has been established that high-grade DCIS progresses 
to invasion and recurrence more quickly than low-grade [444, 445]. In this 
previous study, it was shown that the upregulation of integrin αvβ6 by DCIS-
MECs was associated with recurrence of breast cancer either as in situ or 
invasive disease, independent of tumour grade, with integrin αvβ6-positive DCIS 
cases developing recurrence more quickly than integrin αvβ6-negative DCIS 
cases, with a median time to recurrence of 2.3 versus 11.4 years, respectively 
[114]. In work presented here, consistently no staining for integrin αvβ6 in normal 
tissue or benign lesions was detected, whereas 70% of non-high-grade pure 
DCIS, and 90% of high-grade pure DCIS and DCIS/IDC cases exhibited MEC 
staining for integrin αvβ6. One element not taken into consideration in the 
previous studies from our laboratory was the level of intratumour heterogeneity 
in DCIS. In work presented here, DCIS ducts were analysed on a duct-by-duct 
basis to address this. Analysis of integrin αvβ6 on a duct-by-duct basis in DCIS 
cases identified; 27% (10-59%) of non-high-grade and 45% (24-89%) of high-
grade pure DCIS ducts showed MEC staining for integrin αvβ6. The frequency of 
MEC staining for integrin αvβ6 in DCIS/IDC is significantly higher than in pure 
DCIS, with 68% (33-100%) of DCIS/IDC ducts exhibiting staining. Together, this 
suggests integrin αvβ6 positivity in DCIS-MECs is a marker of DCIS cases more 
likely to progress to invasion and recurrence. 
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Further preliminary studies in our laboratory identified the upregulation of TFN by 
DCIS-MECs compared to normal MECs (29-fold), using Affymetrix cDNA 
microarray analysis of MECs isolated by LCM from normal (n=4) and DCIS tissue 
samples with (n=4) and without (n=1) invasion. The purity of MECs was confirmed 
by comparing MECs isolated from normal breast and DCIS tissue, for MEC and 
LEC-specific differentiation makers using qRT-PCR. The upregulation of TFN in 
DCIS-MECs was reflected at the mRNA level. Here, analysis of TFN on a duct-
by-duct basis in DCIS cases supported these preliminary results; with all DCIS 
cases exhibiting periductal staining for TFN. Low levels of staining for TFN were 
detected in normal ducts or benign lesions, 6% (1-13%) and 21% (7-28%), 
respectively, whereas 70% (8-88%) of non-high-grade and 66% (23-97%) of 
high-grade pure DCIS ducts showed periductal FN expression. The frequency of 
periductal FN expression in DCIS/IDC is significantly higher than in pure DCIS, 
such that it is almost universally expressed, with 87% (20-100%) of DCIS/IDC 
ducts exhibiting staining. The increased deposition of FN in the periductal 
microenvironment was independent of tumour grade and is related to DCIS 
progression to invasion. The excessive deposition of ECM proteins is common in 
cancers with poor prognosis [291], and the increased deposition of FN has 
previously been documented in the stroma surrounding DCIS, and this increases 
in DCIS/IDC [69]. While such studies support our data, these studies analyse FN 
expression in the whole tumour stroma and do not accurately account for 
intratumour heterogeneity within the periductal microenvironment as addressed 
here. Moreover, a study by Hattar and colleagues demonstrated mammary ECM 
isolated from tamoxifen-treated rats has decreased FN levels, and suppressed 
breast tumour cell invasion in vitro. This effect could be reversed by the addition 
of exogenous FN [446], suggesting the tumour-promoting potential of the ECM is 
FN-dependent. Together, these data suggest periductal FN expression is a 
marker of DCIS cases more likely to progress to invasion, and indicate that the 
altered periductal microenvironment is regulated by DCIS-MECs.  
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Furthermore, there was a significant association between the upregulation of 
integrin αvβ6 expression by MECs and the deposition of FN into the periductal 
microenvironment. These alterations correlate with the altered composition of 
DCIS tissues. As such, the increased expression of integrin αvβ6 correlated with 
the increased proportion of epithelium, reflecting the expansion of DCIS ducts by 
neoplastic epithelial cells, whilst the increased deposition of FN correlates with 
the increased proportion of stroma. Recently, it has been demonstrated that the 
expression of integrin αvβ6 by MECs alters their response to changes in the 
properties of the stroma. It has been shown that normal MECs are able to sense 
and respond to increased matrix stiffness via integrin α5β1 binding to FN, thereby 
restoring tensional homeostasis and reducing the forces MECs experience to 
normal. This response is eventually overcome as the stiffness continues to 
increase; however, when MECs express integrin αvβ6, their ability to respond to 
a stiffening microenvironment is lost and consequently MECs experience the 
increase in stiffness more quickly [447]. These changes may be generated 
through alterations to the stroma, including the increased deposition of FN. These 
data suggest another mechanism by which integrin αvβ6 alters the normal 
phenotype of MECs, and may promote progression into invasion. Together, our 
immunohistochemical analyses confirm an alteration to MEC phenotype in DCIS, 
and suggests this alteration is associated with disease progression, since the 
altered phenotype is more frequent in DCIS/IDC. Next, we investigated the 
expression of FN by integrin αvβ6-positive primary DCIS-associated and normal 
MECs, along with MEC lines to further establish the relationship between, and 
function of these molecules in DCIS ducts. 
 
 
 
 
 
 
 
 
 
217 
 
5.2 PHENOTYPIC CHARACTERISTICS IN PRIMARY AND CELL LINE 
MODELS OF NORMAL AND DCIS MYOEPITHELIAL CELLS 
Our laboratory regularly isolates different cell populations from normal and 
tumour breast tissue through enzymatic digestion and cell purification. In this 
study, primary MECs from normal breast and DCIS tissue were used, alongside 
established MEC lines. Consistent with immunohistochemical analyses of DCIS 
tissues, primary DCIS-MECs isolated from an integrin αvβ6-positive DCIS case 
demonstrated a significant increase in FN mRNA expression compared to DCIS-
MECs isolated from an integrin αvβ6-negative case. Similarly, overexpression of 
integrin αvβ6 in primary normal MECs, which normally lack integrin αvβ6, 
demonstrated a concomitant increase in FN protein expression. Moreover, using 
a MEC line with (β6-1089) and without (N-1089) stable expression of integrin 
αvβ6 identified a significant increase in FN protein and mRNA expression in β6-
108 compared to N-1089. All models of integrin αvβ6-positive MECs which 
expressed FN, expressed EDA and/or EDB sequences, which are markers of 
cFN [323]. No significant differences between cFN and TFN levels were detected 
throughout, demonstrating integrin αvβ6-positive MECs dominantly express cFN 
compared to pFN. The assembly of FN into a mature fibrillar matrix is essential 
for the function of FN. Assembly of a FN matrix is the same for both pFN and 
cFN. It has previously been shown that the development of a FN matrix can be 
monitored by the irreversible conversion of DOC-soluble, cell-associated FN, into 
a DOC-insoluble FN matrix. DOC-soluble, cell-associated FN is thought to 
represent FN bound to cell surface receptors which has not yet been assembled 
into DOC-insoluble FN fibrils [359]. Both DOC-soluble and DOC-insoluble FN 
were upregulated in β6-1089, compared to N-1089, with significantly more DOC-
insoluble FN identified in β6-1089, suggesting β6-1089 convert most FN into a 
mature fibrillar matrix. The FN matrix produced by β6-1089 demonstrated an 
increase in FN fibril length and number with time, indicative of a more mature FN 
matrix. These data suggest that integrin αvβ6-positive MECs upregulate FN 
expression, and assembly into a fibrillar matrix. Together with our 
immunhistochemical analyses, these data further support a potential relationship 
between integrin αvβ6 and FN expression by DCIS-MECs, however, the 
mechanism regulating their expression is unclear. 
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5.3 FUNCTION OF PHENOTYPIC CHARACTERISTICS IN PRIMARY AND 
CELL LINE MODELS OF NORMAL AND DCIS MYOEPITHELIAL CELLS 
A primary function of integrin αvβ6 is the activation of TGFβ [207]. This 
mechanism depends on binding to LAP, where LAP is bound to a LTBP. Previous 
work in our laboratory has demonstrated that integrin αvβ6 expressed by β6-1089 
is functional, such that it is able to bind to LAP and activate latent TGFβ1 [114]. 
Following activation, TGFβ may then bind to its receptors to activate TGFβ 
signalling pathways. Canonical TGFβ signalling involves the phosphorylation of 
TGFβRI by TGFβRII following ligand binding. TGFβRI then induces the 
phosphorylation of R-SMADs, which transmit TGFβ signals to the nucleus 
through association with Co-SMAD [238]. Non-canonical signalling pathways 
activated by TGFβ bypass SMAD signalling and involve phosphorylation events 
that activate Ras-ERK signalling pathways, among others [223]. Overexpression 
of integrin αvβ6 in primary normal MECs, led to an increase in p-SMAD2 under 
basal conditions and following stimulation with exogenous TGFβ1. Similarly, β6-
1089 demonstrated increased levels of both p-SMAD2 and p-ERK1/2 under both 
basal conditions and following stimulation with exogenous TGFβ1. This effect 
was reversed by knockdown of integrin αvβ6 expression in β6-1089 using siRNA 
targeting integrin β6. These data support the role of integrin αvβ6 expressed by 
MECs in the activation of TGFβ signalling pathways. Moreover, it has been shown 
that LTBP1 of the LLC must interact with FN as a structural precondition to 
integrin αvβ6-mediated TGFβ1 activation [208]. Data presented here identified 
the knockdown of TFN expression using siRNA targeting TFN in integrin αvβ6-
overexpressing primary MECs and β6-1089, led to a reduction in p-SMAD2 under 
basal conditions and following exogenous TGFβ1. Moreover, knockdown of TFN 
by β6-1089 led to a reduction in both migration and adhesion to LAP. These data 
suggest that both integrin αvβ6 and FN in MECs must be present for the 
activation of TGFβ signalling pathways. Together, these data suggest that DCIS-
MECs are equipped to activate TGFβ. Integrin αvβ6-mediated activation of TGFβ 
functions to promote invasion in cancer cells through an autocrine manner [448]. 
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Previous work in our laboratory demonstrated that integrin αvβ6 expressed by 
MECs is able to promote breast cancer cell invasion in vitro, through paracrine 
mechanisms generated by TGFβ-dependent upregulation of MMP9 [114]. Here, 
we demonstrate the upregulation of FN by integrin αvβ6-positive MECs is 
required to facilitate TGFβ activation, and the knockdown of TFN expression in 
β6-1089 reduced breast cancer cell invasion in vitro. To investigate the 
mechanism by which these alterations in MEC phenotype might contribute to 
DCIS progression, MMP secretion was analysed. MMPs have long been 
associated with cancer invasion and metastasis due to their direct function in 
remodelling the surrounding ECM [288] however, they have been shown to have 
paradoxical roles in cancer progression [415]. Previous work in our laboratory 
has shown that MMP8 is a tumour-suppressive MMP expressed by normal MECs 
however, MMP8 expression is lost in DCIS-MECs [424]. Data presented here 
support these data. We confirm our model of DCIS-MECs, β6-1089 downregulate 
MMP8 compared to normal MECs, N-1089, and this effect is reversed by 
knockdown of integrin αvβ6. In addition to the known upregulation of MMP9, β6-
1089 also upregulate MMP13, and these effects are reversed by knockdown of 
either integrin αvβ6 or TFN expression. Moreover, both MMP9 and MMP13 
expression can be blocked by inhibiting TGFβRII with a blocking antibody. Whilst 
previous studies from our laboratory have focused on the tumour-promoting 
function of MMP9 [114], less is known about MMP13 in DCIS progression. 
MMP13 functions to degrade collagen structures [449], and has previously been 
shown to be upregulated in the progression of DCIS to invasive breast cancer by 
subjacent myofibroblasts in the surrounding stroma [417], which are often 
indistinguishable from DCIS-MECs [450]. Here we demonstrate the knockdown 
of MMP13 expression in β6-1089 reduces breast cancer cell invasion in vitro. 
Together, these data support the paracrine tumour-promoting function of integrin 
αvβ6-positive MECs on breast cancer cell invasion, and this effect is dependent 
on TGFβ-dependent activation of MMP13, in addition to its known effects on 
MMP9 activation.  
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5.4 REGULATION OF PHENOTYPIC CHARACTERISTICS IN NORMAL AND 
DCIS MYOEPITHELIAL CELLS 
TGFβ regulates integrin expression, ECM deposition and protease activity [193]. 
This is shown by fibroblast-to-myofibroblast transition induced by TGFβ, which is 
characterised by stronger actomyosin contractility than resident fibroblast 
precursors and exacerbated ECM remodelling through the production of ECM 
proteins, ECM-modifying enzymes and cross-linking enzymes [300, 451-453]. 
Here we show that stimulation of primary normal MECs and a normal MEC line 
with TGFβ1, upregulated integrin αvβ6 and FN expression. Furthermore, TGFβ1 
stimulation upregulated MMP expression, in particular MMP9 and MMP13 were 
consistently upregulated. These results are consistent with the identification of a 
TGFβ regulatory domain in both MMP9 and MMP13 [454]. These data also 
support previous publications in which exogenous TGFβ stimulation in vitro 
induced the expression of MMP9 [283] and MMP13 [397]. Furthermore, the effect 
of TGFβ in altering MEC gene-expression was shown by inhibition of TGFβRII in 
β6-1089 with a blocking antibody, which resulted in the downregulation of FN 
mRNA and protein expression. Integrin αvβ6 was unchanged, likely due to its 
constitutive expression in β6-1089. The effect of TGFβRII inhibition was attributed 
to the almost complete reduction in TGFβ signalling, compared to the partial 
reduction seen following the knockdown of integrin β6 expression. We postulate 
a positive feedback loop in which active TGFβ upregulates MEC expression of 
integrin αvβ6 and FN. This, in turn, increases TGFβ activation to upregulate MMP 
expression, specifically MMP9 and MMP13. However, the initial production of 
TGFβ and/or its activation is unclear.  
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Breast cancers are stiffer than the surrounding uninvolved tissue. The nature of 
the mechanical perturbations in a solid tumour includes solid stress and 
compression forces resulting from the expanding tumour cells. DCIS and benign 
proliferative lesions are characterised by the proliferation of neoplastic and 
hyperproliferative epithelial cells confined within the ductal-lobular network [16], 
which results in duct expansion from an average normal duct size of 1.3mm2 to 
140mm2 and 90mm2, respectively. Interestingly, DCIS ducts from high-grade 
pure DCIS were larger than those from non-high-grade pure DCIS, with an 
average duct size of 160mm2 compared to 81mm2, while those from high-grade 
DCIS/IDC were similar in size, with an average duct size of 163mm2. These data 
support the histological grading of breast cancers, as low-grade DCIS consists of 
small, cohesive, polarised, uniform cells of low proliferative capacity, while high-
grade DCIS consists of large, pleomorphic cells of high proliferative capacity, 
accounting for the increased duct size seen in high-grade DCIS ducts. Moreover, 
it was shown that integrin αvβ6-positive DCIS ducts on average were larger than 
integrin αvβ6-negative DCIS ducts, independent of tumour grade, with an 
average duct size of 162mm2 compared to 117mm2. These findings demonstrate 
an association between expansion of DCIS ducts and expression of integrin αvβ6 
expression by DCIS-MECs. 
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MECs undergo morphological changes as a consequence of the pressure 
exerted by neoplastic and hyperproliferative epithelial cells in DCIS and benign 
proliferative lesions, respectively [455]. Such that with duct expansion, MECs 
become attenuated and are not easily identifiable in H&E stained breast tissue 
sections, as they are often indistinguishable from subjacent myofibroblasts in the 
surrounding stroma, immunohistochemical staining for SMA is routinely used to 
assist in the identification of MECs [450]. In SMA immunohistochemistry images, 
MECs in normal ducts appeared rounded, while in both DCIS and benign lesions 
appeared flattened or spindle-shaped, with an average minor axis of 6.1µm, 
compared to 2.7µm and 3.6µm, respectively. However, in p63 
immunohistochemistry images, MEC nuclei appeared flattened in DCIS, while in 
both normal and benign lesions appeared rounded, with an average minor axis 
by major axis of 2.2µm by 8.4µm, compared to 4.3µm by 4.7µm and 4.3µm by 
5.1µm, respectively. Interestingly, MECs in integrin αvβ6-positive DCIS ducts 
appeared more significantly flattened or spindle-shaped than in integrin αvβ6-
negative DCIS ducts, with an average minor axis of 2.5µm compared to 3.0µm. 
MEC nuclei were also more significantly compressed and elongated in integrin 
αvβ6-positive DCIS ducts compared to integrin αvβ6-negative DCIS ducts, with 
an average minor axis by major axis of 2.1µm by 8.6µm compared to 2.4µm by 
8.1µm. The change in MEC nuclei is not explained only by physical pressure and 
is also likely due to altered crosstalk in tumours [456]. Breast tumour cells under 
high tension demonstrate elevated integrins and increased integrin signalling, 
suggesting tissue mechanics regulate malignancy by enhancing integrin-
dependent mechanotransduction [299]. This is the first study to suggest that 
MECs under high tension may increase expression of integrin αvβ6 as an 
adaptive response. Together, these results suggest that the morphology of MEC 
nuclei could be helpful in distinguishing between benign proliferative lesions and 
DCIS, and such morphological changes to DCIS-MECs may influence integrin 
αvβ6 expression, though this would need to be investigated directly through cell 
compression analyses. 
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These data indicate MECs in DCIS are subject to significant mechanical stress. 
As with exposure to TGFβ, cells subject to mechanical stress generate sustained 
responses by altering their gene-expression of ECM proteins, ECM receptors and 
ECM-remodelling enzymes to allow modification of the composition, organisation 
and elasticity of their microenvironment [452]. Such modifications to the ECM can 
in turn, activate TGFβ [451]. This mechanism of mechanoreciprocity equips cells 
with the ability to alter their behaviour to correspond with the biophysical 
properties of the surrounding ECM [452]. Mechanical stimulation of primary 
normal MECs and a normal MEC line lead to an increase in integrin αvβ6 and FN 
mRNA and protein expression. With this, CM isolated from all mechanically 
stimulated MECs promoted breast cancer cell invasion in vitro, and this effect 
was not attributed to increased breast cancer cell proliferation. In turn, 
mechanical stimulation of MECs upregulated MMP expression, specifically 
MMP13. The mechanical stimulation of integrin αvβ6 was inhibited by knockdown 
of integrin αvβ6 expression using siRNA however, FN expression was 
maintained. This effect reduced breast cancer cell invasion in vitro, which is likely 
due to the reduction seen in MMP9 and MMP13 expression. Furthermore, 
inhibition of TGFβRII with a blocking antibody, prevented the mechanostimulation 
of both integrin αvβ6 and FN expression. We postulate a positive feedback loop 
in which mechanical tension, provided by duct expansion and increased ECM 
stiffness, facilitates initial TGFβ production and/or activation, which upregulates 
integrin αvβ6 expression and FN deposition. This, in turn, increases force 
production and tension development, to activate TGFβ further. Together these 
changes form a DCIS-MEC phenotype, with the ability to promote breast cancer 
cell invasion through consequent activation of MMP9 and MMP13. 
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The data presented here suggest evolving tissue mechanics during DCIS 
development activate TGFβ to induce an alteration in MEC phenotype from 
tumour-suppressive to tumour-promoting, with upregulation of integrin αvβ6 and 
FN expression. Indeed, we identified DCIS progression is associated with the 
upregulation of integrin αvβ6 expression by MECs and periductal FN deposition, 
and show their expression is associated in DCIS ducts. We also found that the 
transition of a normal breast duct to DCIS is accompanied with a dramatic 
increase in duct size, and demonstrated an association with duct expansion and 
integrin αvβ6 expression. Subsequently, mechanical stretching of MECs induces 
the expression of integrin αvβ6 and deposition of FN in a TGFβ-dependent 
manner. In this way, integrin αvβ6-FN-positive MECs are equipped to further 
mediate TGFβ-dependent activation of MMP9 and MMP13 expression to 
promote breast cancer cell invasion in vitro. Further investigation into the 
mechanism by which mechanical stretching of MECs in DCIS ducts translates 
into altered gene-expression would provide a unique understanding of the 
alteration in MEC phenotype in DCIS. Together, these data support the role for 
DCIS-MECs in altering the TME to facilitate DCIS progression to invasion, and 
suggest integrin αvβ6 and FN may be used as markers to identify DCIS cases 
more likely to progress into invasive disease. 
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SUPPLEMENTARY  
 
 
 
 
 
Tissue area % (range) 
Epithelium Stroma Adipose 
Normal 1% (1-6%) 9% (2-17%) 83 (79-95%) 
DCIS 
Non-High Grade 5% (1-8%) 16% (7-31%) 79% (67-92%) 
High Grade 12% (4-45%) 25% (8-63%) 62% (11-86%) 
DCIS/IDC 14% (2-42%) 21% (4-33%) 65% (45-84%) 
 
Supplementary Table S1. Tissue composition of the final serial section of DCIS and DCIS 
with associated invasion  
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Supplementary Figure S1. DCIS progression is accompanied by upregulation of
integrin avb6 by myoepithelial cells and increased periductal fibronectin deposition.
Immunohistological staining of human breast tumour samples (staining for SMA; panel 1-2,
integrin avb6; panel 3-4, and TFN; panel 5-6) featuring areas of normal, benign, DCIS (non-
high grade and high grade) and DCIS/IDC. Magnification x5 and x20. Scale bar, 200μm and
100mm, respectively. Representative images are shown.
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Supplementary Figure S2. Integrin avb6-positive primary DCIS-myoepithelial cells
upregulate fibronectin expression. a) Immunohistochemical images of an integrin avb6-
negative and integrin avb6-positive DCIS case is shown (additional patients in
Supplementary Figure S2). Magnification x5 and x10. Scale bar, 200mm and 100mm,
respectively. b, c) FACS plots of DCIS organoid samples; D1730 (b) and b6-D2089 (c)
separated by the expression of EpCAM (phycoerythrin (PE) fluorescence; blue gate),
integrin a6b4 and avb6 (Alexa-Fluor 488 and allophycocyanin (APC) fluorescence,
respectively; orange gate). d) qRT-PCR analysis of integrin avb6, TFN, FN-EDA and FN-
EDB mRNA levels in D1730 and b6-D2089. The values are presented as the mean
percentage change in expression relative to D1730. Representative images are shown, and
analyses is shown as a mean of 3 independent experiments ±SEM. p-value ≤0.001 (‘***’),
≤0.01 (‘**’) and ≤0.05 (‘*’) were considered significant, ‘ns’ indicates not significant.
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Supplementary Figure S3. Primary normal myoepithelial cells lack integrin avb6
expression. a, b) FACS plots of reduction mammoplasty organoid samples; N-1989 (a) and
N-3002 (b) separated by the expression of EpCAM (phycoerythrin (PE) fluorescence; blue
gate), integrin a6b4 and avb6 (Alexa-Fluor 488 and allophycocyanin (APC) fluorescence,
respectively; orange gate).
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Supplementary Figure S4. Integrin avb6-positive myoepithelial cell line upregulates
MMP9 expression. Gelatin zymography for MMP9 expression in cCM from N-1089 and b6-
1089, and 1mg/mL recombinant MMP9 (rMMP9; lane 1-3). No expression of MMP2 was
detected in gelatin zymography (data not shown).
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Supplementary Figure S5. Duct expansion in benign and DCIS lesions. a)
Immunohistological staining of human breast tumour samples (staining for integrin avb6;
panel 2-3) featuring normal breast, benign, DCIS (non-high grade and high grade) and
DCIS/IDC ducts. Magnification x5 and x20. Scale bar, 200μm and 100mm, respectively.
Representative images are shown.
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Supplementary Figure S6. Morphological changes in myoepithelial cells in benign and
DCIS lesions. a) Immunohistological staining of human breast tumour samples (staining for
SMA; panel 2-3 and p63; panel 4-5) featuring normal breast, benign, DCIS (non-high grade
and high grade) and DCIS/IDC ducts. Magnification ×20 and x40. Scale bar, 50μm and
25μm, respectively. Representative images are shown.
259
In
te
gr
in
 a
vb
6
SM
A
p6
3
b6-Pos DCISb6-Neg DCIS
Supplementary Figure S7. Morphological changes in myoepithelial cells in DCIS
correlate with integrin avb6 expression. a) Immunohistological staining of human breast
tumour samples (staining for integrin avb6; panel 1-2, SMA; panel 3-4 and p63; panel 5-6)
featuring DCIS ducts with and without the expression of integrin avb6. Magnification ×20 and
x40. Scale bar, 50μm and 25μm, respectively. Representative images are shown.
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